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Abstract 
ABSTRACT 
Chronic myeloid leukaemia (CMEL) is a myeloproliferative disorder, characterised by the 
presence of the Philadelphia (Ph) translocation where ABL gene, on chromosome 9 fuses 
with the BCR gene, on chromosomes 22. The fusion gene results in the production of 
p2 IOBCR-ABL ,a protein with the molecular weight of 21 OkDa. p2 16BCR-ABL is located in the 
cytoplasm and has constitutive protein tyrosine kinase activity and forms complexes with 
multiple cytoplasmic proteins which affect several signalling pathways. However this 
published data exists for CMEL cell lines or p2 IOBCR-ABL transduced cells because primary 
cells express degraddtive enzymes (ADA) which are released when cells are lysed under 
standard conditions, destroying p2 IOBCR-ABL and ABL. Experiments using chloroquine 
indicates that the ADA is predominantly if not completely located within cell lysosomes. 
Chloroquine is very toxic and affects tyrosine phosphorylation in K562 cells but lysing 
cells in high pH conditions mimics chloroquine without effecting cell viability of tyrosine 
phosphorylation. The high pH lysis permits co-immunoprecipitation of p2 IOBcR-ABL or 
ABL and adaptors protein CBL, CRKL and GRB2 in primary CML and non-CML CD34+ 
cells. The co-immunoprecipitation in different cell types showed that CBL and CRKL form 
CML and leukaemia specific complexes but GRB2 forms non-specific complexes with 
p2 16BCR-ABL or ABL in the different cell types. 
The availability of a junction specific BCR-ABL antibody permitted the detection 
IOBCR-ABL I OBCR-ABL f rMS of p2 exclusively. We show that p2 0 foci in CML cells lines and 
primary CD34+ cells but not MNCs. CRKL also forms foci where some CRKL foci are 
completely co-localised with p2 IOBCR-ABL, while other CRKL foci are partially overlapping, 
touching or uncomplexed. Levels of CBL, CRKL and GRB2 complexed with p2 IOPCR-ABL 
are low when analysed by CLSM. 
Interestingly, Imatinib causes translocation of p2 IOBCR-ABL into the nucleus which 
has been suggested to cause apoptosis. Imatinib also dissociates p2 ioBCR-ABL -CRKL and 
lOBCR-ABL CR ABL f 
p2l OBCR-ABL -CBL but not p2 -GRB2 indicating that p2 
IOB - orms 
complexes which are dependent and independent on tyrosine phosphorylation. 
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CHAPTER 1- INTRODUCTION 
Chronic myeloid leukaemia (CMI) is a disorder which originates from a 
haemopoietic stem cell (HSQ in the bone marrow resulting in the malignant expansion of 
myeloid cells. 
M: Normal haemovoietic stem ceUs (HSQ 
1.1.1 - Haemopoiesis 
Haernopoiesis is the process by which the body sustains requirements to replenish 
the mature cells in blood 1. The haemopoietic system has a high cell turn over because the 
mature circulating cells need to be replaced due to their limited lifespan 2. It was an 
accepted theory that during embryonic development, the stem cell originates in the yolk 
sac, migrates to the liver and during final stages of fetal development colonises the bone 
3 
marrow which remains the major site of adult haematopoiesis . In mice the spleen is one of 
the major haemopoietic organS4,5but in humans, the spleen does not have such a major role 
6. The extra-embryonic origin of the haemopoietic stem cells was challenged initially by 
studies in chicken 7 and later in mice indicating an intraembryonic stem cell source, the 
aorta gonad-mesonephros (AGM) as the initial site of adult haemopoiesis 8,9. During 
intrauterine life the production of red blood cells, erythropoiesis, is the major visible 
haemopoietic activity in the fetal blood vessels, liver and spleen. During this period 
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granulocytes can be found outside the major haemopoietic organs in the connective tissue 
but large numbers of granulocytes are not produced until haemopoiesis commences in the 
bone marrow. At birth, haemopoiesis is active throughout the whole skeleton but rapidly 
becomes restricted to the pelvis and sternum with small amounts of activity in the skull, 
ribs and vertebrae. Stem cells circulate in the fetal blood and umbilical cord but very small 
numbers of stem cells are present in the normal adult human circulation. Circulating stem 
cell numbers can be pharmacologically increased by the use of growth factors and/or 
cytotoxic agents and these stem cells can be collected by leucapheresis as a source of stem 
cefls for therapy 
2,10. 
The small HSC population has the potential to self renew and maintain the stem cell 
pool. In contrast, more mature progenitor cells have the ability to differentiate into mature 
cells of eight specific haemopoietic lineages 2 110 (Figure 1.1). Self-renewal, proliferation 
and death of HSCs, which remain in close contact with the stromal, cells in the bone 
morrow microenvironment, are controlled by growth factors and cytokines that are 
produced by the bone morrow microenvirorument 1. Cytokines such as granulocyte- 
macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor 
(G-CSF) and interleukin-3 (IL-3) are involved in HSC and progenitor cell regulation. These 
cytokines activate a number of downstream signalling pathways including the 
phosphatidylinositol Y-kinase (P13K), Janus kinase (Jak)/ signal transducers and activators 
of transcription (STAT) and/or the mitogen-activated protein (MAP) kinase pathways. Cell 
cycle progression, survival, differentiation and cytoskeletal reorganisation are all controlled 
1,11 
by signal transduction pathways 
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Figure 1.1 - Differentiation of HSC into mature haemopoietic tineages. LT-CIC- long- 
term culture-initiating cell; CAFC- cobblestone area-fom-iing cell; CFU-GEMM- mixed 
lineage colony-forming cell; BFU-E- burst-forming unit erythroid; CFU-E- colony-forming 
unit erythroid; CFU-N4K- megakaryocyte colony-forming cell; CFU-Mast- mast cell 
colony-forming cell; CFU-Eos- eosinophil colony-forming cell; CFU-GM- granulocyte- 
macrophage colony-forming cell; CFU-G- granulocyte colony-forming cell; CFU-M- 
12 
macrophage colony-forming cell. Adapted from Szilvassy (2003) . 
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Normal haemopoiesis requires a fine balance between the need to replenish the stem 
cell pool (self renewal) and differentiation to replace mature cells for various cell lineages 
(differentiation). There are two forms of cell division, symmetrical, which is the only way 
stem cells can increase in number, or asymmetrical division. During asymmetrical division 
the stem cell becomes polarized before mitosis so that the daughter cells are not equal. In 
normal haemopoiesis adhesion to bone marrow stroma causes polarisation which leads to 
13,14,15 
asymmetrical division 
1.1.2 - CD34 expression by HSC 
CD34 is a 116 kDa type 1 transmembrane glycophosphoprotein which is expressed 
on primitive haemopoietic cells, most endothelial cells and some neuronal cells and rarely 
on primitive cells from other tissues 16,17 . This antigen has proved very useful for clinical 
and research purposes because the selected CD34+ cells comprise a primitive 
stem/progenitor cell population. These cells may have the ability to differentiate into 
mature cells in the haemopoietic system when stimulated by cytokines and growth factors 
18,19,20 
. Cheng et al 
2' have shown that mice lacking CD34 have significantly reduced 
haemopoiesis in the Yolk sac, marrow and spleen but the maturing cells in the blood 
circulation were normal. It has been proposed that CD34 is capable of inducing adhesion 
but does not seem to have intrinsic kinase activity. Instead it can be phosphorylated by 
protein kinase C 22. CD34 antibodies (i. e. QBENDIO) have been shown to induce 
homotypic (same cells) and heterotypic (different cells) adhesion which mimics ligand 
engagement. Studies have shown that KGla and normal progenitor cells adhere to bone 
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marrow stroma 23, Ua5,26 . Endothelial CD34+ binds to L-seleCtin 27 and may have a role in 
inflammation 28 
. L-selectin does not act as a CD34 ligand on stem and progenitor cells and 
blocking antibodies for L-selectin were not able to inhibit QBENDIO induced aggregation 
29 
. The ligand for CD34 in haernopoietic cells still remains unknown3o, but may be CD34 
itself 29. 
1.2 - The leukaemic stem cefl 
1.2.1 Stem cell origin of CML 
Fialkow et a131 were the first to imply that CMIL originates from a single cell. They 
studied glucose-6-phopsphate dehydrogenase (G6PD) isoenzymes in female heterozygotes 
to determine the origin of CMIL. They showed that only one type of isoenzyme was 
detected in CMIL suggesting that CML arises from a single cell. If two types of isoenzymes 
had been detected it would imply that the disease had a multicellular origin. In addition, a 
study on colonies produced by all lineages of progenitor cells showed that they were 
Philadelphia (Ph) - positive and members of the leukaemic clone 32 . The Ph chromosome 
which is a translocation. between Abelson murine leukaemia virus (ABL) and breakpoint 
cluster region (BCR) on chromosome 9 and 22, respectively, has been identified in all 
haemopoiefic lineages 32,33,34 . There is evidence that some Ph' cells exist in Go phase 
(quiescent), using dual Hoecsht 3342 (DNA label) and Pyrorin Y (RNA label) dyes. These 
Go Ph' cells were capable of causing leukaemic proliferation in irradiated immuno-deficient 
mice which indicates that this quiescent state of the primitive cells is reversible 35 
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Chervenick q a132 were the first to report that normal haemopoietic cells remain in 
CMEL patients BM by diagnosis of granulocyte-macrophage (GM) colonies. It is a well 
established fact that even in different stages of CML, normal and leukaemic haernopoietic 
cells co-exist in the BM 
(Reveed "' 36). Due to the defective adhesion to the BM stroma 
37 
we 
expect that cell division will also be affected in CML patients. Studies in the Drosophila 
male germ line have shown cells bound to the niche divide asymmetrically and detached 
cells divide symmetrically 38 which further supports the concept that defective adhesion in 
CML will affect cell division and expansion in cell numbers. 
Many different mechanisms have been proposed to explain the mechanism for 
myeloid stem cell expansion in CML. Proposed mechanisms include decreased self renewal 
in favour of increased differentiation 39 , increased self renewal of stem cells resulting in 
myeloid expansion 40 , clonal amplification of 
Ph+ cells which outgrow the non-nal 
counterpart 41. Also, it has been proposed that CML stem cells are genetically unstable and 
over time acquire mutations so that new subdones of cells appear as they proliferate. Jiang 
et al 42 hypothesised that stem cells acquire mutations even before treatment has been 
administered to the patient resulting in resistance to therapy. 
1.2.2 - Level of p2jOIBCR-ABL transcript and protein levels in primitive cells 
Studies suggest that therapeutic agents such an imatinib do not target primitive cells 
in CML and consequently, there is a growing interest in trying to understand the 
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mechanism for the failure to target these cells. Many studies have shown that BCR-ABL 
transcript levels are higher in more primitive CML cells 43,44,45 but a recent study by Primo 
et a, 34 suggests that BCR-ABL mRNA expression is high in mature proliferating 
haemopoietic cells. Levels of p2l OBCR-ABL protein levels in different compartments have 
proven to be more difficult to analyse due to the presence of enzymes that degrade ABL 
proteinS 
46,47. 
1.3 CML - Presentation of disease 
1.3.1 - Epidemiology and aetiology 
CML affects approximately 1-2 per 100,000 people per year and includes 15-20% 
of all adult leukaemias in the western world. It affects all age groups but is most common in 
the middle aged and elderly ". Men are more predisposed to acquiring CML than women 
(1.4: 1 - men: women) 
49Tbe aetiology of CML is poorly understood and the only identified 
risk is ionising radiation as demonstrated in survivors of the atomic bombings of 
Hiroshima and Nagasaki5o. 
1.3.2 - Clinical and hematological features 
Hypercellularity, splenomegaly, leukocytosis and anaernia are characteristic 
features of CML. During the mid-nineteenth century there were reports of patients who had 
many CML-like symptoms 
(51,52,53) Reviewed by 54 
. There are three major stages of 
disease in 
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CMIL, chronic phase (CP), accelerated phase (AP) and blast crisis (BC) which have 
different clinical and haematological. features (Table 1.1) 55 . Not all patients progress from 
CP to BC via AP. CP is the initial stage of CMIL which is the most responsive to therapy 
followed by disease progression towards BC resulting in loss of response to therapy. 
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Table 1.1 - Features of all three disease phases in CML56 
Advanced Phase 
Parameters Chronic Phase Accelerated Phase Blast Crisis 
Median disease 
duration 
3-5 years 6-9 months 3-6 months 
White blood cell count >50 x 109/1, ----- ----- 
Percentage blasts in 
blood 
1-15% >15% 30% 
Haemoglobin Normal/slightly low Low Very low 
Platelets Normal/high/low High/low Low 
Cytogenetic BCR-ABL + (Ph) 
Bone marrow Myeloid hyperplasia 
Symptoms 
Fatigue 
Bleeding, Purpura. 
Abdominal fullness 
Weight loss 
Unexplained fever 
Splenomegaly 
Hepatomegaly 
Bone pain 
1 
Severe anaernia 
Bleeding 
Increased infection 
CNS disease 
1 Lymphadenopathy 
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1.3.3 - Molecular biology 
Nowell and Hungerford in 1960 described a minute chromosome, referred to as the 
Ph chromosome, is characteristic of human granulocytic leukaernia 57 which was the first 
time a malignant disease has been associated with a specific chromosomal abnormality 
(Figure 1.2). The Ph chromosome is a characteristic feature of all CMIL patients who 
present with a chromosomal translocation (t(9; 22)) between the normal ABL and BCR gene 
located on chromosomes 9 and 22, respectively. The translocation results in a unique fusion 
gene, which encodes a2 10 kDa protein, p2 ()BCR-ABL 
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Figure 1.2 - The Ph chromosome. Diagrammatic and chromosomal representation of the 
normal chromosome 9 (A), normal chromosome 22 (B), longer chromosome 9 (C) and 
oncogenic Ph chromosome (D). 
1.3.3.1 - p145 
ABL 
The ABL gene (Ableson murine leukaemia virus) was identified as a cellular 
homologue of v-ABL in 1970. It was identified as a variant of the Moloney leukaemia 
virus (M-MuLV) that induces leukaemia in mice 58 and named the Abelson virus 
". The 
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ABL gene spans approximately 230 Kb and, due to alternative splicing, two forms of ABL 
messenger RNA (mRNA) are formed; la, of 6 kb and lb, 7 kb6O. The ABL gene encodes 
for a 145 kDa protein belonging to a group of non-receptor tyrosine kinase proteins which 
is ubiquitously expressed on cells. There are two forms of the ABL protein, one which is 
myristoylated (I b) and the second which not myristoylated (I a), depending on the type of 
mRNA formed 
60,61. In non-haernopoietic cells ABL is located in the nucleus 
62 but in 
haemopoietic cells it is associated with f-actin in the cytoplasm and the plasma membrane 
with nuclear localisation. The protein can shuttle between the nucleus and the cytoplasm63 
due to the presence of the nuclear localisation signal (NLS) and nuclear export signal 
(NES) 64. As well as these two structural motifs, ABL protein has many other structural 
domains (Figure 1.3). The presence of these domains on the ABL protein implies that it is 
involved in many cellular functions. Further evidence of the involvement of ABL in several 
physiological roles has been provided by ABL mouse knockout models which results in 
reduced life span and many other defects involving the spleen, thymus and mature B and T 
- cells 
61,65. The SRC homology (SH) domains allow the interaction of ABL with other 
signalling proteins. 
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Figure 1.3 - p145 ABL protein. Two isoforms of ABL created by alternative splicing, lb 
fon-n is myristoylated (Myr) and the la form lacks the Myr site. SH - Src homology, P- 
D 
Proline rich domains, NLS - nuclear localisation signal, DNA BD - DNA binding 
domains, AB - actin binding site, NES - nuclear export signal. 
The SH3 domain allows protein interactions via the proline rich regions, whilst SH2 allows 
protein interactions by binding tyrosine phosphorylated residues on partner proteins. The 
SHI has a tyrosine kinase domain 
(reviewed by "). The actin binding (AB) domains aid the 
association with actin filaments in the cytoplasm 67 . ABL is an inducer of apoptosis in 
response to stress, contrasting one effect of p2 I OBCR-ABL which may inhibit apoptosis via 
activation of the P13K pathway 68 (refer to 1.3.3.3 - BCR-ABL). 
1.3.3.2 - pl6oBCR 
The BCR gene of 130 kb encodes a protein of 160 kDa and, like p145 
ABL, is 
ubiquitously expressed. It is located in the cytoplasm 69 , 70 (Figure 1.4). At the amino end it 
has a coiled-coil oligornerisation region that allows for dimerisation of p2 I 
OBCR-ABL 
proteins and is involved in the activation of ABL kinase and actin association 
71,67,72 
. 
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Figure 1.4 -pl60l3cR protein. SH - Src homology, Ser/Thr Idnase - Serine/threonine 
kinase domain, DBL BD - DBL binding domain, PH - pleckstrin homology domain, 
Rho/GEF - Rho guanine-nucleotide-exchange factor, CaLB - Calcium dependent lipid 
binding, RAC-GAP - RAC GTPase activating protein. 
The role of the coiled-coil oligornerisation domain in the activation of ABL kinase activity 
in CML and transforming potential remains controversial. Studies have shown that 
replacement of this domain using the leucine zipper of the yeast transcription factor GCN4 
72 or glutathione-S-transferase (GST) with dimerisation capability 73 does not completely 
inhibit the transforming and kinase activity of p2 I OBCR-ABL . This suggests the involvement 
of an alternative mechanism of p2 I OBCR-ABL activation. In the centre of the molecule there 
is a serine/threonine kinase domain which is constitutively active, but a mutation of the 
cysteme residue abolishes kinase activity 
74 
, 
75. 
pl60BCR has several tyrosine residues that 
can be phosphorylated, for example, tyrosine 177 which can bind GRB2 - an important 
adapter protein - once it is phosphorylated 
76,77 
. The Dbl domain has exchange factor 
activity for members of the Rho family GTPases. Normal pl60BcR has been implicated in 
the negative regulation of cell proliferation and oncogenic transformation 78 . Both normal 
and oncogenic BCR are involved in the regulation of cytoskeletal modelling via the Rho- 
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like GTPase, such as Rho, RAC, CDC42 79 . The pleckstrin homology (PH) 
80 and calcium- 
dependent lipid binding (CalB) have been implicated in actin association, lack of this 
domain may contribute the more acute transforming potential of P190BCR-ABL compared to 
p210 
BCR-ABL 
and/or p230BCR-ABL 
81. Studies of BCR-deficient mice have shown that they 
develop normally but their neutrophils develop excess levels of oxygen metabolites 82 . 
13.3-3 - p2 
IOBCR-AIBL 
The breakpoint on the BCR gene determines the type of fusion protein transcribed 
regardless of the break point in ABL (Figure 1.5). In CML and 1/3 of ALL patients the 
BCR breakpoint is found within a major breakpoint cluster region (M-bcr) which spans 5 
exons, exon 12 to 16 (previously called bI and b5). As a result the fusion protein 
transcribed will be p2 IOBCR-ABL which can have one of two breakpoints, el4a2 (b3a2) and 
the eI 3a2 (b2a2) 83 (Figure 1.5 B). These breakpoints are the most common forms in CML. 
Some reports have shown that patients who express the el4a2 have a poor prognosis in 
comparison to patients who express the el3a2 84. However, similar comparisons by other 
groUPs have shown no significant difference between patients who express the el3a2 and 
el4a2 transCriptS 
85. 
A breakpoin. t in the minor BCR region (m-bcr) results in an eI a2 fusion which 
forms a smaller protein of 190kda. p190 
BCR-ABL (Figure 1.5 A) is found in rare cases of 
CM[L and 2/3 of ALL cases. CMIL patients with the pl96BcR"ABL breakpoint have a low 
neutrophil-to-monocyte ratio and features similar to chronic myelonionocytic leukaemia 
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(CMAC) 83 
. 
Lichty et al 86 reported that some CML patients co-express p2 I OBCR-ABL and 
p1 90BCR-ABL due to alternative splicing and when compared to patients who only express 
p2 IOBCR-ABL the group with both fonm of BCR-A-BL had significantly higher white blood 
cell (WBC) and blast cell counts. There have been various reports of a breakpoint in the 
micro-BCR (p-BCR) region between exons, e19 and e20 (c3 and c4), which results in a 
230kDa protein, p230BCR-ABL (Figure 1.5 Q. This results in a mild form of CML which has 
disrupted granulocytic differentiation causing an increase in neutrophils. Therefore, this 
form of leukaemia is also called chronic neutrophilic leukaemia (CNL) 83,87,88 - There is 
much controversy about the prognosis of patients who express the p23013CR-ABL protein. A 
study has shown that expression of this form of BCR-ABL results in improved prognosis " 
but another study has shown the prognosis to be worse 90. A recent paper has shown that 
this transcript may not be associated with a particular type of myeloproliferative disorder 91. 
Other less common breakpoints have been reported 83,92 but the literature for the prognostic 
relevance for different breakpoints is still very controversial. 
In the chimeric protein several domains have been identified as essential for cellular 
transformation. They include the SH I, SH2 and actin binding domains in the ABL portion, 
and the coiled-coil domain , the tyrosine 177 and the two phosphoserine-threonine rich 
sequences present between amino acids 192-242 and 298413 76 . BCR 
has been shown to 
complex with p2 IOBCR-ABL in CML cells 93and ABL in non-CMIL cells 
77. 
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Figure 1.5 - Structural Motifs of P19013CR-ABL. ) p2 
1OBCR-ABL9 p230BCR-ABL proteins. BCR 
domains will determine the type of BCR-ABL protein (A) p190 BCR-ABL present mainly in 
ALL, (B) p210 most commonly present in CML and (C) p230BCR-ABL found in a milder 
form of CMI also called CNL. 
1.3.3.4 - ABL-BCR 
Along with the Ph chromosome the t(9; 22) causes the formation of second fusion 
protein, ABL-BCR. There are two fonns of ABL-BCR, which are dependent on the 
breakpoint in BCR. If the breakpoint occurs between the M-BCR region a 40 kDa protein, 
40 
Chapter 1- Introduction 
p4O 
ABL-BCR is formed 94. P40ABL-BCR is present in approximately 65% of CML patients " 
But if the breakpoint is between the m-BCR region a 96 kDa protein, p96ABL-BCR 94, found 
in I'00% of ALL 96 cases is formed. The presence of the ABL-BCR fusion in both CP and 
97 BC CMIL patients does not appear to have a significant role in CML . Yin et al 
" have 
reported that the ABL-BCR gene provides a protective mechanism such that patients who 
express the gene are likely to achieve a cytogenetic response with Interferon - alpha (IFN- 
a). However, Melo et al " failed to show a correlation between expression of ABL-BCR 
and response to IFN-a- 
1.3.4 - Mechanisms of disease progression 
CML patients progress from CP into AC and BC but the precise mechanism of 
disease progression is unknown. AP is an intennediate stage where the disease starts to 
become refractory to therapy but AP is not seen in all patients who progress to BC. In AP 
the spleen size and total WBC count increases and blasts comprise 10-19% of VvrBC's, > 
20% of circulating basophils, thrombocytopenia develops and/or new cytogenetic 
abnormalities may appear. BC is the terminal stage of the disease which can progress with 
or without the AP. The patient has worsened thrombocytopenia, anaemia and increased 
spleen size. The world health organisafion (VMO) have set criteria for diagnosis of BC 
which specify that patients should have > 20% blasts in the peripheral blood or bone 
marrow, and/or extramedullary blast proliferation, and/or clusters of blasts in the bone 
ReAewed in 100 
marrow as seen in histological sections 
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Many mechanisms for disease progression have been proposed; which include (a) 
duplication of the Ph chromosome, (b) genomic in-stability, (c) differentiation arrest, (d) 
telomere shortening and (e) loss of tumour-suppressor functions. In cell line models of CP 
and BC the levels of p2 ioBCR-ABL protein are higher in the BC models and exerts a dose 
dependent effect on growth factor dependence 101,102,103 , clonogenicity 
101,103 
, migration 
103 
and resistance to therapy 
103 
. The BC cell population consists of predominantly immature 
blast cells and recent developments have shown that immature cells in CML have greater 
amounts of p2 IOBCR-ABL at the transcript level and possibly the protein levels 
45,103,104,105. 
Genomic instability results from the accumulation of genetic mutations that may suppress 
normal haemopoiesis. In CML, cells become incapable of detecting DNA damage in the 
genome caused by genetic instability 42,100. Another important feature of progression into 
BC is the inhibition of cellular differentiation resulting in the expansion of immature blasts 
in the bone marrow. This may occur by suppression of transcription factor CEBPa by 
p2 I OBCR-ABL 
106. CEBPa is expressed by normal BM, CML CP but not CML BC cells and 
p210 BCR-ABL inhibits CEBPa expression by stabilising heterogenous nuclear 
ribonucleprotein. E2 (HNRNPE2), whose expression correlates inversely with CEBPa in 
CMIL BC. Perrotti et al 106 suggest abrogation of CEBPa and induction of HNRNPE2 by 
p210 BCR-ABL may be important in differentiation arrest in CMEL BC. Reports have also 
shown that expression of CEBPa restores cell differentiation in cell lines transduced with 
p210 
BCR-ABL 
and primaiy cells from patients with CMEL BC 
107,108 
. In CML, disease 
progression also results in an decrease in telomere size which has been linked to prognosis 
109,110 
of CML 
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1.4 CML - TherapY, monitorini! and Droanosis 
CNM treatment before the Imatinib era 
1.4.1.1 - Chemotheraputic agents in CMIL 
Two common chernotheraputic agents were busulfun and hydroxyurea. Busulfan 
was the first drug that was reported to be more effective than radiotherapy in CML 111. 
Patients were treated with 0.1 mg/kg until the WBC was reduced by 50% and then the dose 
was reduced to 0.05 mg/kg. When the WBC reached 20-25x 109/1 the drug was discontinued 
as the WBC count will continue to fall for a further two weeks. Resistance to busulfan was 
uncommon but the side effect of busulfan was severe prolonged myelosuppression 112 as 
well as pubnonary ('Busulfan lung'), hepatic and cardiac fibrosis 113,114 . Later, in 1966, 
hydroxyurea become the drug of choice 115 and was given to patients at a dose of 40mg/kg 
daily which was reduced to 20mg/kg daily when the WBC fell below 20xlO9/1. The dose 
was adjusted to maintain the WBC between 2-5x 109/1. The drug is an cycle-specific 
inhibitor of DNA synthesis which needed to be given indefinitely to patients. The side 
effects of hydroxyurea were not severe and were reversible when the treatment was 
terminated 116 . Commonly patients experienced nausea and other gastrointestinal reactions, 
myelosuppression, skin atrophy and fever 
'13,116 
. Other less commonly used 
chemotherapeutic agents were homoharringtonine, (BHT) which was effective alone and in 
combination with arabinosyl cytosine (Ara-C) or IFN -a, but was associated with serious 
cardiovascular complications 
mlieled in 117 
- Ara-C was given to patients as the drug 
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preferentially inhibited CML progenitors rather that normal myeloid progenitors and was 
given at a dose of 15-30 mg/m2 daily for 34 weeks 116 . 
1.4.1.2 - IFN -a in CMEL 
Before Imatinib, IFN -a was the standard therapy for CML patients who were not 
eligible for stem cell transplantation. The agent was considered to be more effective than 
hydroxyurea which was more effective than busulfun 
118,119,120. At this point IFN _ C, 
treatment alone or in combination with other drugs was considered the most effective 
choice. A randomised trial of IFN -a alone and IFN -a in combination with Ara-C 121 
indicated that patients on the combined treatment had a better cytogenetic response but the 
survival of these patients compared to those on IFN-a alone was not significantly different. 
In older CMIL patients a randomised trial suggested that the survival of patients on IFN -a 
was increased compared with busulphun and hydroxyurea but older patients needed lower 
doses of IFN -a due to high toxicity levels 
122 
. Lower doses of IFN -a (15 MIU per week) 
are just as effective as higher doses of hydroxyurea (5 MITJ/mý per week) 123and in a large 
118,124 
follow up study more than 20-53 % of patients reached the 10 year survival point 
IFN -a causes severe toxicity and patients experience influenza-like symptoms such as 
fever, chills, myalgias, malaise and headaches, as well as nausea, vomiting or diarrhoea 
114,119,125 
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Allogenenic stem cell transplant 
An allogeneic stem cell transplant is the only cure for CML and was considered the 
best form of therapy for CML patients until the development of Imatinib. Allogeneic stem 
cell transplant is limited by the lack of suitable donors in CML and is not appropriate for 
older patients who are unable to tolerate the side effects of the therapy 126 . Age, phase of 
disease at the time of transplantation, transplantation from unrelated donor, female donor 
and male recipient and time of diagnosis to transplantation are risk factors that determine 
the survival rates of patients after an allogeneic transplant. These risk factors are used to 
127 
score the transplant risk for each patient (Table 1.2) 
Table 1.2 - Transplantation risk factors and EBNff scores 127 
Categories Score 
Donor BLA-identical sibling 0 
Unrelated donor I 
Stage CP 0 
AP I 
BC 2 
Age < 20 years 0 
20-40 years I 
> 40 years 2 
Sex match Any other than below 0 
Male recipient/female donor I 
Time from diagnosis to < 12 months 0 
transplantation > 12 months I 
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These scores were used by the International Bone Marrow Transplantation Registry 
(IBMTR) and the European group for blood and marrow transplantation (EBMT) for the 
survival of patients who received a transplant between 1978 and 1997. In this analysis over 
18 years the overall survival was 50% for 3372 patients 128 . Also in a report at the 
American Society of Haematology in 1999 119 50% of patients who were given an 
allogeneic stem cell transplant from a matched related donor in the first CP of disease were 
alive and leukaemia-free after 5 years. The 20 year follow up implies a41% overall 
survival for all patients and a 49% survival for those patients who had a EBMT score 0-1 
127,129 
. 1% of patients still relapse more than 21 years after transplantation but the outcome 
of the patients improved with time between 1980 and 2003 129 as a result of improvements 
in techniques. A major disadvantage of an allogeneic stem cell transplantation is the rate of 
mortality and morbidity which can range from 10 - 70% 
127 
.A randomised trial suggests 
that transplantation after therapy using the best agent available, mostly IFN -a for this 
cohort of patients, results in a better survival than transplants given to untreated patients 130 . 
The development and success of Imatinib has made it the first line of therapy and an 
allogeneic stem cell transplant is the second line of treatment with the exception of high 
disease risk and very low transplantation risk patients who can be offered an allogeneic 
127 
stem cell transplantation as a first line therapy 
There are two major components of an allogeneic stem cell transplant. First is the 
destruction of the cancer cells, bone marrow and immune system using chemotherapeutic 
agents and the second is the immunological component, refeffed to as the graft-versus- 
leukaemic (GvL) effect. A major problem of allogeneic stem cell transplants is that patients 
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relapse and the leukaemia progresses. The concept of using leukocytes from the initial 
donor for therapeutic benefits by causing a GvL effect was initially described in 1979 131 
and in 1990 Kolb et al 132 were the first to show GvL reactions in humans. They reported 
that 3 patients with relapsed CML after an allogeneic stem cell transplant achieved a 
complete cytogenetic response when they were treated with IFN-a and infusions of 'buffy- 
coats' (WBC and platelets) from the original transplant donor. The use of 'buffy-coat' 
infusions from the donor is also called a donor lymphocyte infusion (DLI). Initially the 
evidence suggested that GvL effect was accompanied by the development of graft versus 
host disease (GvHD) 133,134,135,136 
. However later it was reported that the GvL effect can be 
induced independently of GvHD in animals and humans 
136,137,138 
. The elimination of CML 
and the effectiveness of the GvL response can be determined by many factors; antigenic 
differences (GvL effect is enhanced if the donor and recipient are mis-matched), disease 
stage (decreasing GvL effect: CP>AP>BC), T-lymphocyte, dose (higher intensity of T-cell 
depletion results in reduced GvL effect), stem cell dose (CD34+ cells dose > 3xlO6/kg and 
peripheral blood enhances the GvL effect compared to bone marrow transplants) and 
immunosuppression (cyclosporin and methotrexate) 139. GvL effects can be enhanced by 
]]FN_(X 140 and interleukin-2 
141,138. Within 3-12 months patients can achieve a molecular 
remission after a DLI and in unrelated donors the remission can occur sooner 142 
In CP CUL an allogeneic stem cell transplant and Imatinib have proven successful 
in the management of the disease but in BC CMIL allogeneic stem cell transplants 
129 and 
Imatimb 143,144,145,146 have not been as successful. Therefore an approach to overcome this 
problem was to use conventional chemotherapy to convert BC into a second CP in relapsed 
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CML patients. However only 30% of patients entered a second CP 147 but with the 
development of new tyrosine kinase inhibitors which are effective in imatinib-resistant 
patients (refer to section 1.4.3) the approach of generating a second CP followed by a 
148 successful allogeneic stem cell transplant looks promising 
1.4.; - Imatinib Therapy 
Imatinib (CGP571418B, ST1571 or Glivec), a 2-phenylaminopyrimidine derivative, 
is a -small molecule tyrosine kinase inhibitor which targets p2 IOBCR-ABL and c-ABL 
149, 
C_ 
Kit, and platelet - derived growth factor receptor (PDGFR) 
150,151 (Figure 1.6). The drug is 
orally administered, has a half life of 12-14 hours and a single daily dose of > 400mg 
152 
maintains the plasma concentration at 1.46[tM . Imatinib is very well tolerated by 
patients and the most frequent side effects identified by the International Randomised Study 
of IFN versus ST1571 (HUS) were haematological suppression (neutropenia, 
A- - uirombocytopenia, anaernia) followed by raised liver enzymes and peripheral oedema 153. 
Based on this study 400mg daily is the standard dose of Imatinib. Studies have also shown 
in smaller groups of patients that Imatinib may cause bone mineral defects 
154 and heart 
failure 155 . The drug 
is not suitable to take during pregnancy 
156. Imatinib has been shown to 
be more effective then IFN 
157,158 
. Intoler-ances to Imatinib 
include skin inflammation, 
elevated transaminases (indicator of liver damage), fluid retention 
144,145,159 
or transient 
- 160 cytopema, all of which can become reasons for terminating Imatinib therapy. The RUS 
study has shown that up to 87% of patients achieve a complete cytogenefic response and 
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No 
many patients who achieve a molecular response have low or undetectable levels of the 
BCR-ABL transcript Recently, an update of this study has supported the data and showed 
that the rate of a haernatological remission is 98%, a major cytogenetic response is 92%, 
160,161 complete cytogenetic remission is 87% and progression free survival is 84% 
Phosphates 
BCR-ABL 
Substrate 
Tyrosine 
Effector 
Substrate 
Imatinib 
Figure 1.6 - Action of Imatinib. (i) ATP binds to p2 I OBCR-ABL and phosphorylates a 
tyrosine residue of a substrate. (ii) Imatinib binds to p2 I 
OBCR-ABL blocking the ATP binding 
siteand preventing the phosphorylation of substrate. Inhibition of p2 I OBCR-ABL may affect 
162 
substrates downstream of BCR-ABL 
A problem emerging in patients who are treated with Imatinib is firstly the 
reduction in response to therapy and resistance to Imatinib caused by the presence of 
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minimal residual disease 
45,163 
or mutations 
164,165 
. Increasing the dose of Imatinib to 800mg 
. r__ - from 400mg may help to restore response but not all patients with gene mutations will 
respond 
144,145 
. Lahaye et al 
166used sequencing analysis to show that approximately 50% 
of imatinib, resistant patients have mutations. Other mechanisms that have been identified 
as causes of resistance are genomic amplification of BCR-ABL or BCR-ABL independent 
67 168 169 
mechanisms 1, loss of functional p53 , 
SRC activation or chromosomal aberrations 
170,171 
1.4.3 - CML treatment after the Imatinib era: new tyrosine kinase inhibitors 
The success of Imatinib therapy and the attempt to improve prognosis of CML 
patients who are resistant/non-responders to Imatinib has resulted in the development of the 
next generation of tyrosine kinase inhibitors (Table 13 summarises some of the new 
tyrosine kinase inhibitors in clinical trials for CMIL). Nilotinib 172 and Dasatinib 173 have 
been through clinical phase I and H trails. Both drugs are active against all known imatinib 
mutant except the T315I mutation. The results from the phase H trails of Dasatinib which is 
a dual ABL and SRC inhibitor, have meant the drug has been approved for clinical use in 
the US and EU. 
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Table 1.3 - New tyrosine kinase inhibitors in clinical trials for CNM 
In hibitor Company Targets Route of Developmental Ref 
administration status 
Nilotinib Novartis ABL, PDGFR, Oral Phase 11 172,174,175 
(AMN107) KIT, EPHB4 
Dasatinib Bristol- ABL, PDGFR, Oral Approved 176,173 
(BMS- Myers FGR, FYN, 
354825) Squibb HCK, LCK, 
LYN, SRC, 
YES, EPH84 
INNO-406 Innovive ABL, LYN, Oral Phase H 
PDGFR, KIT 
MK-0457 Merck Aurora kinases, Intravenous Phase II 
(VX-680) FLT3, JAK2, 
ABL (including 
T3151) 
AZD0530 AstraZeneca Src family Oral Phase H (solid N/A 
kinases tumors) 
PHA- Nerviano Aurora A. B, C Oral Phase II N/A 
739358 
51 
Chapter 1- Introduction 
The phase HI trails of the drug will provide information about effective dosages. MK-0457 
is drug one of the few drugs in phase 11 which is active against the T3151 mutation. The 
ongoing clinical trials may generate interesting information for novel therapies which alone 
or in combination have the potential to further improve the therapy for CML patients. 
1.4.4 - Monitoring disease 
Monitoring patients is an important aspect of patient survival. Patients on Imatinib 
are monitored on three different levels, haematological, cytogenetic and molecular. 
Haematological. responses are monitored every two weeks until a response is achieved and 
then monitoring take takes place every three months. Cytogenetic monitoring is carried out 
on bone marrow aspirates every 6 months until a complete cytogenetic response is achieved 
and then every 12 months. If a cytogenetic response is achieved then molecular response 
should be monitored, and is commonly carried out by quantitative polymerase chain 
reaction (PCR). Table 1.4 summarises the three different stages of monitoring (recently 
reviewed and updated by 
179). 
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Table 1.4 - Responses and monitoting in CML 
179"80 
Definition Monitoring 
Haematological Complete response: - Every 2 weeks, until complete 
response Platelet count < 450 cells/[LI response, then every 3 months 
WBC < 10 cells/pl 
No imamature granulocytes in blood 
Basophils less that 5% of blood 
count 
No palpable spleen 
Cytogenetic Complete - 0% Ph+ Every 6 months until complete 
response (defined Partial - 1-35% Ph+ response achieved and then 
by the proportion of Minor - 36-65% Ph+ every 12 months 
cells with the Ph Minimum - 66-95% W 
chromosome) None - more that 95% Ph+ 
Molecular response Complete - Transcript not detected Every 3 months. Mutational 
Major - BCR-ABL/control gene analysis is required if a 
ratio < 0.1 molecular response is not 
completely or partially achiev 
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1.4.5 - Prognostic factors 
Many groups have attempted to determine prognostic factors which can be used to 
predict the outcome of CML patients. (Table 1.5 - summarises the various prognostic 
i sco n-ng strategies). The first attempt to determine a prognostic staging system was made by 
Tura et al 181 who used six major clinical features of CML to determine the patients 
outcome. In 1982 Cervantes and Rozman 182 also produced a scoring strategy but this study 
was based on a much smaller number of patients. The most widely used prognostic scoring 
method is the Sokal score 183 which incorporates the prognostic factors used previously 
181,182 but uses ge as an additional factor. The prognostic factors used in the Sokal score are 
not effective discriminators of survival for patients treated with IFN-a but are effective for 
patients treated with busulfan or hydroxyurea 184 . Kantaýian et al 
185 developed a similar 
prognostic scoring method which considers the effect of therapy (intensive chemotherapy) 
on the prognostic score and suggested that patients treated with intensive chemotherapy 
have a better score than untreated patients. Later, with the development of new therapies, 
Kantaýian et al 186 used a slightly modified scoring method which shows that it is an 
extremely important indicator of patients treated with IFN-a who will achieve a response. 
They also show that the same prognostic factors can be used to determine the outcome of 
patients who have been treated with other therapeutic agents such as hydroxurea, busulfan 
and combination chemotherapy. 
Hasford et al 187 (Euro) collected data from a large number of CMI patients from 
several groups and used the Sokal 
183 and Kantaýian 185,186 scoring systems to distinguish 
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patient groups but found neither of these systems to be very effective. They developed a 
new scoring method which estimates the survival of CML patients on IFN-a using age, 
spleen size, platelet count, eosinophil count and basophil count. The Euro scoring method 
is more effective in identifying low risk patients treated with IFN-a in comparison to the 
Sokal score 188 . At the Hammersmith hospital a new prognostic scoring method was 
developed for CMEL patients in late CP who failed IFN-a and were then treated with 
Imatinib. This method uses neutrophil count and cytogenetic response to determine low, 
intermediate and high risk groups 189. Alternatively, CRKL a target of p2 I OBCR-ABL which is 
only phosphorylated in CML cells has been used as an indicator of imatinib response which 
is predictive of a molecular response 190"9. Further developments in therapy may result in 
ftu-ther changes in prognostic factors. 
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Table 1.5 - Summary of prognostic scores 
Studies 
N Poor prognosis Prognostic Score 
Reference Institute I 
Tura et al Italian 408 1) Splenomegaly (> 15 cm) Group I-0 or I factor 
(1981)181 Cooperative 2) Hepatomegaly (> 6 cm) (Best prognosis) 
CML study 3) Thrombocytopenia Group 11 -2 or 3 
group (< I 50x I 09AL) or thrombocytosis factors 
(> 500 x 109/L) (Intermediate 
4) High leukocyte count prognosis) 
(>IOOX109) Group III - 4,5 or 6 
5) Peripheral blood non- factors 
granulated (blast) precursors (Worst prognosis) 
N%) 
6) Peripheral blood granulated 
precursors (>20%) 
Cervantes 121 Splenomegaly Stage I-0 or I factor 
and Hepatomegaly (low risk) 
Rozman Erythroid precursors in blood Stage H-2 factors 
(1982) 182 Marrow blasts > 5% (intermediate risk) 
Stage III -3 or 4 
factors 
(high risk) 
Sokaletal Italian 813 1) Age > 45 years Relative risk is 
(1984)183 Cooperative 2) Platelet count (> 700 x 109AL) generated by a 
CMIL study 3) Spleen (>6 cm) formula: - 
group 4) Blasts in blood (> 1%) 
5) WBC (> 100 x 10 9 /L) Low risk < 0.8 
High risk > 1.2 
Kantaajian MD Anderson 303 1) Age > 60 By a formula: - 
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et al (1985) Centre 2) Black race 
185 
3) Marrow basophils (> 3%) Relative risk < 0.8 
4) Blood basophils (>7%) Intermediate risk 0.8 - 
5) Spleen> I Ocm. 1.39 
High risk > 1.4 
Kantadian 406 CP: 
et al (1995) 1) Age > 60 
186 
2) Peripheral blasts (>3%)/bone Stage I-0 or I 
maroow blasts (>5%) (Low risk) 
3) Peripheral basophils Stage II -2 
(>7%)/marrow basophils (>3%) (intermediate risk) 
4) Platelet (>700 x 109/L) Stage III -3 or more 
5) Splenomegaly (>I 0 cm) (high risk) 
AP: 
1) Peripheral blasts (>15%) 
2) Peripheral basophils (>20%) Stage 4- any of the 
3) Peripheral basophils and prognostic factors in 
promyelocytes (>30%) AP category 
4) Platelets (<100 x 109/1, 
unrelated to therapy) 
5) Cytogenetic clonal evolution 
Hasford et Writing 1573 Age >50 By formula: - 
al (1998) 
187 
committee for 1) Splenomegaly 
(Euro) the 2) Blast count Low risk < 780 
collaborative 3) Platelet count Intermediate risk >780 
CML prognostic 4) Eosinophil count and < 1480 
Factors project 5) Basophil count High risk >1480 
group 
Marin et al Hammermith 145 1) Neutrophils (<I 09 AL) Low risk -0 factors 
(2003)189 Hospital 2) Ph( ý: 65%) Intermediate risk -I 
factors 
High risk -2 factors 
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1.5 CML - BioloErv and Cell sip-naRinp- 
Normal ABL lacks transforming potential and BCR has the ability to activate ABL 
tyrosine kinase. The main characteristic features of p2l OBCR-ABL in comparison with normal 
A113L is the deregulated tyrosine kinase activity 192 and change in subcellular location. As a r-x-" 
consequence there is abnormal signalling in CML resulting in deregulated cellular 
proliferation 193 and decreased adherence of leukaemic cells to the bone morrow stroma 37 . 
The effect p2 I OBCR-ABL has on apoptosis is not entirely clear-cut 
194,195. 
1.5.1 - Protein complexes in CML 
Protein complexes have a role in all systems and are essential for the activation of 
the many signalling cascades in many aspects of biology. Two major forms of complexes 
can be formed, homo- and heterocomplexes. Homocomplexes are composed of aggregates 
of the same protein and are usually optimised and permanent. Heterocomplexes consist of 
different proteins and can also be optimised and pennanent but they can also be disrupted 
by external factors and the environment '96. Protein-protein interactions can occur by 
surface receptors, alpha helices of two proteins can form a coiled-coil association or 
proteins can associate by the ridges on the surfaces of the two proteins which form tight but 
specific complexes 197. Proteins capable of forming complexes can express complementary 
domains on the surface which act like 'Velcro' to bind them together. The most common 
types of these domains are SH2 and SH3 domains 
198. The SH2 domain has approximately 
100 amino acids with binding affinity to phosphorylated proteins and has deep pockets 
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consisting of a beta-helical structure sandwiched between two alpha-helices 1"'199. The 
phosphorylated tyrosine residues fit into the deep pockets of SH2 domains which are 
structurally similar between different proteins in this class with minor changes to certain 
residues improving the specificity of some associations 199. For example the SH2 of Src has 
an amino acid residue sequence of pYEEI but the SH2 domain of P85 P13K recognises the 
sequence p)(A4XM 200 . Alternatively, the SH3 domains on proteins recognise polypeptides 
with proline rich regions on partner proteins 
201,202 
. There are no major changes to the 
structure of the SH3 domains on different proteins for example the SH3 domain of Fyn 
binds equally well to the proline rich region of SOS and p85 of P13K. This implies that 
SH3 domains do not bind to other proteins with high specificity but as with the SH2 
domains there are single amino acid changes which may increase the specificity of the 
protein complex. The concentration of proteins in the cell will also influence which protein 
complexes are formed 199. Many proteins contain both the SH2 and SH3 domains together 
and other domains such as the Pleckstrin homology domains which bind to proteins with 
phosphoinosifide ligands '98. Protein-protein interactions give rise to cellular responses 
leading to signals being conveyed through the cytoplasm which affect cellular functions 
which are important in understanding the biology of normal and oncogenic cells. 
Interactions of p2 I OBCR-ABL with protein complexes have been demonstrated in Ph' 
or BCR-ABL transduced cell lines, which may not represent p2 
I dBCR-ABL Si gnalling in Cp 
CML in vivo. Many CML cell lines are transfonned and represent a BC disease stage. 
Ideally, p2 I OBCR-ABL function should be analysed in primary CML haemopoietic material 
which would give a more accurate representation of the disease. However this approach has 
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been limited by a technical difficultly due to the presence of a proteolytic activity present in 
myeloid cells which rapidly and permanently degrades p 145 
ABL 
and p2 I OBCR-ABL upon lysis, 
46,203 thus compromising investigation of complex fonnation by immunoprecipitation (EP) 
and. western blot. Maxwell et al 
204 
and Guo et al 
205 
noted that p2 I OBCR-ABL protein 
detection in CP patients by a protein tyrosine kinase assay was prevented by the presence of 
a large number of mature cells which had high concentrations of degradative enzymes 
whiCh destroyed p2 I OBCR-ABLduring IySiS. 
1.5.1.2 - p2 
OBCR-ABL associated protein complexes 
Abnormal tyrosine kinase activity and cytoplasmic localisation allows p210 
BCR-ABL 
to interact with many cytoskeletal. and other proteins potentially resulting in an abnormal 
and complex signalling cascade involving a number of pathways. 
We have an interest in the association of p2 IOBCR-ABL and the adaptor proteins 
CRKL, CBL and GRB2. There is an extensive literature about these interactions in cell 
lines and transduced cells (summarised in Table 1.6 and Figure 1.7). 
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Table 1.6 - p2 
1OBCR-ABL associated protein complexes. Protein complexes of p2 I ()BCR-ABL 
with adaptor and focal adhesion proteins in Ph+ and transduced cell lines - 
Co-immunoprecipitating proteins CeU type used to demonstrate Reference 
the co-immunoprecipitation 
P210 GRB2 Meg-01 76 
Transduced rat fibroblast 
206 
32D. p210 
207 
Ba/F3. p2l0 
208 
GAB2 Ba/F3. p2l0 
208 
rasGAP 32D. p210 
209 
SHC K562 210 
Mo7. p2lO 
211 
32D. p210 
207 
CBL Ba/F3. p2lO 
212,213 
32D. p210, K562 
214 
CRKL KT-1 215 
COS-I. p210 
216 
32D. p210 
217 
P13K (p85) Ba/F3. p2lO 
208 
GRB2 CBL Ba/F3. p2lO 
219 
U9371F 219 
SHC K562 206 
32D. p210 
207 
Transduced rat fibroblast 
219 
SOS U9371F 220 
Transduced rat fibroblast 
206 
P13K (p85) Ba/F3. p2lO 
218 
CBL P13K (p85) K5629 BV173, BaF3/p2lO ýMg 
CRYCL K562,32D. p210 
213,214 
Ba/F3. p210, K562 
213 
Paxillin Ba/F3. p2 10, K562 
221 
Talin Ba/F3. P2l0, K562 
221 
CRKL K562 222 
GRB2 Ba/F3. p2lO 
223 
T-Cells 224 
CRKL P13K (p85) Ba/F3. p2lO 
213 
Paxillin K562,32D. p2lO 
225,226 
C3G Ba/F3. p2lO 
223 
SOS K562 216 
CBL Primay CML BC, AML, ALL 227 
SHC P13K (p85) Ba/F3. p2lO 
228 
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Figure 1.7 - Protein complexes in CML. Protein complexes have been shown in 
W or 
transduced cell lines cells Adaptor proteins G"2, CBL, SHC and CFXL bind p2 10 
BCR-ABL 
in CML cell lines linking further downstream signalling targets to p2 
IOBCR-ABL resulting in 
chariges in cellular proliferation, apoptosis and adhesion (reproduced from Marley and 
Gordon, 2005 with pennission) "'. 
L3-R 
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1.5.1.3 - p2joBCR-ABL and CRKL 
CT10 Regulator of Kinase-Like ý(CRKL) was first cloned by ten Hoeve in 1993 
230. 
They found an SH2 domain, termed CRK-like gene, CRKL, on chromosome 22. The gene 
231 
encodes for a 39 kDa protein that is most abundantly found in haemopoietic tissue 
CRKL has an SH2 domain and two SH3 domains (Figure 1.8 A). Many independent 
groups reported that CRKL is a major tyrosine phosphorylated protein in Ph+ K562 cells 
and COS-1 cells transfected with p2 I OBCR-ABL' 216 peripheral blood ftom CML and Ph+ 
ALL patients 
232, CML neutrophils, 
232,233 
and CNffi platelets 234. Ph- cell lines and primary 
216,232,233, n4,235. cR 
cells lack phosphoxylated CRK-L but do express CRKL protein ML 
complexes with p2l OBCR-ABL in W cell lines 
215,216,217 and for the first time we have shown 
CRKL and p2 I OBCR-ABL complex in primary CD34+ cells using our high pH lysis assay 
46 
by ýco-IP. CRKL is a major target of p2 IOBCR-ABL and 
levels of phosphorylation can be used 
as an indirect measure of p2 I OBCR-ABL levels and response to therapy. This can be analysed 
by western bloting 190. However due to the large cell numbers required a fluorescence 
activated cell sorting (FACS) assay was developed and is now being used CML research 
191 
The SH3 domain of CRKL mediates the interaction with proline rich regions of 
p210 
BCR-AI3L 
and p145 
ABL 
. However, the 
direct interaction with the proline rich region on 
p145 
A13L 
and p2 lOBCR-ABL is not required for CRKL phosphorylation implying that CRKL 
may carry out its fu nctions via indirect interactions with p2 
IOBCR-ABL and other signalling 
proteins such as CBL or GRB2 
217 
. Mutations in the tyrosine 
207 of the SH3 domain 
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prevent phosphorylation of CRYL in Ph+ cells implying it mediates phosphorylation of 
CRKL 236 but loss of phosphorylation due to a mutation in tyrosine 207 can act as a 
negative regulator by increasing complex formation of the SH2 domain resulting in 
increased CRKL function 237 
- The SH3 domain of CRKL can also bind p145 
ABL and Son of 
I Sevenless (SOS) 216 , 231 and C3G (only in the presence of p2 IOBCR-ABL) . C3G is a guanine 
nucleotide exchange factor for Rap- I which activates RAS signalling and enhances cell 
223 238 migration and can affect cytoskeletal structure . Mutation in the tyrosine 207 has no 
effect on the signalling targets, SOS and C3G suggesting these interactions are independent 
of CRKL phosphorylation 
236. Over expression of CRKL in P190BCR-ABL transgenic mice 
enhances the development of lymphoblastic leukaemia 239 . The cytoplasmic tail of CD34 
has . been shown to complex with the SH3 domain of CRKL 240 as demonstrated by co-IP in 
KGla cells. CD34. failed to complex with ABL, C3G, CBL, SOS or Dock180 which 
implies that the complex association between CD34 and CRKL is very specific and that 
CRKL may be involved in haemopoiesis due to its involvement with CD34241. Interaction 
of CRKL and CD34 implies that CRKL has a role in cell adhesion which is fin-ther 
supported by studies using fibronectin as an adhesive medium. Thus, Uemura et al 242 
suggest that expression of CRKL increases adhesion to fibronectin and the expression. of 
full length CRKL affects cell morphology of Ba/F3 cells on fibronectin-coated plates. 
Adhesion to fibronectin. also regulates the kinase activity and subcellular localisation of 
p145 ABL as binding to fibronectin results in the recruitment of p145 ABL to the focal contacts 
of the fibroblasts 243 and adhesion to fibronectin is impaired when the N terminal SH3 
domain of CRKL is mutated, further impling that the CRKL and p145 
ABL /p2 I ()BCR-ABL 
association can affect adhesion of cells to fibronectin. Other cytoskeletal proteins involved 
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in intregrin signalling and cytokeletal organisation are paxillin 
225 
9 p13 OCAS 
244, Hefl 245. 
The studies to date imply that CRKL phosphorylation is important in CMI and CRKL 
plays a major role in adhesion in normal and, in particular in leukaemic cells (Figure 1.8 
B). 
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Figure 1.8 - Structure and protein interactions of CRKL. (A) CRKL has three SH 
domains (B) CRKL binds directly to p2 IOBCR-ABL via its SH3 domain, binds PUK and focal 
adhesion molecule, paxillin and also RAS activator SOS via its second SH3 domain and 
CBL can complex via its SH2 domain activating P13K signalling. 
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1.5.1.4 - p2joBCR-ABL and CBL 
Casitas B-Imeage Lmphoma (CBL) is a proto-oncogene which has three major 
domains, PTB - phosphotyrosine binding domain, RF - ring finger domain, PRO - Proline 
rich region, which encodes for a protein of 120 kDa (Figure 1.9 A). The nuclear and 
cytoplasmic distribution of CBL is not affected by CBL phosphorylation M and the protein 
247 is ubiquitously expressed but the highest expression is in haemopoietic cells 
CBL is tyrosine phosphorylated in Ph+ CMIL, AML, Ph- T and B -ALL 
227,246 but 
213 
over expression in the cytoplasm does not have the potential to induce transformation 
However, mutations that result in constitutive phosphorylation of CBL can activate its 
transforming potential. Mushinski et al 248 demonstrated that if 60% of CBL is deleted 
making the protein structurally similar to v-CBL it can transform B-lymphoid cells and 
fibroblasts. v-CBL is a natural viral oncoprotein of the CAS NS- I retrovirus; that induces B- 
cell lymphoma and myeloid leukaemia in mice 
(222, Reviewed in 249) 
-. 
An internal deletion in 
the amino acid in position 17 in CBL also causes a mutation with transforming potential 246. 
De Jong et al 222 predicted that constitutive activation of CBL by a mutation or oncogenic 
tyrosine kinase such as p2l OBCR-ABL contributes to oncogenesis. p2 1013CR-ABL is able to 
cause a CMIL-like disease in mice lacking CBL suggesting that CBL is not required for 
induction of leukaemia by p2l OBCR-ABL 
250. 
The complexes of CBL are summarised in Figure 1.9B. p2l OBCR-ABL 
is complexed 
with CBL 
213,246 
via the SH2 domain on ABL but the interaction is dependent on the 
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phosphorylation of CBL. Deletion of the SH2 domain does not alter this interaction 
suggesting that there is another mechanism of interaction between p2 IOBCR-ABL and CBL. 
CRKL (see above - section 1.5.1.3) is another protein that links p2l 
OBCR-ABL with CBL 
indirectly which has been shown to complex with p2 1013CR-ABL via its SH3 domain and CBL 
via its SH2 domain 
213,214,215,216,217 
. GRB2 is an adaptor protein that can indirectly associate 
p210 
BCR-ABL 
with CBL, but this association decreases as CBL becomes phosphorylated 
224,251,252 
. The C terminal SH3 domain is sufficient for the interaction between GRB2 and 
CBL as the lack of N terminal SH3 domains does not inhibit the interaction. However the N 
and C terminals can bind proline rich regions of CBL equally Well 218. p85, the regulatory 
subunit of P13K complexes with the SH2 domain of CBL in normal quiescent cells and the 
association is increased by 14 fold in p2 10 BCR-ABL transformed cells. The GRB2 SH3 
domain complexes with p85 P13K while the GRB2 SH2 complexes with tyrosine, 177. of 
p210 BCR-ABL . The GRB2 - 
CBL complex is not required for interaction of CBL and 
BCR-ABL 218 
p210 but is an alternative method of interaction . CBL via its many 
interactions 
causes activation of the P13K and RAS signalling cascades. P13K catalyses the generation 
of a phosphoinositide product that regulates many cellular functions including mitogenesis, 
cell survival, n-figration and vesicular membrane traffic "'. The RAS pathway is involved 
in cell proliferation and cell cycle 254. CBL is involved in ubiquitination in normal cells 
255,256. Miyoshi-Akiyana et al 
257 
reported that overexpression of CBL and ABL in 293T 
cells causes phosphorylation. of CBL. In these cells CBL, Nck (an SH2/SH3 protein 
involved in actin association 258 ) and ABL were shown to form protein complexes. They 
also reported that Nck and ABL may compete for the SH2 domain of CBL. 
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Overall, the literature suggests that CBL is involved in pathways of ubiquination , 
RAS and P13K signalling and can complex with normal p145 ABL and oncogenic p2 I OBCR- 
ABL (Figure 1.8 B). 
-A] 
[B 
SH2 ABL P 
CRKL 
SOS SH2 
SH3 G Grb2 rb2 
5 
SH3 
T- 
I 
N-SH2 SH3 C-sw i 
P85 
PI3K 
Pilo 
L 
Interacton is reduced as CBL becomes 
phosphorylated 
Figure 1.9 - Structure and protein interactions of CBL - (A) Domains of 
CBL are: PTB 
- phosphotyrosine binding domain, RF - ring 
finger domain, PRO - Proline rich region. 
(B) CBL interacts with the p2 OBCR-ABL SH2 domain directly and indirectly via CRKL of 
G"2 (in its unphosphorylated form). The p2 I OBCR-ABL and CBL interaction activates the 
P13K pathway. 
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1.5.1.5 - p2loBCR-ABL and GRB2 
Growth Receptor Binding protein 2 (GRB2) is a SH2/SH3 (Figure IOA and B) 
adaptor protein of 27 kDa that acts as a direct molecular link between tyrosine kinase 
receptors and the RAS pathway. The GRB2 SH2 domain binds to phosphorylated tyrosine 
residue 177 on BCR (normal BCR and oncogeneic p2JOBCR-ABL) in vivo and in vitro 
76,206,200,259 
. Other tyrosine residues on BCR were analysed 
for their ability to bind GRB2 
butlailed to demonstrate GRB2 association with p2 I OBCR-ABL 
200. Pendergast et al 
76 
suggested that normal ABL and BCR are incapable of forming complexes with GRB2 in 
COS- I cells but Ma et a, 77 in the same cell line has shown that ABL, BCR and GRB2 form 
a complex as demonstrated by co-IP which implies more work is required to finther analyse 
the complexes with normal ABL and BCR. In CMEL a complex between p2 IOBCR-ABL and 
GRB2 recruits Son Of Sevenless (SOS) which causes activation of RAS signalling. 
p185 BCR-ABL which lacks tyrosine 177 was shown to transform fibroblasts but not 
haemopoietic cells in culture which implies that RAS activation maybe be an important 
S260. pathway involved in the transformation of haemopoietic cell 
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Figure 1.10 - Structure and protein interactions of GRB2 - (A) SH domains of GRB2 
(B) GRB2 binds to p2 I OBCR-ABL via the tyrosine 177 residue on p1 60BCR . Association 
between GRB2 and SOS activates the RAS signalling pathway. Interactions with SHC and 
CBL can activate the P13K signalling pathway. SHC can act as a intermediate indirectly 
linking G"2 with p2 I OBCR-ABL. 
GRB2 forms complexes with Src Homologous and Collagen gene (SHC), which is 
an adaptor protein and has three distinct isofomis, of 46,52 and 66 kDa, of which p52 
seems to be the predominant form. p52 and p46 isoforms are tyrosine phosphorylated in 
K562 cells. It has been shown that SHC is phosphorylated in CMIL CD34+ cells 261 and 
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AML CD34+ cells 262,263 implying that SHC phosphorylation is a feature of leukaemic cells 
rather than nonnal cells. 
However this finding was challenged by Yang et al 264 who suggested that SHC 
phosphorylation is associated with cell maturation rather than malignant transformation. 
The p46 isoform of SHC is the only isoform that complexes with p2 IOBCR-ABL and GRB2 in 
Cm ,L 206 suggesting that SHC indirectly links p2 IOBCR-ABL and GRB2 which activates RAS 
signalling. Studies have shown that SHC also activates P13K signalling by forming a 
complex with P13K in CNI]L 265. SH2-containing phosphatidylinositol 3,4,5 - trisphosphate 
5-phosphatase (SHIP2) 210,266 and Gads, a novel protein similar to GRB2 
267 
, are tyrosine 
phosphorylated and complex with SHC in CMIL, which can activate RAS and P13K 
simalling. 
The association of GRB2 and p2 IOBCR-ABL either directly or indirectly via SHC, can 
activate RAS and P13K signalling (Figure 1.10). Targeting the GRB2 - SOS complex for 
therapy has been suggested as preliminary studies have shown that targeting this complex 
reduces proliferation 
268,269 
. 
71 
Chapter 1- Introduction 
1.5.2 - CeH signalling abnormalities in CML 
1.5.2.1 - The RAS Pathway in CMEL 
As mentioned above G"2, can bind directly to p2 IOBCR-ABL or indirectly via, 
CRKL and SHC resulting in the recruitment of SOS. This stimulates the conversion of 
RAS, which is a key regulator of cell growth, from the inactive GDP form to the active 
f rM 
206 GTP 0. Activated RAS binds to RAF-I where it is tyrosine phosphorylated at the 
plasma membrane 270 . Activation of RAF-I causes downstream signalling of the mitogen- 
activated protein kinase (NIAPK). Activation of this RAS-RAF-MEK-ERK pathway can 
influence the tyrosine kinase activity of p2 I OBCR-ABL 
193. Other modulators of MAPK are, 
Rsk (also referred to as MAPKAP kinases) and stress activated protein kinases (SAPK, 
also referred to as Jun NH kinase or JNK), involved in cell cycle and apoptosis 271,272 . The 
RAS and MAPK pathways have been shown to regulate gene transcription by activating the 
nuclear transcription factors Elk- 1 273 . The RAS pathway activates cycle regulators such as 
cyclin DI, p2lwAF""Pl, p27 Kipl and cdc25A, and transcription factors such as c-Myc. RAS 
activation affects cell cycle by inducing expression of cyclin D I, repressing expression of 
p27K'Pl, and inducing expression of c-myc and cyclin dependent kinase inhibitor, 
p2 IWAF/cipl 
254 (Figure 1.11). It has been suggested that p210 
BCR-ABL 
may negatively 
regulate the MAPK pathway as studies using IFN-a have shown that it activates the MAPK 
274,275 
pathway 
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Figure 1.11 - Diagram of RAS signafflng - Activation of GRB2 via p2 I 
OBCR-ABL, CBL, 
CRKL and SHC activate SOS. Activated SOS causes conversation of RAS to the active 
GTP form at the plasma membrane and then activates the RAS-RAF-MEK-ERK pathway 
thereby affecting gene transcription. 
1.5.2.2 - The P13K Pathway in CML 
P13K is a heterodimer that is made up of two subunits, a 110 kDa subunit that has a 
catalytic role and an 85 kDa regulatory subunit. The p85 subunit contains SH2 and SH3 
domains which interact with adaptor proteins that activate the pI 10 subunit resulting in the 
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activation of the P13K enzyme and affecting cellular proliferation and apoptosis (reviewed 
by Kharas, et al 276) (Figure 1.12). In CML the P13K pathway is activated by complex 
formation between p2 I OBCR-ABL and CBL or CRKL directly or indirectly via GRB2. A 
major downstream target of P13K is AKT 
277,278,279 
which phosphorylates nuclear factor IkB 
resulting in the release of NFkB which translocates to the nucleus where it induces 
expression of genes involved in cell survival 277. 
-\ .0............ . Membrane P13K85 
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Figure 1.12 Diagram of P13K signaffing - Direct or indirect activation of CBL activates 
P13K resulting in phosphorylation of AKT. AKT can affect two different cellular processes, 
cell ý survival is affected by activation of 
IkB which activates NF-kB which translocates to 
the nucleus and apoptosis is affected by activation of BAD and BCL-XL. 
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AKT can also phosphorylate pro-apoptotic factor BAD, increasing levels of BCL-xL 
and reducing apoptosis. Levels of BAD are higher in CMIL but after complete 
dephosphorylation (inactivation) of BAD a fraction of cells still survives which suggests 
that. there are BAD-independent survival pathways 280. In CMI, P13K is linked to 
proliferative defects via cyclin dependent inhibitors 281 and enhanced cell survival 280 but 
adhesive defects may not be involved 
282 
. 
1.5.2.3 - The JAK-STAT pathway in CNM 
Cytokines and growth factors activate Janus kinase (Jak) protein tyrosine kinases 
which results in the phosphorylation of one or more of the signal transducer and activator 
of transcription (STAT) transcription factors that translocate to the nucleus and bind to 
specific DNA sequences regulating cell viability and proliferation 283 . It has been suggested 
that in CMEL p2 I OBCR-ABL co-immunoprecipitates and phosphorylates the common Bc chain 
of E, L-3 and GM-CSF receptors resulting in the activation of Jak2 284 which can affect the 
proliferation and differentiation of cells. Interestingly work in our laboratory has 
demonstrated abnormal responses to Bc cytokine signalling in CMEL 11,285 . Normal 
haernopoietic cells require cytokines for growth but the expression of p2 IOCR-ABL results in 
cell growth and differentiation in a cytokine-independent manner286. Others have suggested 
that p2 10 
BCR-ABL 
-positive cells can activate STAT5 directly via the SH2 and SH3 domains 
on p210 
BCR-ABL 287 
and can contribute to the malignant transformation in CNI[L288but in 
mice STAT5 which inhibits apoptosis by activation and upregulation of BCL-xL is not 
281,289,290 
required for leukaemia induction 
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1.5.2.4 - Growth factor independence and inhibition of apoptosis induced by p2jOBCR- 
ABL 
Expression of p2 1OBCR-ABL in growth factor dependent cell lines eliminates 
apoptosis caused by growth factor withdrawal286,29' and these cells exhibit increased 
resi -stance to apoptosis induced by DNA-damaging agents 
194,292 
. It has been proposed that 
resistance to apoptosis even after growth factor withdrawal and exposure to high doses of 
ionising radiation, may potentially relate to the in vivo situation 275 . However in primary 
cells the results are more controversial, as Bedi et al 194 showed that CMIL cells have more 
resistance to apoptosis compared to normal cells, in contrast Amos et al '95found that 
growth factor withdrawal and ionising radiation affect apoptosis in normal and CML 
progenitors equally. 
Subcellular localisation of p2 IOBCR-ABL may play a role in inducing apoptosiS 
293. AS 
treating cells with imatinib causes the p2 IOBCR-ABL protein to translocate to the nucleus and 
when cells are also treated with leptomycin B, a blocker of nuclear export which causes the 
BCR ABL 293,294 
p210 - protein to remain in the nucleus, rapid apoptosis was observed 
1.5.2.5 - Adhesive abnormalities to bone marrow stroma in CNM 
Normal haemopoietic cells bind to bone marrow stroma via fibronectin/p I -integrin 
receptors and may inhibit progenitor cell proliferation 
295 
. Gordon et a137 were the first to 
demonstrate that CML progenitor cells exhibit defective adhesion to bone marrow stroma. 
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This implies that CMI progenitor cells are not affected by adhesion-related regulatory 
signals unlike normal progenitor cells and may explain the abnormal appearance of 
immature blasts in the peripheral blood of CML patients. It has been proposed that the 01- 
integrin on the surface of CML progenitor cells is defective and therefore the cells are 
unable to adhere to the bone marrow stroma correctly 296. However it is unclear what the 
exact mechanism for defective integrin function is 
297,298 but it is Proposed that as p2 I OBCR- 
ABL interacts with integrins, it may interfere with normal signal transduction 24". Signalling 
proteins such as CRYL 
242, FAK, pI 30CAS 213 , Hefl 
2" 
and PaXillin 225,300 which are 
involved in cell adhesion also complex with p2 IOBCR-ABL . Adhesive defects in CML are 
independent of tyrosine phosphorylation and inhibiting the tyrosine kinase of p2l oBCR-ABL 
may not counteract the adhesive defects in CM[L 301 but IFN-a does reverse the defective 
acffiesion phenot)Te in CMEL 
302. 
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CHAPTER 2- MATERL4, LS AND METHODS 
2.1: CeRs 
2.1.1 - CeR Unes 
Cells of the K562, KBM5 (kindly provided by Professor Beran, M. D Anderson 
centre, Houston) BAF. p210 1, BV173 t, HL60 1, KCL-22 * and KYO-I * cell lines (t cell 
lines were maintained in our laboratory, * kindly provided by Professor Junia Melo, 
Imperial College, Faculty of Medicine, UK) were maintained in RPMI 1640 medium 
(GEBCO Brl, Paisley, UK), supplemented with 10% fetal calf serum (FCS) (Biowest, 
Nuailld, France), and 1% penicillin/streptomycin (GIBCO Brl) and incubated at 37'C in 
humidified 5% C02- 
2.1.2 - Primary ceUs 
Chronic phase (CP) and blast crisis (BC) chronic myeloid leukaemia peripheral 
blood (CML-PB) samples and non-leukaemic samples (referred to as normal) were 
obtained from untreated patients at the outpatient haematology clinic of the Hammersmith 
Ho9pital. 
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Leucapheresed CML blood samples were a source of CN11L cells in larger quanfities 
obtained from the stem cell laboratory of the Hammersmith Hospital. Leukapheresis is 
routinely performed on CML patients who present to the haernatology clinic with high 
WBC counts. This procedure requires blood to be extracted from one arm into a 
leukapheresis machine. The machine then sorts the blood into different components based 
on the density and weight of cells. WBC are removed from the blood and then returned to 
the patient via a needle in the other arm. This process can take up to 3-4 hours. 
All samples were obtained with informed consent and Research Ethics Committee 
approval. 
2.1.3 - Imatinib Treatment 
BV 173, K562 and CD34+ CML cells were incubated with I gM Imatinib (kindly 
provided by Professor Junia Melo, Imperial College, Faculty of Medicine, UK) in alpha 
MEEM medium supplemented with 15% FCS for up to 24 hours. Treated and untreated cells 
were used for immunofluorescence, IN and westem blot. 
2.1.4 - Cell viability 
Untreated and treated cells were added to an equal amount of 4% trypan blue 
(Northumbria Biologicals, UK). Trypan blue positive cells were counted as dead while 
trypan blue negative cells were counted as viable and the percentage cell death calculated. 
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2.2: Primary cell preparations 
2.2.1 - Mononuclear ceH (MNQ separation 
All blood samplýes were diluted in Hanks' buffered salt solution (HBSS) (GIBCO 
Brl). The sample was transferred on to the surface of 15ml Lymphoprep (Axis-Shield, Oslo, 
Norway) and centrifuged for 30 minutes at 1800 rpm with the brake off. MNCs were 
harvested from the interface and washed twice in HBSS by centrifuging for 5 minutes at 
1800 rpm with the brake on. Resuspended ceffs were then counted using a haemocytometer 
after dilution in 3% glacial acetic acid (Sigina, Poole, UK) to lyse any red blood cells 
present, to obtain the cells concentration in the suspension. 
2.2.2 - Purification of CD34+ ceUs 
CD34+ cells were labeled using MiniMacs technology according to the 
manufacturers' instructions (Miltenyi Biotech, Camberley, UK). Cells were resuspended in 
350gl of MACS buffer (phosphate buffered saline (PBS) (GIBCO Brl), 0.5% bovine serum 
albumin (BSA) (PAA laboratories, Pasching, Austria) and 2mM EDTA (Sigma)) per 108 
cells with 100gl FcR blocking reagent and 50gl of microbeads conjugated to monoclonal 
anti-CD34 antibody (QBEND 10) and incubated for 15 minutes at 4'C. The ceRs were then 
washed and resuspended in 2ml of MACS buffer per 108 cefls. 
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Labelled cells were then passed through a pre-washed MS MiniMacs column 
mounted on a magnet. Following this, the column is washed 4 times with Macs buffer, 
removed from the magnet and the cells eluted with 2n-A MACS buffer. CD34+ cells were 
counted using a haernocytorneter. 
2.3: Identification and inhibition of iD210 
BCR-ABL /AIBL specific degradative activity 
(ADA) 
2.3.1 - Reagents and Antibodies 
Monoclonal mouse anti-ABL and anti-actin was supplied by Santa Cruz 
(California, USA) and HRP-conjugated rabbit anti-mouse antibodies were supplied by 
DAKO (Glostrup, Demnark). ZVAD, lactacystin and chloroquine (were supplied by 
Sigma) which targets the caspase cascade, proteasomes and lysosomes respectively. 
2.3.2 - Conventional cell lysis 
Cells were washed twice in Ca ++/Mg ++ -free PBS. The cell pellet was manually 
dispersed and then vigorously resuspended in 200 gl ice-cold standard lysis buffer (1% 
Triton X-100 (Sigma, Poole, UK), 150 mM NaCl, I MM MgC6 10% glycerol (Invitrogen, 
Paisley, UK), 20 mM Tris @ pH8 and a proprietary protease inhibitor cocktail 
(CompleteTm tablets, Roche, Mannheim, Germany)) per 107 cells. The lysate was incubated 
on ice for 10 min then the cells were sheared by rapid expulsion through a 21 g needle. The 
81 
Chapter 2- Materials and methods 
crude lysate was centrifuged at 40C for 3 min at 13,000 rpm. For western blotting, the 
lysates were mixed with an equal volume of loading buffer (2.3% sodium dodecyl sulphate 
(SDS), 10 mM DL-dithiothreitol (DTT), 0.01% bromophenol blue (all Sigma, Paisley, 
UK), 10% glycerol. and 62.5 mM Tris @ pH6.8) and boiled for 5 min at 10- For 
immunoprecipitation cells were lysed as described above and the unboiled, cleared lysate 
was used immediately for immunoprecipitation without addition of loading buffer (refer to 
section 2.5). 
2.3.3 - High pH lysis to abrogate ADA. 
Cells were washed and pelleted as described in 2.3.2. For p2 I 
OPCR-ABL 
quantification by western blot, cells were lysed in 200 ýLl per 107 cells of high pH lysis 
buffer (I % Triton X- 100 (Sigma), 150 mM NaCl, I IIIM MgC12! p 10% glycerol (Invitrogen) 
ý 20 mM Tris 
@ pH8 and a proprietary protease hiMbitor cocktail (CornpleWý tablets) as 
follows: Immediately before lysis, 1.25% (2.5 gl per 107 cells) of 10 M NaOH was added 
to the lysis buffer. The high pH lysis buffer was added immediately to the cell pellet which 
was vigorously disPersed. After 10 min incubation on ice, the lysate was sheared and 
centrifuged at 13,000 rpm for 3 min. The supernatant was mixed with an equal volume of 
loading buffer and boiled for 5 min at IOOT for western blotting. For immunoprecipitation 
cells were lysed as described and the unboiled, cleared lysate was used immediately for 
immunoPrecipitatiOn without addition of loading buffer (refer to section 2.4). 
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2.3.4 - Assay of ADA. 
To demonstrate anti-p2 IOBCR-ABL degradative activity in MNC, p2 IOBCR-A. 
BL_ 
positive K562 cells were was used as a reporter. For lysate mixing experiments, MNC were 
mixed in varying ratios with K562 cells and co-lysed at 200gl lysis buffer per 107 cells for 
10 min on ice as described in 2.3.2. The cleared lysate was added to equal volumes of 
loading buffer, boiled for 5 min and then western blotted to detect intact p2 IOBCR-ABL. 
2.3.5 - Western Blotting 
To assay the ADA, protein lysates from cell mixtures and coloured. molecular 
weight markers (BioRad, Hemel Hempstead, UK) were run in parallel on 6.5% SDS-PAGE 
minigels (37.5: 1 acrylamide: bisacxylamide; Biorad, Hemel Hempstead, UK) (Table 2.1) 
and then transferred to polyvinylidenedifluoride membranes (ImmobilonTm, Sigma, Poole, 
UK) using a semi-dry transfer system (Biorad, Hemel Hempstead, UK). The membranes 
were blocked with 1% milk (Marvel milk powder, Nestle, Croydon, UK) in TBS-Tween, 
stained overnight at'40C with monoclonal anti-ABL and anti-actin antibodies, washed four 
times in TBS-Twcen, stained for 30 min at room temperature with anti-mouse BRP- 
conjugated secondary antibody in 1% milk in TBS-Tween, washed four times again in 
TBS-Tween and visualised by chemiluminescence (ECL, Amersham Biosciences, Little 
Chalfont, Bucks, UK) on Kodak Biomax MR film (Sigma, Poole, UK). 
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Resolving Stacldng Gel 
gel (Tris IM) 
(6.5%) pH 6.8 
37.5: 1 Acrylamide/Bis 2.2m] 830gl 
(30%) 
Water 6.1ml 3.4ml 
Tris (1.5M) 2.5ml 630gl 
pH 8.8 (pH 6.8) 
SDS 10% IOOAI 50gl 
(Reducing agent) 
Ammonium 100gl 50pl 
Persulfate 
(APS) 
Temed 6gl 5gi 
Total Volume I IMI 5MI 
Table 2.1 - Composition of 6.5% SDS-PAGE resolving and stacking minigels 
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2.3.6 - Inhibition of potential intracellular sources of ADA. 
106 MNC were incubated for 24 hours at 370C, 5%CO2 in 25 cný tissue culture 
flasks (VWR, Poole, UK) containing 5 ml a-MEM (GIBCO) with 15% FCS and with or 
without the caspase inhibitor ZVAD (100pM and I MW 303 the proteosome inhibitor 
lactacystin (10ýLM and 50 ýLm) 
304,305 
or the lysosome inhibitor chloroquine (5pM, 501M, 
500ýM and 5MM) 
306,307. The cultured MNC were counted, viability was checked by 
trypan blue dye exclusion (refer to section 2.3.5) and then the cells were washed 0 in 
Ca++/Mgý+-free PBS before undergoing conventional lysis and assayed for ADA by 
western blot. Changes in ADA were determined by comparing p2 IOBCR-ABL signal from 
treated and untreated cells by densitometry. 
2.3.7 - Densitometry 
Scion Image software (Scion Corp, USA) was used to measure densitometry. 
Western blot films were scanned and uploaded in to Scion Image (Figure 2.1: A), the band 
of interest was selected and the mean intensity of the area (x) was measured (Figure 2.1: 
B). Similarly the background (y) was also measured (Figure 2.1: Q, the results are 
displayed in a table (Figure 2.1: D) and the mean density of the band was calculated by 
subtracting the background (Figure 2.1: E). All western blot measurements were also 
corrected for the loading control (actin) which was measured as described in Figure 2.1. 
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Figure 2.1 - measuring the density of band on a western blot band. (A) Westem blot 
bands were uploaded in to scion image, (B) the density of the band was measured, (C) the 
density of background was measured, (D) results were displayed in a table and the (E) 
mean density is calculated by subtracting the mean background density from the mean 
density of the band. 
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2.4: Detection of Brotein complexes by immunoprecivitadons aP) 
2.4.1 - Reagents and Antibodies 
The ExactaCruz IP kit and/or protein A/G agarose beads (Santa Cruz) were used for 
IP. Anti-ABL, anti-BCF, anti-CBL, anti-CRKL and anti-GRB2 antibodies (all from Santa 
Cruz) were used as the primary antibodies for the IP's and westem blots. Secondary 
antibodies, anti-mouse HRP (DAKO), anti-Rabbit HRP (DAKO) or the appropriate HRP 
r-- - from the ExactaCruz IP kit (Santa Cruz) were used for the western blots. 
2.4.2 - Agarose Bead Immunoprecipitation of p2jOBCR-ABL (normal pH) 
Cells were lysed in conventional lysis buffer (refer to section 2.3.2). The cleared, 
unboiled lysate was dispersed in 2 ml of ice-cold RIPA buffer (150 mM NaCl, I% Triton 
XI 00ý 0.1 % SDS, 10 mM Tris @ pH8.0 and protease inhibitors) containing a 1: 50 dilution 
(v/v) of primary antibody for Ih at 4'C. Protein A/G agarose beads were added at 100 pl 
packed Volume/, 07 input cell number. Where pre-conjugated beads were used, the primary 
antibody step was omitted. Following Ih of gentle agitation at 4'C, the beads were 
removed by centrifugation and washed four times in I ml of ice-cold FJPA buffer. ) 
suspended in 50 jil of loading buffer per 107 of input cell number and boiled for 5 min and 
then western blotted to detect protein complexes (as described in section 2.4.5). 
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2.43 - Exactacruz 
TM Immunoprecipitation of p2jOBCR-ABL (conventional pH and high 
pH) 
ExactaCrUZTM (Santa Cruz) was also used to immunoprccipitate p2 IOBCR-ABL from 
cell lines (conventional pH lysis) and primary cells (high pH lysis). The Exactacruirm 
matrix was prepared as per the manufacturer's protocol. In brief, for 107 cells lysed in 200 
gl high pH lysis buffer, antibody-matrix complex was formed by incubating 100 gl of IP 
matrix and primary antibody or IgG antibody in 500 gl of Ca++/Mg'-free PBS for 2h at 
4c'C. The matrix was washed twice with cold Ca++/Mg-free PBS and then incubated with 
cell lysate, for I hour at 41C. After two washes in 500gl cold Ca++/Mg++-free PBS, the 
matrix was suspended in 80 ýLl of loading buffer, boiled for 5 min and then western blotted 
to detect protein complexes (as described in section 2.4.4). 
2.4.4 - Western Blotting 
Protein complexes were detected by western blotting. Total lysates (TL), IgG IP 
lysate, ABL IP lysate and coloured molecular weight markers (BioRad) were run in parallel 
on 6.5,8,10 and 15% SDS-PAGE minigels (37.5: 1 acrylamide: bisacrylamide; Biorad, 
Hemel Hempstead, UK) (Table 2.2 and 2.3) and then transferred to 
polyvinylidenedifluoride membranes (ImmobilonTm, Sigma, Poole, UK) using a semi-dry 
transfer system (Biorad, Hemel Hempstead, UK). The membranes were blocked with 1% 
milk (Marvel milk powder, obtained from a local retailer) in TBS-Tween, stained overnight 
at 49C with monoclonal anti-ABL, BCR, CBL, CRKL and GRB2 antibodies, then washed 
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four times in TBS-Tween. Membranes were stained for 30 min at room temperature with 
anti-mouse or anti-rabbit HRP-conjugated secondary antibody or BRP from the 
ExactaCruz IP kit in 1% milk in TBS-Tween, washed four times again in TBS-Tween and 
visualised by chemilurninescence (ECL, Amersharn Biosciences, Little Chalfont, Bucks, 
UK) on Kodak Biomax MR film (Sigma, Poole, UK). 
Table 2.2 - Composition of resolving gels 
R olving Gel 
6.5% 8% 10% 12% 15% 
37.5: 1 
Acrylamide/Bis 
(30%) 
2.2ml 2.6ml 3.3ml 4ml 5ml 
Water 6.1ml 5.7ml 5ml 4.3ml 3.3ml 
Tris (1.5M) 
pH 8.8 
2.5ml 2.5ml 2.5ml 2.5ml 2.5ml 
SDS 10% 
(Reducing agent) 
100gl 100gl 100gl 100gl 100gl 
APS 100gl 100gl 100gl 100gl 100gl 
Temed 6gl 61LI 6gl 6gl 6gl 
Total Volume I imi I Imi IlgI IIgI IIgI 
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Table 2.3 - Composition of stacking gel 
Stacking 
Gel 
37.5: 1 
Acrylamide/Bis 
(30%) 
830gl 
Water 3.4ml 
Tris (1M) 
pH 6.8 
63091 
SDS 10% 
(Reducing agent) 
50gl 
APS 50gl 
Temed 5gi 
Total Volume 5ml 
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2.5: Visuafisation of the subceHular distribution of P2 OBCR-ABL protein and complexes 
by confocal laser scanning microscopy (CLSM) 
2.5.1 - Antibodies and reagents 
Primary antibodies were mouse anti-BCR-ABL (b2a2 junction specific) antibody 
(Cell Signalling Technology*, MA, USA), anti-ABL, anti-BCR, anfi-CBL, anfi-CRKL and 
anti-GRB2 antibodies (all supplied by Santa Cruz). Negative controls were mouse IgG2a 
isotype, mouse IgG, or rabbit IgG (BD Biosciences Pharmingen, Oxford, UK). Secondary 
fluorescent antibodies were anti - mouse AlexaFluo? 
o 488, anti - rabbit AlexaFluoio 488, 
anti - rabbit AlexaFluoiý 564 and anti - goat AlexaFluore 594 dyes, supplied by Sigma. 
Anti-fade reagent, VECTASIRELD, containing 4,6 - diamidino-2-phenylindole (DAPI) 
(Vector Laboratories, Burlingame, CA) was used to mount the slides. 
2.5.2 - Immunofluorescent labelling of single antigens 
CMEL cell lines, primary CML MNCS and CML CD34+ cells were resuspended in 
alpha MEM medium (GIBCO) at 10 6 cells/ml and 30gl aliquots were air dried on to glass 
microscope slides (VWP, Leicestershire, UK) and fixed in 2% paraformaldehyde in PBS 
for 10 minutes at room temperature. For intracellular staining cells were permeabilised 
using 0.2% Triton X (Sigma) in PBS for 10 minutes at room temperature. Non-specific 
sites were blocked using 5% fetal calf serum (FCS) (Biosera, Ringmer, UK)/3% bovine 
serum albumin (BSA) (PAA Laboratories, Linz, Austria) in PBS (blocking solution) for I 
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h. Specific primary antibody in blocking solution was incubated with the cells for Ih at 
room temperature. After four 5 minute washes in 3% FBS/l% BSA in PBS (wash solution), 
cells were incubated with the appropriate secondary AlexaFluor* dye in blocking solution 
for I hour in the dark. After four 5 minute washes in wash solution in the dark, slides were 
mounted in VECTASHIELD containing DAPI (Vector laboratories). For dual staining, 
cells were treated as- described above except primary and secondary antibodies for both 
antigens were incubated together. 
2.5.3 - Confocal laser scanning microscopy (CLSM) 
Immunostained cells were analysed by a Zeiss Meta 512 confocal microscope (Carl 
Zeiss, Jena, Germany) using an argon and HeNe I laser to view the Alexa Fluo? D 488,564 
and. 594 secondary conjugates. 
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2.6- Analysis of-p2joBC'R-ABL foci and subceHular distribution 
2.6.1 - Strategy for scoring p2 1OBCR-ABL positive foci 
In order to quantify the number of p2 IOBCR-ABL positive foci we devised the scoring 
system depicted in Figure 2.2. After acquiring the Z scan images of CML cells using 
I OBCR-ABL f; Ci confocal microscopy the distinct p2 0 in each section were scored. Any diffuse 
green signal on the images was considered as background staining and not included in the 
count. We define a focus by the following criteria: 
(1) High intensity of staining around a point represents a focus. 
(2) Staining has to clearly stand out from the background. 
(3) Any irregular elongated foci were considered as one focus. 
Scoring from the Z scans eliminates the possibility of counting any of the foci more than 
once. 
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Figure 2.2 - Strategy to score p2 
1OBCR-ABL positive foci. 
KCL-22 cells stained with anti-p2 I OBCR-ABL antibody. (A) Z scan of a KCL-22 cell stained 
for p2 1013CR-ABL and (B) red circles (0) indicate the p2 I OBCR-ABL positive foci scored. 
2.6.2 - Strategy for scoring percentage of p2jOBCR-ABL in foci (IMAGE J) 
The percentage of p2 10 
BCR-ABL in the foci was scored using Image j 
308. Confocal 
images from representative z scans were uploaded into Image J (Figure 2.3: A), the region 
of interest (ROI) was selected and the integrated density (ID) was measured for the whole 
cell (Figure 2.3: B) followed by the ID of all the foci individually (Figure 2.3: B). The 
percentages of p2 
IOBCR-ABL in the foci and diffused p2 I OBCR-ABL were calculated using the 
following formulae: 
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1- 
Percenta e of p2 , OBCR- _ ABe in f Ci 0 
(ID of single foci 
x 100 
ID of whole cell , 
Percentage of diffuse Percenta Fe of p2 I 
OBCR- 
D2 I OBCR-ABL 
100 - AB in foci 
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(B) Measize the total ID (Area x 
rnean derwity) forthe whole area 
(D) Generate a table of results in 
broge J 
(E) In Microsofl Excel calculate 
the percentage of p2 I O=L--ým 
in foci and diffuse 
Figure 2.3 - Mean density of p210 
BCR-ABL arranged in foci and diffusely. A single plane 
of a CLSM image from Z scans are uploaded in to Image J (A). The area of interest (ROI) 
was selected and the integrated density (ID) was measured (B). A table of results was 
generated and the percentages of p2 1013CR-ABL in foci and diff-usely stained regions were 
calculated in Microsoft Excel (C). 
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2.63 - Proportion of protein colocalisation 
Colocalisation of two proteins was analysed on randomly selected dual stained cells (n 
> 20 per measurement) using Zeiss LSM 5 10 Meta software. The colocalisation. coefficient, 
defined by Manders et a1309 (1993) is calculated such that I indicates complete colocalisation 
whilst 0 indicates no colocalisation. The intensity of the pixels does not affect the calculation 
as the pixel intensity in a certain channel is normalised by the total number of pixels and 
pixels with zero intensity are considered as background. Briefly, the region of interest (ROI) 
is selected (Figure 2.4: A) which generates a scatter diagram of the number of red pixels 
against the number of green pixels (Figure 2-4: B). In order to accurately determine the 
proportion of yellow signal a threshold, which is automatically calculated by the software at 
the mean fluorescence intensity (MFI) of ROI +2 standard deviations, is set (Figure 2.4: 
The software generates the colocalisation coefficient for each protein which individually 
provide the proportion of each protein complexed 310 (Figure 2.4: D). As a colocalisation 
coefficient of I indicates 100% colocalisation of each protein, 1-colocalisation coefficient 
detemunes the unbound proportion of each protein. 
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Figure 2.4 - Measuring the proportions of protein colocalisation. Ziess LSM 5 10 meta 
software was used to measure the colocalisation coefficient. The ROI was selected (A), the 
histogram is generated for the ROI plotting x vs y (B), the threshold can be set 
automatically or manually (MFI of ROI + 2(standard deviation)). This separates the pixels 
into red signal (1), green signal (2) and yellow signal (colocalisation) (3) on the scatter 
diagram (C). The table of results generated by the software OD). 
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CHAPTER 3- DEVELOPMENT OF AN ASSAY TO DETECT 
p2l OBCR 
ABL IN PRlNL4LRY CD34+ CM[L CELLS BY WESTERN 
BLOTTING 
3.1: Introduction 
In the cytoplasm p2 IOBCR-ABL interacts with various signalling proteins resulting in 
abnormal signal transduction. As discussed in the introduction (Chapter 1) a wide range of 
literature shows that p2 IOBCR-ABL forms multimolecular complexes with these signalling 
1OBCR-ABL 
&. 
L 213,233,300,213 protems. Briefly, p2 binds the adaptor proteins GRB2, CRIK CBL 
C 262 f aCtin 
311 
and - SH as well as . which has been demonstrated by IP and western blotting 
in CMIL cell lines or p2 1OBCR-ABL transduced cell lines. Downstream signalling pathways 
influenced by these initial p2 I OBCR-ABL interactions include the RAS 
312,76,313,206,312,3149 jAK_ 
STAT 315,316,317,318 and the P13K 
281,319,320,213 
pathways. The resultant abnormal signalling 
and expression of p2 IOBCR-ABL can alter cell adhesion 
37 
modulate cell signalling pathways 
responsible for proliferation and transformation 193 and potentially affect apoptosis 
194,292,195 
although this remains controversial 
The association of p2 IOBCR-ABL with intracellular signalling intermediates has been 
described principally in Ph+ cell lines but it remains for these fmdings to be confirmed or 
refuted in primary CML cells. Studies of this aspect have been limited by the presence of a 
proteolytic activity in myeloid cells which rapidly degrades ABL and p2 
IOBCR-ABL proteins 
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upon cell lysis. This activity was first noted in 1987 204 when it was shown to inhibit ABL 
protein kinase function. Later in 199 1, it was reported that high concentrations of these 
degradative enzymes hindered attempts to detect the kinase activity of p2 IOBCR-ABL protein 
in chronic phase CML patients 205 - The ADA was not prevented by any of the conventional 
protease inhibitors used in the preparation of cell lysates, thus compromising attempts to 
quantify p2 IOBCR-ABL or to describe its protein-protein interactions or kinase activities 
directly in primary. haemopoietic cells. It has been reported that the ADA was present 
mainly in mature cells which contain high concentrations of ADA 204,205 .A regime using 
boiling lysis buffer permits detection of p2 IOBCR-ABL from primary cells by western blotting 
103,32' but boiling precludes immunoprecipitation because it disrupts protein complexes. 
However, abrogation of p2 jOBCR-ABL degradation by a method that maintains protein- 
protein interactions would permit immunoprecipitation of intact p2 IOBCR-ABL from primary 
CML haemopoietic material to investigate the associations between p2 I OBCR-ABL and cell 
signalling proteins implied by studies of cell line models. This would allow the dynamics of 
protein associations during therapy to be studied as well as ftinctional aspects of p2lOBCR- 
ABL 
such as tyrosine kinase activity. 
Identibjing the cellular source of the ADA may provide clues about the mechanism 
of inhibition. Cells readily degrade proteins that are incorrectly fonned or denatured or if 
they are recognised as foreign proteins, in order to decrease the concentration of target 
protein. Cells have mechanisms to target extracellular and intracellular proteins but because 
p210 
BCR-ABL is an intracellular protein this section will focus mainly on the relevant 
mechanisms. Briefly, extracellular proteins can be degraded by three types of digestive 
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proteases which cleave the protein backbone (endoproteases), remove residues from the N- 
or C-terminals (exopeptidases) or break oligopeptides in to di or tripeptides (peptidases) 322. 
Intracellular proteins can be degraded by enzymes contained in lysosomes or proteasomes. 
Lysosomes are membrane bound intracytoplasmic organelles which were first 
discovered by de Duve in 1949 (reviewed in 323) . Lysosomes are formed from the 
endoplasmic reticulum and golgi apparatus and contain more than 50 enzymes, also 
referred to as acid hydrolases because they require an acidic environment and water to 
. r_ - -- 
324 
function and aid protein degradation . The internal environment of lysosomes is very 
acidic and morphologically lysosomes have no major features but can be identified by the 
presence of two characteristic properties - (1) detection of a single membrane and (2) 
detection of one or more acid hydrolases by cytochemical staining 323 . The lysosomal 
membrane prevents leakage of degradative enzymes into the surrounding cytoplasm, which 
may cause damage to normal cells, and also contains proteins that act as proton pumps 
maintaining the acidic internal enviromnent 324 . Endogenous and exogenous proteins are 
targets of lysosomes (refer to Figure 3.1). Endogenous particles and organelles are digested 
by microautophagy and macroautophagy, respectively. Exogenous proteins can be 
internalised by lysomomes using receptor-mediated endocytosis (lysosomes enclose 
macromolecules enclosing them into membrane which pinches off and forms an 
intracellular vesicle) and pinocytosis (ingestion of extracellular fluid containing dissolved 
material). Exogenous particles are targeted by phagocytosis (material taken up by 
engulfinent). Endogenous materials are digested by autophagy and exogenous material is 
digested via heterophagy 
325,326,327. Wibo and Poole (1974) 
306 demonstrated that 
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chloroquine targets cell lysosomes by altering the internal pH which is essential for 
lysosome function. 
Receptor bound 
ENDOCYTOSIS 
Memebrane 
Receptor bound 
PINOCYTOSIS 
0 
MACROAUTOPRAGY 
DEGRADATION 
0M 
PHAGOCYTOSIS NUCROAUTOPHAGY 
0 
Exop-enous material 
(heterop aLyv) 
Acid dependent I 
enzymes 
I 
Endoeenous material 
(autog)hagyl 
Figure 3.1 - Action of cefl lysosomes. Diagrammatic representation of mechanisms 
involved in the processing of endogenous material and internalisation of exogenous 
material by lysosomes. 
Proteasomes (also called the 26S proteasome) are large 'tunnel-like' macromolecules 
located in the cytoplasm and nucleus 328 - For proteasomes to recognise the target protein a 
'tag', called ubiquitin is attached. There are three types of enzymes that transfer and carry 
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ubiquitin, E I, E2 and E3. They act as a cascade were EI activates E2 and this goes on to 
activate E3. This cascade repeats several time and tags the target protein3293-" which is 
recognised by the proteasome and degraded. This process is termed the ubiquitin - 
proteasome pathway (Figure 3.2 A). 
The 26S proteasome is a 20OOkDa multiprotein complex and has a 20S core particle 
containing four stacked rings which has very little proteolytic activity. There are one or two 
19S regulatory particles at one or both ends of the proteasome structure, which act as 
structural caps preventing any inappropriate proteins from entering the structure 305 (Figure 
3.2 B). 
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Figure 3.2 - Ubiquitin - proteasome pathway. A. Ubiquitin binds to ubiquitin-activating 
enzyme (EI) then to ubiquitin-conjugated enzyme (E2) finally to ubiquitin-ligase (E3) 
which binds ubiquitin to target protein for degradation. B. The structure of the 26S 
proteasome bound to ubiquitinated target protein. The 20S core has two a rings and two B 
rings and binding of the 19S core/s fonns the 26S proteasome. 
Proteins tagged with ubiquitin attach to the 19S subunit which removes the ubiquitin 
331 from the protein which is then denatured (unfolded) and passed through the 20S core 
The denatured protein then passes through a channel formed between the 19S unit and the 
two outer rings of the core. The catalytic chamber of proteasomes is formed by two inner B 
rings, containing three active sites. These sites are called chymotrypsin-like, trypsm-like 
and post-glutamyl peptide hydrolase-like (PGPH) named after the enzymes of similar 
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activity to the sites 332 . The core then degrades the target protein by the proteases which 
breaks the protein down into small peptides and amino acids 333 . Lactacystin is a chemical 
304,305 inhibitor of proteasomes 
Apoptosis (Figure 3.3) is a mechanism through which organisms eliminate cells in 
response to DNA damage, growth factor deprivation, and inappropriate expression of 
oncogenes and/or tumour suppressor genes. Apoptosis is also a vital process during 
embryonic development as organisms use apoptosis to regulate cell numbers 334. This 
process is regulated by a family of proteins, capases, which are activated in an orderly 
335 
cascade fashion. Activation of caspases has been implicated in apoptosis of CMIL cells 
There are two groups of caspase proteins 336 synthesised as inacti. ve procaspases. One type 
of procaspase (i. e. 3,6 and 7) is expressed as a heterodimer which has two active sites and 
cause cell death (apoptosis) by cleaving cellular substrates. The second type of procaspase 
(8,0 and 10) exists as monomers that are activated upon dimerisation or oligomerisation 
which occurs due to proteolytic cleavage 337 . ZVAD acts as an inhibitor of the caspase 
335,303 
cascade 
Apoptosis can be activated via extrinsic or intrinsic factors. Extrinsic factors such 
as hormones, growth factors, nitric oxide 338 or cytokines Le FAS-ligand or tumor necrosis 
factor (TNF) bind to their respective receptors and act as death signals. This causes 
activation of caspase 8 localized in the cytosol but this varies in different cell types. In 
certain lymphoid cells caspase 8 is highly activated and directly activates downstream 
capsascs such as capsase 3 
339,340 
. However, in other cell types caspase 8 is unable to 
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activate caspase 3 directly so Bid, a proapoptotic341 protein, is activated which then affects 
the mitochondria and activates the mitochondria-induced. apoptosis34'0. The Bcl-2 family of 
proteins acts as intrinsic factors that activate the caspase cascade. Certain members of the 
family such as Bcl-2 or Bcl-XL can inhibit apoptosis 
342,343 -344 but other protein members of 
this group such as Bax, Bak, Bad, Bid, Bik/Nbk and Hrk act as inducers of apoptosis 
341,345,346,347,348,349,350,351. The Bcl-2 family of proteins migrate to the mitochondria in 
response to cellular damage to either inhibit or activate apoptosis. As a consequence the 
mitochondrial membrane becomes permeabilised and molecules within the mitochondria 
are released into the cytoplasm of the cells. Cytochrome C is one of the molecules released 
by the mitochondria which causes oligomerisation of Apaf-I in the presence of ATP 
fonning a apoptosome 352 resulting in the activation of caspase-9. The mitochondria also 
release molecules which activate caspases to inhibit apoptosis 352,353 . Mitochondrial 
permeability is another feature of apoptosis and Bcl-2 proteins are able to promote or 
inhibit apoptosis either by direct action on mitochondrial permeability, or indirectly through 
other proteins. Importantly, the actions of some Bcl-2 proteins are able to stop apoptosis 
even if cytochrome c has been released by the mitochondria 354 0 
Although many pathways and signals lead to apoptosis, there is only one 
mechanism; which is occurs after appropriate stimulus has been received by the cells and 
the necessary controls exerted, a cells will undergo the organised degradation of cellular 
organelles by activated proteolytic caspases 355 . Apoptosis progresses quickly and 
its 
products are quickly removed by macrophages without damaging surrounding tissue 
"6. 
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Figure 3.3 - Simplification of apoptosis. Extrinsic signals from hormones, growth factors, 
nitric oxide and or cytokines bind to their appropriate receptors and can activate caspase 8 
followed by caspase 3 directly or indirectly via Bid protein. Intrinsic factors, the Bcl-2 
family of proteins are activated as a result of cellular stress causing the Bcl-2 family of pro- 
or anti-apoptoic proteins (varies depending on signal) to migrate to the mitochondria which 
burst and release their contents in the cytosol. A component of the mitochondria is 
cytochrome C which binds to Apaf- I resulting in the activation of caspase 9. Activation of 
caspases results in apoptosis of the cell. 
The aim of this chapter is to identify the cellular source of the ADA in order to inhibit 
its ftinction, and permit analysis of p2 I OBCR-ABL _ or ABL - related protein complexes in 
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primary CML cells by co-IP and western blots . We used a co-lysis assay where primary 
MNC or CD34+ cells are mixed with K562 cells in equal quantities. Using this assay we 
identified cell lysosomes as the most likely source of the ADA, as a prelude to developing a 
suitable technique for its inhibition. We show here that in a high pH milieu, ADA in CML 
chronic phase peripheral blood cells can be abrogated sufficiently to allow detection of 
p210 BCR-ABL and ABL levels by western blotting without affecting tyrosine phosphorylation 
and protein complex formation in CML CD34+ cells. 
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3.2: Results 
3.2.1: Cell types that express the ADA 
3.2.1.1 - ADA is present in CML MNC's and affects p2jOBCR-ABL and ABL but not 
BCR 
Both ABL and p2 IOBCR-ABL are readily detectable in lysates of the Ph+ K562 cell 
line, but not in primary CML cell lysates, because primary cells express a potent 
degradative activity. that degrades p2 IOBCR-ABL and ABL. Here we show that the ADA 
remains when cells are lysed and western blotted under normal conventional conditions. 
Interestingly normal BCR is not affected by this ADA and was detected in the cell lysates 
of the four cases of CML tested (Figure 3.4). ABL, BCR and p2 I OBCR-ABL are detected in 
the control K562 cell lysate (Lane 1). These results demonstrate that K562 cells contain 
little if anly ADA and in primary cells the ADA is selective for ABL proteins. Since K562 
cells do not contain the ADA, the p2 IOBCR-ABL they express can be used as a target for ADA 
detection in other cell types. CML MNC and K562 cells were mixed in equal quantities and 
co-lysed in boiling lysis buffer which removed the degradative activity (Lane 2). However 
both p2 I OBCR-ABL and ABL, but not BCR, were degraded completely when CMIL MNC: 
K562 cell mix was co-lysed in cold lysis buffer as shown in four different CML patients 
(Figure 3.4A Lanes. 3-6). 
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Figure 3.4 - The degradative activity is present in CML NINC ceH preventing 
detection of p2jOBCR-ABL and ABL. Lane 1: 106 K562 cells were lysed in cold lysis buffer 
and lane 2: K562: CML MNC were co-lysed boiling lysis buffer. Lane 3-6: CML MNC 
cells from 4 different patients were co-lysed with equal concentrations of K562 cells in cold 
lysis buffer. Blot A shows levels of p2 I OBCR-ABL , ABL and BCR 
in the different cell lysates 
and blot B shows levels of actin which is used as a loading control. C. The density of each 
band was measured in triplicate and the average was used to determine the levels of 
p2 I OBCR-ABL, AIE3L and BCR which is expressed relative to levels in the K562 cell lysate. 
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3.2.1.2 - ADA is also present in non-CML cells from normal peripheral blood 
progenitor ceUs (PBPQ and bone marrow (BM). 
The ADA also affects ABL (pl45ABL) as well as p2 I OBCR-ABL which has a role in normal cell 
signalling dependent on protein-protein interactions. The ABL and BCR proteins are 
ubiquitously expressed in non-malignant cells 70 and appear to have multiple cellular 
regulatory functions. The nuclear localisation of ABL suggests a trafficking role for the 
protein and the three SH domains carry tyrosine phosphorylation sites potentially allowing 
complexing with adaptor proteins such as GRB2 or CRKL via their SH2 domains. 
Functionally, ABL would appear to modulate cell cycle regulation, effects of genotoxic stress, 
and response to integrin signalling 61. 
We show here that the degradative activity is also present in the MNC fraction of 
normal PBPC (Figure 3.5) implying that the activity prevents detection of ABL proteins in 
normal cells in the absence of p2l. OBCR-ABL . K562 cell lysate was loaded as a control (lane 1) 
and ADA was inhibited by co-lysing K562 cells and PBPC MNC's in boiling lysis buffer 
(lane 2). However, when the same mix of cells was lysed in cold lysis buffer, the p2 IOCR-ABL 
and ABL were both destroyed (lane 3). The same results were seen in the MNCs from normal 
BM cells (Figure 3.6). These data suggest that the activity is not unique to CML cells and 
confirms the finding made by Maxwell et al 204 in 1987. 
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Figure 3.5 - The ADA is present in normal PBPC MNC. 106 K562 cells were lysed in 
cold lysis buffer (lane 1), K562: PBPC were lysed in boiled lysis (lane 2) or cold lysis 
buffer (lane 3) buffer. Blot A shows levels of p2 IOBCR-ABL and ABL in the different cell 
lysates and blot B shows the levels of actin which is used as a loading control. C. The 
density of each band was measured. The experiment was repeated 3 times with MNC 
samples from different patients and the average was used to determine the levels of 
p2 I OBCR-ABL and ABL relative to levels in K562 cell lysate ± SD, n--3. 
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Figure 3.6 - The ADA is present in normal BM-MNC preventing p2jOBCR-ABL and 
ABL. 106 K562 cells were lysed in cold lysis buffer (lane 1), K562: BM were lysed in 
boiled lysis (lane 2) or cold lysis buffer (lane 3) buffer. Blot A shows levels of p2 10 BCR-ABL 
and ABL in the different cell lysates and blot B shows the levels of actin which is used as a 
loading control. C. The density of each band was measured. The experiment was repeated 3 
times with MNC samples from different patients and the average was used to determine the 
levels of p2 I OBCR-ABL and ABL relative to levels in K562 cell lysate ± SD, n=3. 
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3.2.2: CD34+ CML cells contain less ADA than CNM MNCIs. 
It has been proposed 
204,205 
that the degradative activity is present only in mature 
mydloid cells. Therefore we reasoned that it may be possible to detect p2 IOPCR-ABL and 
ABL proteins in the isolated CD34+ cell fraction from CML. To analyse this we co-lysed 
graded numbers of CML MNC (Figure 3.7) or CD34+ cells (Figure 3.8) with K562 cells in 
order to detect p2 IOBCR-ABL and ABL. Our data shows 44% and 52% of p2 IOBCR-ABL and 
AA BL signal, respectively was detected when MNC: K562 cells were mixed at 1: 16 dilution 
but only 8% of p2 1OBCR-ABL and ABL was recovered from the 1: 8 mix of MNC: K562 cells 
(Figure 3.7). Co-lysing K562 cells mixed with CML CD34+ cells (Figure 3.8) diluted at 
1: 8 (CD34+: K562) allowed detection of 50% and 45% of p2 IOBCRABL and ABL, 
respectively and a 1: 16 (CD34': K562) mix of CD34' cells and K562 cells resulted in the 
detection of 65% and 66% of p2 IOBCR-ABL and ABL, respectively. Even at a 1: 4 
(CD34+: K562) mix 17% of p2 IOBCR-ABL and 8% of ABL proteins were detected. 
This suggests that CD34' cells have slightly less degradative activity compared with 
MNC but that the selection of CD34+ cells does not remove the activity completely which 
still precludes immunoprecipitation of p210 
BCR-ABL 
in primary cells. This experiment was 
repeated three times with similar results. 
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Figure 3.7 - p2jOBCR-ABL and AIBL recovery after titrating CMEL MNC's. CML MNC's 
are mixed with K562 cells serially in 2-fold dilutions and co-lysed in cold lysis buffer for 
10 min on ice. The cleared lysate was mixed with an equal volume of sample buffer and 
boiled for 5 min at 100'C. Final dilution ratios of primary K562: MNC cells are shown. 
K562 (lane: K562) lysate-only control diluted 1: 1 with lysis buffer only. Blot A shows 
levels of p2 I OBCR-ABL and ABL in different cell lysates and blot B shows the levels of actin 
which is used as a loading control. C. The density of each band was measured. The 
experiment was repeated 3 times with MNC samples from different patients and the 
average was used to determine the levels of p2 I OBCR-ABL and ABL relative to levels in 
K562 cell lysate ± SD, n--3. 
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Figure 3.8 - p2jOBCR-ABL and ABL recovery after titrating CNM CD34+ ceUs. CML 
CD34+ were mixed with K562 cells serially in 2-fold dilutions and co-lysed. in cold lysis 
buffer for 10 min on ice. The cleared lysate was mixed with an equal volume of sample 
buffer and boiled for 5 min at 100'C. Final dilution ratios of primary K562: CD34+ cells are 
shown. K562 (lane: K562) lysate-only control diluted 1: 1 with lysis buffer only. Blot A 
shows levels of p2 10 BCR-ABL and ABL in different cell lysates and blot B shows the levels 
of actin which is used as a loading control. C. The density of each band was measured. The 
experiment was repeated 3 times with CD34' cells samples from different patients and the 
average was used to determine the levels of p2 I 
OBCR-ABL and ABL relative to levels in 
K562 cell lysate ± SD, n--3. 
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3.2.3: Effects of inhibition of ceflular organefles and the caspase cascade on ADA and 
tyrosine phosphorylation in CMIL MNC 
We investigated the cellular source of the ADA present in MNC in order to identify 
335,303 
and specifically inhibit its action. Three candidate targets were the caspase cascade 
proteasomes 
305,304 
and lysosomes 
307,306 
, inhibited by ZVAD, lactacystin and chloroquine, 
respectively. 
3.2.3.1 The degradative activity is not a component of the caspase cascade. 
The caspase cascade initiates ýprogrammed cell death', apoptosis. It has been 
suggested that apoptosis induced by cepharanthine, a membrane stabilizer degrades 
p2 I OBCR-ABL . However when cells were treated with the caspase 
inhibitor, ZVAD, apoptosis 
and degradation of p2 I OBCR-ABL were both inhibited 
335. As ZVAD has been reported to 
prevent degradation of p2 I OBCR-ABL 
335 
we pre-treated MNC: K562 cell mix with I OOpM and 
I mM ZVAD for 24 hours before lysis with the aim of inhibiting the degradative activity. 
This treatment had no major effect on the cell viability on a cell mixture of K562 and CNIL 
NlNCs (Figure 3.9 A). Figures 3.9 B and C shows the effects of ZVAD treatment by 
western blot (B) and densitornetry (C). K562 cells alone (lane: K562) are used as a positive 
control. However when the K562: CML MNC mix is pre-treated with lOOgM or ImM of 
ZVAD for 24 hours p2 I OBCR-ABL and ABL were still degraded (lanes: 1001M and ImM) 
suggesting that the degradative activity is not a property of the caspase cascade. 
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Figure 3.9 -ZVAD does not inhibit degradation of p2jOBCR-A-BL and ABL. 
106 untreated 
K562 cells (K562) and K562: CML MNC (1: 1) mix pretreated with lOOgM and ImM 
ZVAD for 24 hours was lysed in cold lysis buffer. Cell viability was analysed in treated 
and untreated cells using trypan blue (A). B shows levels of p2 I 
OBCR-ABL and ABL in the 
different cell lysates and actin is used as a loading control. C. The density of each band was 
measured. The experiment was repeated 3 times with MNC samples from different patients 
and the average was used to detennine the levels of p2 I OBCR-ABL and ABL relative to levels 
in K562 cell lysate ± SD, n=3. 
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3.2.3.2 ADA is not a feature of proteasomes 
Proteasomes may be a potential source of ADA because their main function is to 
degrade damaged or unneeded proteins by proteolySiS 322. Proteasomes are large complexes 
of protein that are found in the nucleus and cytoplasM 328 . They break the peptide bonds of 
the target protein by a chemical reaction which is carried out by enzymes called proteases. 
The protein degradation process fonns, small peptides of 7-8 amino acids which are ftuther 
degraded into single amino acids that can be reassembled to make new proteins 322 . For our 
studies we treated cells with lactacystin 357,358which is a specific inhibitor of proteasomes. 
We pre-treated MNC: K562 cell mix with lOgM and 50pM of lactacystin for 24 hours 
before lysis which had no major effect on the cell viability on a cell mixture of K562 and 
CMEL MNCs (Figure 3.10 A). Figure 3.10 B and C show effects of lactacystin treatment 
by western blot (B) which was quantified by densitometry (C). K562 cells (lane: K562) are 
used as a positive control. However when a K562: CML NNC mix was pre-treated with 
lOgM or 50pM of lactacystin for 24 hours p2 IOBCR-ABL and ABL were degraded (lanes: 
I OOpM and I mM) suggesting the ADA is not located with in proteasomes. 
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Figure 3.10 - Lactacystin does not inhibit degradation of p2 
OBCR-ABL and ABL. 106 
untreated K562 cells (K562) and K562: CMEL MNC (1: 1) mix pretreated with lOgM and 
50g M lactacystin for 24 hours was lysed in cold lysis buffer. Cell viability was analysed in 
treated and untreated cells using tr"an blue (A). B shows levels of p2 IOBCR-ABL and ABL 
in the different cell lysates and actin is used as a loading control. C. The density of each 
band was measured. The experiment was repeated 3 times with MNC samples from 
different patients and the average was used to determine the levels of p2 I 
OBCR-ABL and ABL 
relative to levels in K562 cell lysate ± SD, n--3. 
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3.2.3.3 ADA is located within cell lysosomes 
Lysosomes contain enzymes which degrade old cellular organelles, bacteria or 
viruses by digestive enzymes. Chloroquine, a specific inhibitor of lysosomes, was first 
discovered in 1974 306 . To test if the activity degrading p2 
IOBCR-ABL and ABL kinase is 
located in the lysosomes we pre-treated a MNC: K562 cell mix with 5pM, 50pM, 5OOpm 
and 5mM of chloroquine for 24 hours. Treatment with chloroquine at higher 
concentrations, 500pM and 5mM, resulted in high levels of toxicity in a mixture of K562 
and CMEL MNCs. Figure 3.11 A shows that treatment with 500ýM and 5mM of 
chloroquine results in 87.73% and 44.13% cell viability. Figure 3.11 B and C shows 
effects of chloroquine treatment by western blot (B) which was quantified by densitometry 
(C). K562 cells (lane: K562) are used as a positive control. However when the K562: CML 
MNC mix is pre-treated with 5gM, 50pM and 500gM of chloroquine for 24 hours p2 I OBCR- 
ABL and ABL degrades (lanes: 5jiM, 50pM and 500gW. But when the cells are treated with 
5mM chloroquine 92.61% and 75.63% of p2l OBCRABL and ABL, respectively are recovered 
relative to the control K562 lysate. Recovery of p2 IOBCR-ABL and ABL implies that the 
degradative activity is likely to be mainly, if not entirely, located within lysosomes of intact 
MNC. 
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Figure 3.11 - Chloroquine inhibits degradation of p2 
OBCR-ABL and ABL. 106 untreated 
K562 cells (K562) and K562: CML MNC (1: 1) mix pretreated with 5pM, 50pM, 500gM 
5mM chloroquine for 24 hours was lysed in cold lysis buffer. Cell viability was analysed in 
treated and untreated cells using trypan blue (A). B shows levels of p2 I OBCR-ABL and ABL 
in the different cell lysates and actin is used as a loading control. C. The density of each 
band was measured. The experiment was repeated 3 times with MNC samples from 
different patients and the average was used to determine the levels of p2 I 
OBCR-ABL and ABL 
relative to levels in K562 cell lysate ± SD, n=3. 
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3.2.3.4: 5mM Chloroquine reduces tyrosine phosphorylation in K562 ceUs. 
Although the use of chloroquine indicates a possible solution to the difficulties 
experienced in western blotting and immunoprecipitating p2 I OBCR-ABL froM priMary CNIEL 
CD34 + cells, it required 24 hours incubation under non-physiological conditions with high 
concentrations of chloroquine associated with high levels of toxicity. Chloroquine 
treatment up to 24 hours substantially reduced the pH of the culture medium, raising 
concerns that chloroquine may also affect tyrosine phosphorylation of proteins. Untreated 
K562 cells and K562 cells pre-treated with chloroquine (concentration: 5pM, 50pM, 
500uM and 5mM) were lysed with standard lysis buffer and tyrosine phosphorylation 
levels were analysed by western blotting (Figure 3.12). Chloroquine at low concentrations 
has no significant effect on the phosphorylation pattern (Lane: 5pM, 50pM and 500gM) but 
when cells were pre-treated with the chloroquine concentration required to inhibit the 
degradative activity, tyrosine phosphorylation of all protein bands, including p2 
IOBCR-ABL 
was significantly reduced (Lane: 5mM). This further confirms that chloroquine is not a 
suitable agent for inhibiting the p2 
1013CR-ADL 
-associated degradative activity because the 
protein complexes 'in CML maybe dependent on tyrosine phosphorylation. since they 
dissociate when tyrosine kinase of p2 10 
BCR-ABL 
is inhibited using imatinib (see Chapter 6). 
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Figure 3.12 - High chloroquine concentrations severely affect the tyrosine 
phosphorylation of proteins in CML ceffs. 106 K562 cells were lysed in cold lysis buffer 
(Lane: K562), and K562 cells pre-treated with 5 gM, 50 IiM, 500 1W and 5 mM 
chloroquine (Lanes: 5pM, 50pM, 500jiM and 5mM). 20gl each lysate was loaded, run on a 
8% and 15 % polyacrylamide gel and transferred on to nitrocellulose membrane. 
Membranes were blocked for I hour at room temperature and probed with anti- 4G 10 
phosphotyrosine and anti-actin antibodies overnight at 4'C. Actin. was used a loading 
control. 
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3.2.4 Inhibition of the ADA by high pH lysis 
Since, chloroquine treatment at concentrations required to inhibit degradation of 
p2 IOBCR-ABL and ABL reduces cell viability and tyrosine phosphorylation significantly it 
does not provide an adequate method for detecting p2 IOBCR-ABL by immunoprecipitation 
from primary cell lysates. 
3.2.4.1 Mimicking the effects of chloroquine with pH lysis inhibits the ADA. 
Lysosome function is optimal when the internal pH is acidic and chloroquine 
inhibits lysosome function by increasing the internal PH. We hypothesised that the effects 
of chloroquine could be mimicked by lysing cells in high pH lysis buffer. In Figure 3.13 A 
K562 cells were lysed in cold lysis buffer (lane: K562) and CML CD34+ cells were lysed in 
boiling lysis buffer (lane: boil) and cold (lane: cold) lysis buffer. To optimise the yield of 
p2 I OBCR-ABL and ABL from primary cells, CML CD34+ cells were lysed in cold lysis buffer 
containing increasing concentrations of I OM NaOH (lane: 0.625,1.25,2.5,5,10%). 1.25% 
I OM NaOH in cold lysis buffer permitted maximal recovery of p2 IOPCR-ABL and ABL at 
levels relative to K562 control samples. A concentration of 1.25% corresponds to a pH > 12 
(limit of the scale on the pH meter). Using densitometry (Figure 3.13 B), 93.23% of 
p2 I OBCR-ABL and 66.4 1% of ABL were recovered from CML CD34+ cells lysed in lysis 
buffer containing 1.25% IOM NaOH without affecting cell viability (Figure 3.14). This 
data finther confirms that ADA in primary CML cells is located within the cell lysosomes. 
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The dose response curve is biphasic suggesting that inhibition of ABL degradation at 
10 higher concentrations is possibly due to mechanisms other than ADA. 
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Figure 3.13 - Increasing lysis buffer pH results in abrogation of p2 
IOBCR-ABL and ABL 
-degradative activity in mononuclear cell lYsates. (A) 106 K562 cells lysed in cold lysis 
buffer (Lane: K562) and CMIL CD34+ cells lysed in boiled (lane: boil) and cold (lane: cold) 
lysis buffer. CML CD34-'- cells were lysed in increasing concentrations of IOM NaOH in 
cold lysis buffer (lane: 0.625,1.25,2.5,5,10%). Membranes were probed with anti-ABL 
antibody or anti-actin antibodies overnight at 4'C. (B) The density of each band was 
measured. The experiment was repeated 3 times with CD34+ cells samples from different 
patients and the average was used to determine the levels of p2 I 
OBCR-ABL and ABL relative 
to levels in K562 cell lysate ± SD, n=3. 
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Figure 3.14 - The effects of pH on cell viability. K562 cells or CD34+ cells were mixed 
with varying concentrations of I OM NaOH and the cell viability was accessed using trypan 
blue. The experiment was repeated 3 times from different patients and the average was used 
to determine cell viability ± SD, n=3. 
3.2.4.2 Mgh pH lysis does not affect tyrosine phosphorylation 
As previously mentioned we show in Chapter 6 that certain p2 10 
BCR-ABL 
_ 
associated protein complexes in CML are affected by changes in tyrosine phosphorylation. 
Treatment with chloroquine inhibits the degradative activity but it also reduces tyrosine 
phosphorylation significantly. Here we analyse the effects of high pH lysis on tyrosine 
phosphorylation (Figure 3.15). K562 cells were lysed in convenfional lysis buffer (lane: 
K562) and 1.25% IOM NaOH lysis buffer (lane: 1.25% NaOH) on ice. The high pH lysis 
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condition had no effect on the phosphorylation of p2 IOBCR-ABL and lower molecular weight 
proteins in comparison to the standard lysis (lane: K562). This finding suggests high pH 
lysis provides an effective technique for detecting p2 IOPCR-ABL and ABL by western 
blotting and immunoprecipitation. 
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Figure 3.15 - High pH lysis retains the tyrosine phosphorylation of proteins in CML 
cells. 106 K562 cells were lysed in cold lysis buffer (Lane: K562) and high pH lysis buffer 
(lane: 1.25% NaOH). 20gl each lysate was loaded, run on a 8% and 15 % polyacrylamide 
gel and transferred on to nitrocellulose membrane. Membranes were blocked for I hour at 
room temperature and probed with anti- 4G 10 phosphotyrosine and anti-actin antibody 
overnight at 4'C. Actin was used a loading control. 
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3.3. Discussion 
The fusion gene BCR-ABL encodes for a protein of molecular weight of 210 kDa, 
p210 BCR-ABL , which has been shown to complex with various cytoplasmic and cytoskeletal 
proteins in cell line models or cells transduced to express p2 IOBCR-ABL . There is a lack of 
information about these associations in primary CMEL cells because lysis of haemopoietic 
cells releases a degradative activity, ADA, that destroys p2 I OBCR-ABL and ABL thereby 
preventing detection of p2 IOBCR-ABL and associated protein complexes in CMIL by 
immunoprecipitation. 
The ADA present in CML MNCs affects both p2 IOBCR-ABL and ABL but BCR is not 
affected which confmns that the degradative activity affects ABL kimases only 
204,205 
. The 
ADA is not a unique feature of CML as we show in Figure 3.5 and 3.6 where it is also 
present in MNC from normal PBPC and normal bone marrow, respectively. Boiling the 
lysate prior to incubation with the K562 lysate removed the degradative activity in all 
samples. Therefore, the degradation of p2 IOBCR-ABL in CML MNCs is a result of a heat 
sensitive activity common to normal as well as neoplastic primary haemopoietic material. 
Although the ADA can be substantially destroyed by boiling, this step precludes 
immunoprecipitation experiments to investigate complexes in primary cells. It has been 
reported that the ADA was present mainly in mature cells containing a high concentration 
of the enzymes which prevent detection of p2 IOBCR-ABL using a protein kinase assay 
204,205. 
However, selection of CD34+ cells did not remove the ADA completely although CD34' 
cells contain a slightly lower level of activity compared with MNC (Figure 3.7 and 3.8). 
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To identify the cellular source of the ADA three candidate targets were selected based 
335,303 305,304 307 
on their cellular roles. The caspase cascade , proteasomes and lysosomes 
were inhibited by ZVAD, lactacystin and chloroquine, respectively. Inhibition of the 
caspase cascade using ZVAD prevented cleavage of p2 lOBCR-ABL and ABL associated with 
TP53-induced erythroid differentiation in K562 cells 
335. ProteosomeS 305,304 and lysosomes 
307 were targeted because they are natural reservoirs of enzymatic activities. Figures 3.9 
and 3.10 suggest that ZVAD and lactacystin have no effect on the recovery of p2 IOBCR-ABL 
and ABL suggesting the caspase cascade and proteosomes are not involved in the 
degradation of p2 IOBCR-ABL and ABL. One study suggests that inhibition of proteasomes 
reduces p2 IOBCR-ABL levels and tyrosine phosphorylation in K562 cells 
359 
. The same study 
shows that proteasome inhibition does not affect nonnal ABL or BCR. 
Lysosomes were targeted with chloroquine. When cells were treated with 5mM 
chloroquine for 24 h prior to lysis there was significant inhibition of the ADA resulting in 
recovery of 92.6 1% of p2 10 BCR-ABL and 75.63% of ABL recovery relative to K562 control 
lysates (Figure 3.11). This implies that the ADA is associated mainly if not completely 
within cell lysosomes. A disadvantage to using chloroquine is that it requires incubation of 
cells under non-physiological conditions for 24 h before the effect is maximal. Also, whilst 
chloroquine can be used to inhibit the ADA, it reduces cell viability and tyrosine 
phosphorylation of p2 
IOPCR-ABL and lower molecular weight proteins. Therefore 
chlproquine may affect protein complexes in CML. Chloroquine inhibits lysosomal activity 
and is an example of a lysosomotropic agent. These are agents that are generally weak 
bases that accumulate within the lysosome and therefore increase the internal pH of the 
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lysosomes. Chloroquine becomes concentrated within the lysosome 306. Ohkuma et al 
demonstrated that chloroquine increased the pH within the lysosome and an increase of pH 
up to 6.5 would be adequate to inhibit the action of lysosomal acid proteineases 
360,361 
The mechanism of chloroquine action provided the rationale for the experiment with 
high pH lysis buffer which allowed recovery of p2 10 
13CR-ABL 
and ABL and did not affect the 
tyTosine phosphorylation in K562 cells. p2 IOBCR-ABL and ABL recýovery from CMEL CD34+ 
cells (see Figure 3.13) was optimal when the cells were lysed in 1.25% 10 M NaOH in 
cold lysis buffer. Thus ADA can be abrogated by high pH which further supports the 
identity of the activity as a lysosome-associated acid-dependent hydrolase. 
In summary we have identified the potential source of the p2 
OCR-ABL 
-degradative 
activity and developed an assay that allows detection of p2 lOBCR-ABL and ABL proteins 
from primary CML CD34+ cells (Figure 3.13) without compromising cell viability (Figure 
3.14), tyrosine phosphorylation (Figure 3.15) and protein complex formation (see Chapter 
4). This assay will provide opportunity to investigate p2 lCjBCR-ABL associated protein 
complexes in CMEL as well as ABL-related complexes in CML and non-CML primary cells 
and supplement or enhance our knowledge of these protein complexes that has hitherto 
been based on cell line studies. 
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CHAPTER 4- PROTEIN COMPLEXES IN CML AND NON- 
CML CD34 + CELLS 
4.1 Introduction 
Cytoplasmic protein complexes with p2 I OBCR-ABL in CML may have an important 
role in the development of disease. The ABL protein tyrosine kinase motif of p2 IOPCR-A]3L 
is constitutively activated and allows the protein to phosphorylate, a broad range of 
signalling targets. Many of these protein complexes have been described only in cell lines, 
either derived from CML patient material or other lines transduced. with p2 I ()BCR-ABL 
(summarised in Chapter 1: Figure 1.7 and Chapter 1: Table 1.6). We have already 
described the difficulty in analysing protein complexes in CML patient material. Briefly, 
analysis of protein complexes in primary CML cells has been prevented due to the 
expression of a potent ADA which degrades both normal ABL and oncogenic p2 IOBCR-ABL. 
We have developed a high pH lysis assay which inhibits the degradation of p2 IOBCR-ABL 
and ABL (Chapter 3). The presence of ADA has been a major obstacle in preventing work 
in primary cells but other major advantages of cell lines are the availability of high cell 
numbers and ability to transduce the cell lines with mutant variants of p2 I OWR-ABL to 
determine the roles of specific molecular motifs. However, cell lines do not represent 
primary cells due to the abnormal genomes and over expression of the p2 16WR-ABL 
transcript and protein. Also, they lack the biological variation exhibited between samples 
. P-- - 
362 
from different CML. patients . 
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p2 I OBCR-ABL has deregulated tyrosine kinase activity which is the primary defect in 
CML. The resultant clinical outcome is an unregulated expansion of the myeloid series. 
There is no overt maturational block in the neoplastic clone at this chronic phase stage but, 
if the disease is managed purely by controlling the white cell count, the ultimate acquisition 
of further genetic lesions will permit the emergence of an overt acute leukaemic phase, 
363,364,365 blast crisis, which is generally chemorefractoiy and fatal 
The ABL and BCR proteins are ubiquitously expressed in non-malignant cells 70 
and appear to have multiple cellular regulatory functions. The domains on p2 IOBCR-ABL 
determine the protein interactions and abnormal signalling in CML. BCR carries a serine 
threonine kinase and several tyrosine phosphorylation sites, can modulate actin 
polymerisation through RAC via GTP-ase activity 
366 
, activate the transcription factor 
NFKB by driving GTP substitution for GDP on RHO 367 and may influence the RAS 
pathway through interaction with the adaptor protein, GRB2 77 . BCR knockout mice are 
viable 82 . The ABL protein is predominantly nuclear, with some plasma membrane and f- 
actin-associated. expression 
61,62,70,72 
although a cytoplasmic ABL distribution has been 
noted in primary haemopoietic cells 63. The expression of nuclear localisation and exit 
motifs on ABL suggest a trafficking role for the protein and the three SH domains carry 
tyrosine phosphorylation sites potentially allowing complexing with adaptor proteins such 
as GRB2 or CRKL via their SH2 domains. Functionally, ABL would appear to modulate 
cell cycle regulation, effects of genotoxic stress, and response to integrin Si gnalling 61 . ABL 
knockout mouse survival is severely impaired 
368,369 
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In contrast to ABL, p2 IOBCR-ABL distribution is restricted to cytoplasmic f-actin- 
associated focal adhesions. The protein tyrosine kinase of the ABL component of the 
molecule is constitutively activated and in cell lines p2 lOBCR-ABL binds the adaptor proteins 
GRB2 76, CRKL 215,216,217, CBL 212,213,214 and SHC 211,262,210,207 as well as f-actin. The list of 
p2 IOBCR-ABL substrates is extensive (reviewed by 
229,68, Chapter 1: Figure 1.7 and 
Chapter 1: Table 1.6). These adaptor proteins mediate interactions of p2 I OBCR-ABL which 
activate downstream signaling cascades such as RAS 
193 , 206,254,270,271,272,273,274,275 
. JAK- 
STAT 283,286,287,288,370 and P13K 
276,277,278,279,280,281,282 
pathways. These abnormal signaling 
pathways have been shown to alter cell adhesion 37,2% and modulate proliferation and 
transfortnation 
193 
. The effect p2 
IOBCR-ABL has on apoptosis is not entirely clear-cut. 
Exogenous p2 IOBCR-ABL expression has been shown to make cells more susceptible to 
apoptosis than their, parent cells 
371 
. while other studies have shown no difference 
195,372 
. 
However p2 IOBCR-ABL expression has been shown to prevent apoptosis post growth-factor 
withdrawal in factor-dependent murine cells 
291,373 
and human cell lines 
286 
, and also to 
confer some resistance to apoptosis, induced by DNA damage 
194,292 
. It follows that the 
abnormal cell function and protein complexity in CMI may be linked in some way and, 
further, that variations in complex formation may contribute to clinical and biological 
362 
heterogeneity that has been observed amongst CML patients 
The complexes described in CML so far have been demonstrated using an anti-ABL 
antibody to detect p2l 
OBCR-ABL which makes it difficult to determine if the complexes are 
with p2 10 
BCR-ABL 
and/or ABL unless the partner protein is targeted in the IP. The literature 
is not clear about the complexes between ABL and adaptor proteins CBL, CRKL, GRB2 
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and SHC (summarised in Table 4.1). ABL contains SH domains which theoretically have 
the potential to form complexes in similar ways to p2 OCR-ABL . The tyrosine 177 residue 
on the BCR portion of p2 I OBCR-ABL is the binding site for GRB2 
76,206,200,259 in CML Cells 
but some studies indicate that normal BCR does not complex with GRB2 76 . However other 
studies have shown that BCR can mediate the association between ABL and GRB2 77 .A 
recent study by Ren et al 374 showed that GRB2 may potentially bind to ABL on the C 
terminal end but the association has not been demonstrated by co-IP. The binding of CRKL 
to ABL is also unclear because some studies show that they compleX 299,217 while others 
show that they do not 
375,237,351. Much of the literature also shows that CBL and ABL do not 
214,257,218,246 form a complex . However a study 
investigating the role of ABL and apoptosis 
demonstrates that A13L and CBL can complex 256 . These data concerning - ABL related 
protein complexes still remain controversial and inconclusive. 
We have analysed ABL protein complexes in primary CML and non-CML cells by 
using the high pH lysis assay we have developed (chapter 3). We chose to analyse the 
associations of p2 I OBCR-ABL and ABL with the adaptor proteins CBL (see chapter 1: 
section 1.5.1.4), CRYL (see chapter 1: section 1.5.1.3) and GRB2 (see chapter 1: section 
1.5.1.5) because they bind to p2 IOBCR-ABL directly (Chapter 1: Figure 1.7). 
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Table 4.1 - ABL or BCR-related protein complexes in non-CMIL cells. 
Reports of ABL or BCR complexing or not with GRB2, SHC, CRKL and CBL in various 
non-CML cell lines. COS cells - African green monkey cells, M07e cells - myeloid cell 
line (BCR-ABL-negative), H7 cells - non-CML cells. CHO - Chinese hamster ovary cell, 
293T - non-CMIL cells, BaF3 cells - murine B cell lines, 32D cells - murine myeloid cell 
line. 
Protein Complexes with: - Method Cell type Reference 
AIBL BCR 
GRB. NO NO Co-IP COS cells 
YES Sequencing, IP Fibroblast 374 
BCR YES Co-IP SMS-SB 77 
COS cells 
SHC NO Co-IP 32D 207 
H7 
CRKL YES IP, GST 32D 217 
binding assay 
YES Co-lP M07e / H9 300 
NO Co-IP NIH3T3 375 
NO Co-lp NM3T3 237 
NO Co-T COS-1 216 
CBL NO Co-IP NlH3T3 257 
NO Co-IP 32D 
214 
YES Co-IP CHO / 293T 
256 
70Z/3 
NO Co-IP BaB cells 
U6 
NO Co-T, GST 
218 
binding assay 
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4.2 Results 
For the immunoprecipitation experiments in this chapter we used the high pH lysis assay 
described in chapter 3. 
4.2.1: Development of the IP protocol using protein agarose conjugated (AC) 
antibody. 
4.2.1.1 - Non-speciflic bands related to immunoglobulin (1g) fragments obstruct 
detection of co-immunoprecipitating partner proteins with p2jOBCR-ABL in K562 ceUs 
IP of p2 IOBCR-ABL was performed using pre-conjugated anti-ABL antibody in K562 cefls. 
To determine the specificity of bands seen for p2 jWWR-ABL and co-immunoprecipitating 
proteins pre-conjugated rabbit anti-IgG was also used for an IP in parallel with the IP of 
p2 IOBCR-ABL. Western blotting was preformed on total lysate (TL), IgG IP and ABL IP 
lysate and probed with anti-ABL , CBL, GRB2, CRKL (Figure 4.1). The bands seen in 
positions expected for co-precipitating proteins CBL, CRKL and GRB2 are IgG related 
non-specific bands because they are also detected in the IgG IP. In contrast there was no 
non-specific band seen for p2 I OBCR-ABL when probed with anti-ABL. 
137 
Chapter 4- Protein complexes in CML and non-CML CD34' cells 
TL 
p210 VVB - ABL 
CBL WB - CBL 
CRKL WB - CRKL ! login 
I 
GRIB2 WB - GR-B2 
Figure 4.1 - Co-IP of p2lOBCR-ABL or IgG and adaptor proteins using AC conjugated 
beads. 2x 107 K562 cells were lysed in lysis buffer on ice for 10 minutes and lysate was 
incubated 100ýLl/ml anti-ABL AC bead or normal rabbit IgG AC bead suspension for I 
hour at 4'C. TL, ABL IP and IgG IP lysates were separated on 6.5%, 8%, 12% and 15% 
SDS-PAGE mini-gels due to the MW range of the partner proteins and probed for anti- 
ABL, CBL, CRKL and GRB2, respectively. 
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4.2.2: Methods to overcome the non-specific IgG - related artefact seen with co- 
precipitating proteins 
4.2.2.1 - Pre-clearing cell lysates prior to the IT of p2jOBCR-ABL does not remove IgG 
fragments 
Non-specific contaminants in the cell lysate can be removed by pre-clearing. Therefore, 
K562 cells were lysed in lysis buffer on ice and resuspended in RIPA buffer. The cell lysate 
suspension was pre-cleared using normal rabbit IgG AC beads, centrifuged and the 
supernatant transferred into a fresh tube. IP using anti-ABL AC beads or normal rabbit IgG 
AC bead was then performed on the pre-cleared lysate. Total lysate (TL), IgG negative 
control IP lysate (IP - IgG) and ABL IP lysate (IP - ABL) were separated by western blot 
and probed using anti-ABL and anti-CBL (Figure 4.2). Pre-clearing did not remove the 
IgG-related artefact band seen in the IP - IgG lane when probed for CBL. 
139 
Chapter 4- Protein complexes in CML and non-CML CD34+ cells 
TL 
IP - IgG IP - ABL 
(pre-cleared) (pre-cleared) 
p210 ABIL 
CBL "h"- WB - CBL 
Figure 4.2 - Effects of pre-clearing on co-IP. 2x 107 K562 cells were lysed on ice for 10 
minutes and resuspended in 2ml RIPA buffer. 50gl/ml normal rabbit IgG AC bead was 
incubated with the cell lysate for 30 minutes, centriftiged and the supernatant was incubated 
with 100gl/ml anti-ABL AC or rabbit IgG AC bead suspension. TL, IP-ABL and IP-IgG 
lysates were separated on 6.5% and 8% SDS-PAGE mini-gels and probed for anti-ABL and 
CBL, respectively 
4.2.2.2 - Nlis-match of antibody species used during the IP and NVB procedure and 
pre-absorbed secondary EIRP - conjugated antibodies failed to eliminate the non- 
specific IgG related artefact band in pre-cleared K562 cell lysate 
Artefacts detected with the co-precipitating proteins were the IgG fragments of the antibody 
used during the IP procedure. Santa Cruz, the manufacturers of the antibodies suggested 
that these IgG related artefact bands could be minimised or eliminated by using antibodies 
of mis-match species in the IP and western blot procedures. In addition we used pre- 
absorbed HRP antibodies (pre-absorbed antibodies developed by Santa Cruz 
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Biotechnologies) for western bloting. However, both of these modifications combined 
failed to prevent the detection of the IgG related artefact seen when co-precipitating CBL 
(Figure 4.3). 
TL 
Figure 4.3 - Effects of mis-matching antibody species and pre-absorbed HRP 
antibodies. 2x 107 K562 cells were lysed on ice for 10 minutes and resuspended in 2ml 
RIPA buffer. Cell lysate was pre-cleared using 50gl/ml normal rabbit IgG AC bead for 30 
minutes, centrifuged and supernatant was incubated with 1001il/ml anti-c-ABL AC and IgG 
AC bead suspension. TL, IP-ABL and IP-IgG lysates were separated on 6.5% and 8% SDS- 
PAGE mini-gels and probed for anti-c-ABL and CBL, respectively. 
4.2.2.3 - ExactaCruz 
TM (Santa Cruz) eliminates the IgG related artefact. 
During the course of this study ExactaCruz TM an W kit that ..... effectively eliminates 
detection of heavy and light chains ofIP antibody " (Santa Cruz) became available. The kit 
uses a gel-based IP matrix and a HRP secondary antibody that prevents the detection of the 
IgG fragments. Anti-ABL antibody and IP matrix were incubated for I hour at 4'C to form 
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the antibody-matrix complex. Cells were lysed on ice and incubated with the antibody- 
matrix complex for I hour at 4'C. To analyse co-immunoprecipitation, cell lysate was 
separated by western blot and probed for ABL and CBL Figure 4.4 shows co- 
immunoprecipitation of p2 I OBCR-ABL with CBL in K562. Mouse IgG IP was preformed as a 
negative control to ensure specificity of the bands seen in the co-immunoprecipitation blots. 
The results indicate that the use of ExactaCruz TM eliminates the IgG-related artefact bands 
seen when IP is carried out with agarose beads and p2 1013CR-ABL complexes with CBL in 
CML cells. 
IP - IP - TL IgG ABL 
p210 (JMM WB - AIBL 
CBL WB - CBL 
Figure 4.4 - The ExactaCruZTM IP kit to detect protein complexes in K562 cells. 
I Ogg/ml anti-ABL or mouse IgG antibody and 100gl/ml of mouse matrix was incubated in 
500gl of PBS for I hour at 4'C. 2x 107 K562 cells were lysed in lysis buffer on ice for 10 
minutes and incubated with the antibody-matrix complex for I hour at 4'C. TL, fP-IgG and 
IP- ABL lysates were separated on 6.5% and 8% SDS-PAGE mini-gels and probed for anti- 
c-ABL, CBL respectively. Appropriate secondary antibodies from the ExactaCruzTm kit 
were used for each gel. 
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4.2.3 - Analysis of protein complexes in CMEL cells using ExactaCruzTm IP kit 
1OBCR-ABL Cr 4.2.3.1 CBL, CRKII, and GRB2 complex p2 VM cell lines, K562, KBM5 
and BAF. 210 
We use the ExactaCruz 
TM IP kit to analyse the p2 IOBCR-ADL -associated protein complexes in 
vari. oUs CML cells lines. K562 (p2lOllcR-ABL+/ABL+), BAF. 210 (p2lOl3cR-ABL+/ABL+) and 
KBM5 (p2 IOBCR-ABL+/ABL-) cells were lysed and the anti-ABL antibody and IP matrix 
were incubated for I hour at 4'C to form the antibody-matrix complex. Cell lysate, and 
antibody-matrix were incubated for I hour at 4'C. To analyse co-immunoprecipitation, cell 
lysate was separated by western blot and probed for ABL, CBL, CRKL and GRB2. The 
results confirm that p2 10 BCR-ABL complexes with the adaptor proteins, CBL, CRKL and 
GRB2 in CML cell lines (Figure 4.5). Figure 4.4 shows using conventional lysis buffer 
(no addition of NAOH) we can detect the p2 IOBCR-ABL and CBL complex. However, the co- 
IP experiments shown in Figure 4.5 were carried out in using high pH lysis buffer (as 
described in chapter 3) to check that the high pH lysis conditions, required to detect 
protem complexes in primary CD34 + cells do not affect the p2 IOBCR-ABL -associated protein 
coriqplexes. 
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Figure 4.5 - p2 
jOBCR-ABL associated protein complexes in CML cell lines. 10gg/ml anti- 
ABL or mouse IgG antibody and 100gl/ml of mouse matrix was incubated in 500gl of PBS r-Iju 
for I hour at 4'C. 2x 107 K562, BAF. p210, and KBM5 cells were lysed in lysis buffer 
containing 1.25% 1 OM NaOH on ice for 10 minutes and incubated with the antibody-matrix 
complex for I hour at 4'C. TL, IP-IgG and IP-ABL lysates were separated on 6.5%, 8%, 
12% and 15% SDS-PAGE mini-gels and probed for anti-ABL, CBL, CRKL and GRB2, 
respectively. Appropriate secondary antibodies from the ExactaCruzTm kit were used for 
each gel. 
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4.2.3.2 Adaptor proteins bind both p2jOBCR-ABL and normal ABL in K562 cells. 
The CML literature. suggests that proteins which bind to p2 1013CR-ABL do not complex with 
normal ABL (Chapter 1: Table 1.6) Our co-IP experiments in CML cells were carried out 
using an anti-ABL antibody because until recently there was no commercially available 
antibody which recognises oncogenic p2 IOBCR-ABL protein (refer to chapter 5 which shows 
the use of the anti-BCR-A-BL antibody for CLSM). Consequently, were unable to 
distinguish whether the adaptor proteins, CBL, CRKL and GRB2 bound to oncogenic 
p2 1 OBCR-ABL and/or normal ABL. However, by doing IN on the adaptor proteins, CBL, 
CRY, L and GRB2 and probing with the anti-ABL antibody we can determine if the 
p2 IOBCR-ABL and ABL are present in the complex with the IP protein. We lysed K562 cells 
and used the (A) anti-CBL, (B) anti-CRKL or (C) anti-GRB2 antibodies for the IP. The 
appropriate IP lysate was separated on to the SDS-PAGE gels and probed for the either 
anti-CBL, CRKL, GRB2 and/or ABL (Figure 4.6). These data indicate that both p210BCR- 
ABL and normal ABL complex with the adaptor proteins in K562 cells. 
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TL IP - IgG IP 
IP - CBL 
CBL VM - CBL 
P210 
IP - CBL 
VM - ABL 
ABL =I 
CRKL 4M IP - CRKL WB - CRKL 
p210 
id 
ABL 
IP - CRKL 
WB - ABL 
GRB2 IP - GR-B2 
WB - GRB2 
P210 
IP - GRB2 
WB - ABL 
ABL 
Figure 4.6 - IP of CBL, CRKL and GRB2 with p2jOBCR-ABL and ABL. lOgg/ml anti- 
CBL, CRKL and GRB2 or Rabbit IgG antibody and 100[tl/ml of rabbit matrix was 
incubated in 500gl of PBS for I hour at VC. 2x 107 K562 cells were lysed in lysis buffer 
containing 1.25% IOM NaOH on ice for 10 minutes and incubated with the antibody (A: 
anti-CBL, B: anti-CRKL, C: anti-GRB2) - matrix complex for I hour at 4'C. TL, IP-IgG 
and- IP lysates were separated on 6.5%, 8%, 12% and 15% SDS-PAGE mini-gels and 
probed for anti-ABL, CBL, CRKL and GRB2, respectively. Appropriate secondary 
antibodies from ExactaCruzTm kit were used for each gel. 
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4.2.3.3 p2jOBCR-ABý-associated protein complexes in primary chronic phase CMIL cells 
Chapter 3 describes the difficulty in analysing p2 10BCR-ABý-associated protein complexes 
in primary CML cells. We also found that ADA is located in the cell lysosomes and can be 
inhibited by high pH lysis buffer. Our high pH lysis assay allows us to purify the p2 10 BCR- 
ABL from CD34+ CML cells. We use this assay to IP p2 I OBCR-ABL and analyse co-EP partner 
proteins in CML cells from patients. CD34+ CML cells were isolated from four CML 
patients (A, B, C, D) and lysed using the high pH lysis assay. CD34+ cells were lysed in 
high pH lysis buffer and the anti-ABL antibody was used for the IP. The appropriate IP 
lysate, was separated on to the SDS-PAGE gels and probed for the either anti-CBL, CRKL, 
GRB2 or ABL (Figure 4.7). We show the first demonstration of p2 IOBCR-ABL -associated 
protein complexes in primary CD34+ cells which indicates that p2 I OIBCR-ADL complexes 
with adaptor proteins CBL, CRKL and GRB2 (n = 4). 
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Patient A 
0 
IP - IP - K TL IgG ABL 
p210 AI 
Padent B 
IP - IP- K TL IgG ABL 
Am& -26 rq 
Patient C Patient D 
IP - IP IP - IP - K TL IgG ABL K TL IgG ABL 
Figure 4.7 - p2jOBCR-ABL -associated protein complexes in CML CD34+ cells from 
patients. 10ýtg/ml anti-ABL or Mouse IgG antibody and 100ýtl/ml of mouse matrix was 
incubated in 500gl of PBS for I hour at 4'C. 2x 107 CD34+ CML cells from 4 individual 
patients (A, B, C, D) were lysed in lysis buffer containing 1.25% 10M NaOH on ice for 10 
minutes and incubated with the antibody - matrix complex for I hour at 41C. K562 (K) 
lysate was the positive control. CD34+ TL (TL), IgG IP lysate (IP-IgG) and ABL IP lysate 
(IP-ABL) were separated on 6.5%, 8%, 12% and 15% SDS-PAGE mini-gels and probed 
for anti-ABL, CBL, CRKL and GRB2, respectively. Appropriate secondary antibodies 
from ExactaCruzTm kit were used for each gel. 
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4.2.3.4 - p2 1ORCR-ABL -associated protein complexes in primary blast crisis CMPL cells 
A major factor in CMIL is the stage of disease which will determine the survival and 
prognosis of the patients. Disease progression is also a major determining factor of 
response to therapy 
144,145 
. Therefore analysing differences in signalling protein complexes 
between CP and BC samples may provide a better understanding of disease processes. With 
the introduction of Imatinib, to the clinic the frequency of progression to blast crisis is very 
low (2-4%) 160 and the availability of BC samples is very rare. Consequently, we were only 
able to analyse two samples. Using the high pH IP protocol for primary CD34+ analysis in 
CML cells we analysed the associations of p2 IOBCR-ABL in two BC patient samples. 
Interestingly we found that one of the two patients lack the p2 IOBCR-ABL and CBL complex 
(Figure 4.8: A and 1B). 
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GRB2 
Figure 4.8 - Co-immunoprecipitation of p2 
IOBCR-ABL and CBL, CRKL and GR. B2 
from CML blast crisis CD34+ cells using high pH lysis with ExactaCruz TM 
immunoprecipitation. 2.5x 107 CML CD34+ cells from patient A and B were lysed with 
high pH lysis buffer. K562 control lysates, CML CD34+ total lysates, ABL IP's and IgG- 
only IP's were western blotted for c-ABL, CBL, CRYL and GRB2 respectively. 
4.2.4: Analysis of protein complexes in p2jOBCR-ABL -negative cells 
4.2.4.1 - ABL-associated protein complexes in p2 
OBCR-ABL 
-negative cell lines KGla 
and HL60 cells. 
Interestingly, our co-IP work in CNIL cell lines suggests that p2 I OBCR-ABL as well as normal 
ABIL complexes with CBL, CRKL and GRB2 (Figure 4.6) which contradicts the 
information published so far (Table 4.7). Normal ABL contains SH domains that also have 
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the ability to form complexes with proteins similar to p2 I OBCR-ABL 
376, 
providing the 
rationale for analysing the ABL related protein complexes in non-CMIL cells. We used 
KG Ia cells derived from acute myelogenous; leukaemia (AMI) 
377and HL60 cells derived 
from human promyelocytic leukemia cells, a subset of AML . Both these cell lines are 
p2 I OBCR-ABL -negative and ABL-positive. KG Ia and HL60 cells were lysed in conventional 
lysis buffer because cell lines do express ADA and anti-ABL antibody was used to IP ABL 
from the cell lysate using the ExactaCruzTm IP kit. The TL and IP cell lysate was separated 
on to the SDS-PAGE gels and probed for the either anti-CBL, CRKL, GRB2, BCR or ABL 
(Figure 4.9). This result shows that normal ABL also complexes with BCF, CBL, CRKL 
and GRB2 in non-CML cell lines KG Ia and HL60. 
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KGla 
Figure 4.9 - ABL-associated protein complexes in cell lines. 10ýtg/ml anti-ABL or 
Mouse IgG antibody and 100gl/ml of mouse matrix were incubated in 500ýtl of PBS for I 
hour at 4'C. 2x 107 KG Ia and HL60 cells were lysed in lysis buffer on ice for 10 minutes 
and incubated with the antibody - matrix complex for I hour at 4'C. K562 (K) lysate was 
the positive control. KGla or HL60 TL (TL), IgG IP lysate (IP-IgG) and ABL IP lysate 
(IP-ABL) were separated on 6.5%, 8%, 12% and 15% SDS-PAGE nuni-gels and probed 
for, anti-ABL, BCR CBL, CRKL and GRB2, respectively. Appropriate secondary 
antibodies from ExactaCruzTm kit were used for each gel. 
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4.2.4.2 - AIBL-associated protein complexes in CD34+ cells derived from non- 
leukaemic patients. 
ADA that we have described in Chapter 3 affects both oncogenic p2 OCR-ABL in 
CML and normal ABL in CML and non-CMIL primary cells. As a consequence of ADA 
there is no published demonstration of ABL-associated protein complexes in primary CML 
or non-CMI cells similar to p2 IOBCR-ABL. Our high pH lysis assay (described in chapter 3) 
can inhibit the degradation of ABL as well as degradation of p2 I OBCR-ABL. CD34+ cells 
were isolated from five non-CMI, patients (A, B, C, D, E) and were lysed in high pH lysis 
buffer. Using the anti-ABL antibody and ExactaCruzTm we prefonned the ABL IP. The TL 
and IP lysate firom the CD34+ cells were separated on SDS-PAGE gels and probed for the 
either anti-BCF, CBL, CRKL, GRB2 or ABL (Figure 4.10). Our data shows that BCR and 
GRB2 complex with ABL in all 5 samples but CRKL complexes with ABL in only I of 5 
patients and CBL does not complex with ABL in any of the samples (Summarised in Table 
4.2). 
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Figure 4.10 - ABL-associated protein complexes in CD34+ cells from non-leukaemic 
patients. 10[tg/ml anti-ABL or Mouse IgG antibody and 100gl/ml of mouse matrix were 
incubated in 500gl of PBS for I hour at 4'C. 2x 107 CD34+ non-leukaemic cells from 5 
individual patients (A, B, C, D, E) were lysed in lysis buffer containing 1.25% 10M NaOH 
on ice for 10 minutes and incubated with the antibody - matrix complex for I hour at 4'C. 
K562 (K) lysate was the positive control. CD34+ TL (TL), IgG IP lysate (IP-IgG) and ABL 
IP lysate (IP-ABL) were separated on 6.5%, 8%, 12% and 15% SDS-PAGE mini-gels and 
probed for anti-ABL, BCR, CBL, CRKL and GRB2, respectively. Appropriate secondary 
antibodies from the ExactaCruzTm kit were used for each gel. 
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CeU type BCR CBL CRKL GRB2 
KGla 
HL60 
Patient A 
Patient B 
Patient C 
Patient D 
Patient E 
Table 4.2 - ABL-associated protein complexes in non-CNM cell lines and CD34+ cells. 
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4.3 - Discussion 
In CMEL the fusion gene encodes for a protein of molecular weight 2 10 kDa, p2 I OBCR- 
ABL 
, which has been shown to complex with various cytoplasmic and cytoskeletal proteins 
in cell line models or cells transduced to express p2 IOBCR-ADL . There is no demonstration of 
these associations in primary CMEL cells because the lysis of haemopoiefic cells releases . 
enzymes that destroy p2 10 
BCR-ABL 
and ABL thereby preventing detection of p2 I OBCR-ABL 
and associated protein complexes in CML by IP. Although ADA can substantially be 
103,321,205 destroyed by boiling this step precludes IP experiments to investigate complexes 
in primary cells. The features of ADA that we (chapter 3) and others 204 '205 have described 
are: 
(1) It is a feature of malignant and normal haernopoietic cells. 
(2) It is temperature dependent 
(3) The activity is more concentrated in mature haemopoietic cells but CD34+ selection 
does not eliminate ADA. 
(4) Its is located in the cell lysosomcs and is affected by changes in pH 
(5) Chloroquine, which targets cell lysosomes by increasing the internal pH, will inhibit 
ADA but has adverse affects on viability and tyrosine phosphorylation. 
(6) Lysing cells in high pH lysis buffer mimics the effects of chloroquine and inhibits 
the degradation of p2 I OBCR-ABL and ABL in primary CD34' CML cells without 
affecting tyrosine phosphorylation or cell viability. 
156 
Chapter 4- Protein complexes in CML and non-CML CD34' cells 
There is a wide range of proteins which bind with p2 1OBCR-ABL but for the purposes of this 
study we have focused on the associations of p2 IOBCR-ABL or ABL with the adaptor proteins 
CBL, CRKL and GRB2 in CML and non-CML cells. 
Our work in CML CP has shown that p2 l0BCR-ABL complexes with CBL, CRKL and 
GRB2 in primary CML CD34' cells (Figure 4.7) which confirms the findings in the 
literature based on cell lines. Interestingly, we have shown that in one CML BC patient 
tested for protein complex lacks the p2 I OBCR-ABL - CBL complex but we have only studied 
two patients (Figure 4.8) and so it is difficult to make firm conclusions based on these 
experiments. However this may reflect heterogeneity in cell signalling amongst BC patients 
and. further may contribute to the difficulty in treating advanced disease phase is so difficult 
to treat. In CML CRKL has been of recent interest because the phosphorylated form of this 
protein can be an indicator of response 190"91. The protein has one SH2 domain and two 
SH3 domains which are capable of forming complexes with other proteins. Many 
independent groups reported that CRKL is a major tyrosine phosphorylated protein in CML 
cell lineS216 and primary CML and Ph+ ALL patient material 
232,233,234. Ph- cell lines and 
prunary cells 
215,216,217,234 lack phosphorylated CRKL but do express CRKL protein. CRKL 
complexes with p2 IOIBCR-ABL in W cell lines (Chapter 1: Table 1.6) and the tyrosine 207 
residue on the SH3 domain of CRKL is the major site for p2jeCR-ABL /ABL binding 
236. 
We have shown CRKL and p2 I OBCft: -ABL complex in primary CD3, V- cells using the high pH 
lysis assay by co-IP. CRKL has been implicated in adhesion potentially through its 
interaction with CD34 24' and studies on fibronectin. have shown that CRKL increases cell 
adhesion to fibronectin 
7A 2. CRKL can act as an indirect link between p2 I OBcR-ABLand CBL 
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as it complexes p2 I 
OCR-ABLvia its SH3 domain and CBL via its SH2 domain 
213,214,215,217 
. 
CBL is another protein that can bind directly to p2 I OBcR-ABL/ABL and is ubiquitously 
expressed in celIS247. CBL is tyrosine phosphorylated in Ph+ CML, AML, Ph- T and B- 
ALL 227,246 and over. expression does not have the potential to induce transforniation 
211. 
p2 I OBCR-ABL is able to cause a CML-like disease in mice lacking CBL suggesting that CBL 
is not required for induction of leukaemia induced by p2 I OBCR-ABL 
250. 
p2 I OBCR-ABL is 
complexed. with CBL 213,246 via the SH2 domain on ABL but the interaction is dependent on 
ý1- - uae phosphorylation of CBL. Deletion of the SH2 domain does not alter this interaction 
suggesting that there is another mechanism of interaction for p2 
IOBCR-ABL and CBL. GRB2 
or CRKL may act as linker proteins which indirectly link p2 
IOBCR-ABL and CBL 
224,251,252 
. 
The literature suggests that CBL is involved in pathways of ubiquination 
255,256 
, RAS and 
P13K 218 signaling and can complex with normal ABL and oncogenic p2 I 
OBCR-ABL 
. The 
SH2 domain of GRB2 can also bind p2 1013CR-ABL directly via the tyrosine 177 residue on 
BCR 76,206,200,259 which requires tyrosine phosphorylation. 
76 
. In CMI a complex 
between 
p2lopCR-ABL and GRB2 recruits SOS which cause activation of RAS signalling. 
The data from cell lines suggest that these adaptor proteins, CBL, CRKL and GRB2 
facilitate the downstream activation of multiple signaling cascades. Our co-IP work shows 
that these complexes also form in primary CD34+ CNIL cells which have the ability to 
activate downstream signaling cascades similar to those described in cell 
line models. 
Using the high pH lysis assay it would be interesting to extend the investigation to 
complexes downstream of the adaptor proteins in primary cells because we predict that they 
will differ from cell lines if they exist in this area of the signaling cascade. 
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A more controversial and is less well understood aspect of protein complexes is the 
association of normal ABL with proteins that complex with p2 I OBCR-ABL . The nuclear and 
cytoplasmic localisation of normal ABL 63 suggests that ABL may form complexes that 
differ from p2 I OBCR-ABL complexes. In the CML related literature many studies have 
shown that ABL does not complex with proteins such as CBL, CRKL and GRB2, which 
complex p2 I OBCR-ABL whilst a small number of studies have shown that ABL complexes 
with CBL, BCR, CRKL and GR132 in cell lines (refer to Table 4.1). To determine if CBL, 
CRKL and GRB2 bound to p2 1OBCR-ABL specifically we preformed reverse IP's and 
western blotted with an anfi-ABL antibody and interestingly we found that both p2 IOBCR- 
ABL and ABL complex with these adaptor proteins in K562 cells (Figure 4.6). This raised 
questions about the protein associations of nonnal ABL. Therefore, we analysed ABL 
related complexes in non-CML cell lines, KG Ia and HL60 both of which originate from 
patients with AML. These co-IP experiments strengthened our finding that normal ABL 
complexes with CBL, CRKL and GRB2 (Figure 4.8). Based on the data for ABL- 
associated complexes we analysed these complexes in primary cells which has not been 
done due to the presence of the degradative enzymes in primary cells. But using the high 
pH lysis assay we analysed the association of ABL with CBL, CRKL and GRB2 in primary 
CD34+ cells from non-CML patients. Surprisingly, we found that GRB2 and BCR bound to 
normal ABL but CBL and CRKL (except patient A who had a CRKL and ABL complex) 
did not (Figure 4.9 and 4.10). Even though Pendergast et a176 suggest that nonnal ABL are 
incapable of forming complexes with GRB2 in COS- I cells, Ma et al 77 in the same cell 
line has shown that pI 45ABL, pl6oBcRand GRB2 form complexes demonstrated by co-IP. 
Also, ABL may be capable of forming a complex with GRB2 in similar ways to CRKL ""' 
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Both of these studies propose two different mechanisms by which ABL and GRB2 can 
complex (Figure 4.1 1). Based on our data it is difficult to distinguish which of these 
mechanisms have potentially exist in primary cells. 
Figure 4.11 - Mechanisms of ABL and GBR2 associations. ABL can mediate an 
association with GRB2 via BCR as an intermediate (A) or directly (B). 
The lack of CBL and CRKL complexes with ABL in cells of non-leukaemic origin 
suggests that the phosphorylation of these proteins in malignant cells may be essential for 
complex formation between the proteins and ABL. In the case of CRKL, it is well 
established that in Ph-negative cells the protein is not phosphorylated 
215,216,217,234 
which 
may prevent CRKL and ABL from complexing in cells which are not of CML origin. CBL 
is tyrosine phosphorylated in cells from a range of different types of leukaemias, such as 
CML BC, AML, Ph- T and B -ALL 
227,246 
. The association between 
CBL and p2 1()BCR-ABL 
214,246 
is dependent on tyrosine phosphorylation of CBL . This supports our 
findings that 
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norr. nal ABL complexes with CBL in leukaemic cells, from CMIL and AML patients but not 
in non-leukaernic cells which in theory lack phosphorylated CBL. In contrast to CRKL and 
CBL, GRB2 is phosphorylated in under various physiological conditions such as PDGF 
treated vascular smooth muscle 378 , anti-CD3 stimulated primary murine T-lymphocyteS 
379 
and cells stimulatedwith epidermal growth factor (EGF)380 implying GRB2 
phosphorylation is not specific to leukaemic cells. These findings provide a potential 
explanation for the lack of CBL and CRKL complex with normal ABL and the association 
of GRB2 with ABL in non-leukaemic CD34+ cells. 
Our protein complex work indicates these associations of p2 l0BCR-ABL and ABL 
may vary based on cell type where protein complexes may be CML-specific, leukaemia- 
associated or non-specific (Table 43) and the phosphorylation of the proteins may 
influence the complexes it forms. 
CML - specific Leukaemia - specific Normal - specific 
CBL x 
CRKL x 
GRB2 
Table 4.3 - Classification of protein - protein interactions. 
4: indicates an association 
and'X: indicates no association. The co-IP experiments suggest that CBL and CRKL form 
CML and leukaemia specific proteins complexes but GRB2 forms non-specific complex. 
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CHAPTER 5- SUBCELLULAR DISTRIBUTION AND 
QUANTIFCATION OF p210 
BCR-ABL IN CML CELLS 
5.1 Introduction 
The p2 lOBCR-ABL fusion protein is well known to form intracellular complexes with 
multiple protein partners in cell lines, as demonstrated by immunoprecipitation and western 
blotting (reviewed by 229,275,68 ). These observations have invoked a model in which 
p2 IOBCR-ABL recruits signaling enzymes and adaptor molecules into multimolecular 
complexes which activates them. 
As previously discussed, p2 I OBCR-ABL 
is one the major fusion proteins that form as a 
result of a translocation between BCR and ABL genes. Briefly, the breakpoint on the BCR 
gene determines the type of protein transcribed (Chapter 1: Figure 1.5). p2 IOBCR-ABL, 
present in the majority of CML and 1/3 of ALL patients, arises due to a break in the M-bcr 
region (exons; 12 to 16). Most CML cases express either the el4a2 (b3a2) or e13a2 
(b2a2) 
breakpoints 83 .A very small proportion 
(approximately 1-2%) of patients express much 
rarer breakpoints 83,331 which may have an effect on the clinical phenotype of the 
disease 83. 
The'el4a2 breakpoint has been linked to a poorer prognosis 84,382 but similar comparisons 
by other groups have shown no significant difference between patients who express the 
el3a2 and el4a2 transcri PtS 
85. An association between the breakpoint of p2 IOBCR-ABL and 
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the duration of chronic phase has been reviewed 383 . There still remains some controversy 
with regard to the prognostic relevance of different breakpoints. 
The subcellular distribution of normal ABL and oncogenic p2 1013CR-ABL is a major 
distinguishing feature between the normal and oncogenic proteins. Normal ABL is found in 
the nucleus and the cytoplasm 62,63 and can shuttle between the two compartments due to 
the presence of the nuclear localisation signals (NLS) and nuclear export signal (NES)64. In 
contrast p2l OBCR-ABL is located exclusively in the cytoplasm even though the protein 
expresses the NLS and NES regions 63,83 which suggests that NLS is inactive or NES 
predominates. In the cytoplasm p2 I OPCR-ABL is closely associated with f-actin which is 
mediated via the actin binding domain on the c-terniinal of p2 I 
6BCR-ABL 67,384. 
p2lo 
BCR-ABL 
also complexes with and phosphorylates other focal adhesion proteins 221 . Interestingly, 
nuclear ABL induces apoptoSiS 
61 
and cytoplasmic p2 IOBCR-ABL inhibits apoptosis via 
signalling pathways such as the P13K pathway 
385,386. 
p2 1013CR-ABL does not translocate to 
the nucleus in CML but inhibition of the tyrosine kinase activity by Imatinib causes its 
translocation to the nucleus. When the cells are co-treated with Imatinib and leptomycin 
which is a drug that blocks nuclear export, the protein only remains in the nucleus. 
Reactivation of p2 1013CR-ABL tyrosine, kinase activity once the protein is in the nucleus 
causes apoptosis of the cells rapidly 293 . These observations imply that the subcellular 
localisation of p2 IOBCR-ABL can be important in understanding and treating CML. 
Cytoplasmic localisation and tyrosine phosphorylation of p2 IOBCR-ABL permits it to 
phosphorylate and form complexes with certain intracellular signalling proteins. An 
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important binding protein is CRKL, on chromosome 22, which was first cloned by ten 
Hoeve in 1993 230 . The gene encodes for a 39 kDa protein that is found most abundantly in 
haemopoietic tissue 231 . Ph- cell lines and primary cells express CRKL protein but lack 
phosphorylated CRKL 
216,233,232,234,235 
. CRKL is a major tyrosine phosphorylated. protein in 
CML which has been demonstrated by many independent groups in K5 62 cells and COS- I 
cells transfected. with p2l oBCR-ABL 
232 
, peripheral blood from CM[L and Ph+ ALL patients 
233,232 234 216,215,217. Cp 
'K CML neutrophils and CML platelets CL complexes with p2 I 
OBcR- 
ABL in Ph+ cell lines 
215,216,217 
and we have shown CRKL and p2 1013CR-ABL complex in 
primary CD34+ cells by co-IP using the high PH lysis assay 
46 (refer to Chapter 3). Levels 
of CRKL phosphorylation in response to therapy can be used as an indirect marker of 
changes in p2 I OBCR-ABL function assayed by western blot '90 and FACS 19. 
Many questions remain about the composition of the protein complexes in primary 
CML cells. In particular, it is not known if the complexes incorporate all of the implicated 
proteins all of the time, if their composition can be modified or what implications changes 
may have on intracellular signalling or cell function. Confocal laser scanning microscopy 
(CLSM) can be used to analyse co-localised proteins in single cells 63 but studies of 
proteins co-localised with p2 IOBCR-ABL have been confounded by the lack of an antibody 
that specifically recognises the fusion proteins. Instead, antibodies to ABL or BCR have 
been used although these detect the normal cellular proteins as well. Studies were 
conducted by Wetzler et al 63 and Skourides et al 311 which demonstrated that the p2 I OIWR- 
ABL/ABL protein is distributed in punctuate structures in the cytoplasm. The study by 
Wetzler et al 63 analysed the differences between the subcellular distribution of p2 I OB'cR- 
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ABL 
, normal A13L and normal BCR in various cell lines and Skourides et a1311 
demonstrated a similar cytoplasmic distribution of p2lOl3cR-ABL /ABL in transfected 
haemopoietic and fibroblastoid cells. They further showed that p2 I OWR-ABL/ABL and 
adaptor proteins such as GRB2, SHC and CBL co-localise with p2 IOBCR-ABL in transfected 
fibroblasts. The recent availability of a p2 10 
BCR-ABL 
antibody that recognises the b2a2 
junction sequence (Cell Signalling Technologies'ý') means that the specific distribution of 
the b2a2 version of p2 IOBCR-ABL can be visualised 
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5.2 Results 
5.2.1: Anti-BCR-ABL antibody detects the p2jOBCR-ABL with the b2a2 breakpoint. 
The anti-BCR-ABL antibody is specific to one of the major breakpoints of p2 IOBCR-ABL , To 
analyse the specificity of this antibody we used BV 173 cells, which express p2lO'3CP'-AB" 
with the b2a2 (e I 3a2) breakpoint and K562, which express p2 IOBCR-ABL with the b3a2 
(e I 4a2) breakpoint. We tested the specificity with using western blots, FACS analysis and 
immunofluorescence. 
5.2.1.1 - Specificity of the anti-BCR-A-BL antibody by western blots ana sis 
K562 and BV173 cell lysates were was used to detemAne the specificity of the anti-BCR- 
ABL antibody by western blot. This showed that p2 IOPCR-ABL and ABL proteins were 
detected in both cell lines by the anti ABL antibody (Figure 5.1 A) but the breakpoint - 
specific anti-BCR-ABL antibody only detected p2l6BcR-ABL in BV 173 cells (Figure 5.1 B). 
Thus the antibody does not detect b3a2 or normal ABL proteins. 
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K562 
P210 BCR-ABL 
ABL 
Actin 
BV173 
(A) VVB: Anti-ABL 
P2 1 OBCR-ABL 
ABL 
K562 BV173 
Ammummok 
Actin 
me-sm 
(B) WB: Anti-BCR-ABL 
Figure 5.1 - Detection of p2jOBCR-ABL and ABL using the anti-c-ABL and anti-BCR- 
ABL antibody. 106 K562 and BV173 cells were lysed in cold lysis buffer and cleared 
lysate was added to equal volumes of sample buffer and boiled for 10 minutes. 20gl each 
lysate was loaded, run on a 6% polyacrylamide gel and transferred on to nitrocellulose 
membrane. Membranes were blocked for I hour at room temperature and probed with anti- 
ABIL (A) and anti-BCR-ABL (B) antibody overnight at 4'C. Actin was used as a loading 
control. 
5.2.1.2 - Specificity of the anti-BCR-ABL antibody by 
FACS 
FACS can also be used to analyse the protein expression and quantify the level of protein 
present in the two cell types. Again, K5 62 and BV 173 cells were used to deternline the 
specificity of the anti-BCR-ABL antibody. Figure 5.2 shows the anti-BCR-ABL antibody 
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1013CR-ABL in CML cefls 
recogmses a p210 
BCR-ABL_Positive 
population in BV 173 cells (A, B). However, there was 
some false positive signal when K562 cells (C, D) (negative control) were analysed. This 
implies that the anti-BCR-ABL antibody is not suitable for FACS analysis. 
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Figure 5.2 - Expression of p2jOBCR-ABL (b2a2 breakpoint) by FACS. 5x 
105 cells were 
stained as per the manufacture's protocol using the 'Fix and Perm' kit. 1.25gg/ml (1: 20 in 
reagent B) Anti-BCR-ABL or mouse IgG2aisotype antibody determines the expression of 
p2 I OBCR-ABL with the b2a2 breakpoint. (A/B) BV 173 cells and (C/D) K562 cells shows 
density plots showing the expression of p2 I OBCR-ABL and IgG in BV 173 cells and the 
histogram shows the overlay of p2 I OBCR-ABL (M ) and IgG (. ). (E) Overlay of the 
histograms for p2 I OBCR-ABL expression in K562 cells (ý) and BV173 cells (M). 
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5.2.1.3 - Specificity of the anti-BCR-A-BL antibody using confocal microscopy 
Microscopy can be used to determine the expression of protein but has the advantage over 
western blot and FACS analysis that the cellular distribution of the protein can be analysed 
in single cells. The specificity of the anti-BCR-ABL was determined using confocal 
microscopy. Both K5 62 and BV 173 cells are positive using anti-ABL and anti-BCR 
antibodies but only BV173 cells are positive using anti-BCR-ABL Ounction specific) 
antibody. The isotype controls were all negative (Figure 5.3). This suggests that the anti- 
BCR-ABL antibody detects only the p2 IOCR-ABL with the b2a2 breakpoint when analysed 
by CLSM. 
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Figure 5.3 - Speciflcity of 
anti-BCR-ABL aunction 
specific) antibody. 
K562 and BV 173 cells were air 
dried, fixed in 2% PFA and 
permeabilised in 0.2 % triton in 
PBS. Blocked in 5% FBS/3% 
BSA and anti-c-ABL, anti- 
BCF, anti-BCR-ABL (+) or 
matched isotype control (IgG) 
was incubated for I hour at 
room temperature. After three 
washes cells were incubated 
with either AF 488 or AF 564 
and washed and mounted with 
VectaShield plus DAPI. All 
cells were analysed using the 
CLSM. 
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5.2.2: SubceHular distribution of p2 1OBCR-ABL in CML ceUs 
The results in Figure 5.3 suggested a degree of subcellular localisation of p2 I OB CR-ABL 
since areas of high intensity staining were visible in the BV 173 cells. To investigate this 
pattern further we used CLSM on the BV173 (A), KCL-22 (B) and KYO-I (C) cell lines, 
all of which express p2 I OBCR-ABL With the b2a2 breakpoint. The results in Figure 5.4 A, B 
and C show clearly that a multifocal distribution of p2 IOBCR-ABL could be discerned in all 
three cell lines, myeloid as well as lymphoid. Next we investigated the distribution of 
p210 ABL in primary CD34+ and mononuclear CML cells. Three independent CMEL 
samples (Figure 5.5: CML 1, CML 2, CMIL 3) were analyzed. The CD34+ cells exhibited 
clear foci (Figure 5.5 A), like the cell lines, but more diffuse staining characterised the 
mononuclear cells (Figure 5.5 B). This observation indicates that the distribution of 
p210 
BCR-ABL 
may be related to cellular maturation. 
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I Anti-BCR-ABL Anti-IgG I 
BV173 cells 
KCL-22 cells 
KYO-I cells 
Figure 5.4 - Subceflular distribution of p2jOBCR-ABL in CML cefl lines. (A)BV173, (B) 
KCL-22 and (C) KYO- I cells which express p2 IOBCR-ABL with the b2a2 breakpoint were air 
dried on to glass slides. Dried cells were Rxed in 2% PFA and penneabilised in 0.2 % triton 
in PBS, blocked in 5% FBS/3% BSA and incubated with anti-BCR-ABL or matched 
isotype control (IgG) was incubated for I hour at room temperature. After three washes 
cells were incubated with AF 488 and washed and mounted with VectaShield plus DAPI. 
All cells were analysed using CLSM. 
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CML CD34+ cefls (n =3) 
Anti -BCR-ABL 
Anti -IgG 
CML MNC 3 
CML mononuclear cells (n=3) 
Figure 5.5 - SubeeRular distribution of p2jOBCR-ABL 
in primary CML ceRs 
Three CML patients (CML 1, CML 2, CML 3) which express p2 I OBCR-ABL With the b2a2 
breakpoint were selected and (A) CD34+ cells (CML CD34+ 1, CMIL CD34+ 2, CML 
CD34+ 3) and (B) MNC (CML MNC 1, CML NINC 2, CML MNC 3) cells from each 
patient were air dried on to glass slides. Dried cells were fixed in 2% PFA and 
permeabilised in 0.2 % triton in PBS, blocked in 5% FBS/3% BSA and incubated with anti- 
BCR-ABL or matched isotype control (IgG) was incubated for I hour at room temperature. 
After three washes cells were incubated with AF 488 and washed and mounted with 
VectaShield plus DAPI. All cells were analysed using CLSM. 
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5.2.3: Quantification of p2jOBCR-ABL -positive foci in CML cell lines (BV173, KCL-22, 
K-YO-1) and primary CMEL ceRs (CML 1, CML 2, CML 3). 
In order to quantify the observed differences in the number of foci per cell in cell lines and 
primary CD34+ CML cells we devised a scoring system described in Figure 5.6 and 
chapter 2. We define a focus by the following criteria: 
(1) High intensity of staining around a point represents a focus 
(2) Staining has to clearly stand out from the background 
(3) Any irregular elongated staining scored as one focus. 
Z scans from one hundred cells of each cell line and primary CD34 + cells per patient (n7-3) 
were scored in this manner Table 5.1. This data is summarised in Figure 5.7 where (A) 
shows the number of foci per cell in the CML cell lines (KCL22, KYO 1, BV 173) and in 
three primary CD34+ CMIL samples (CML I, CMEL2 and CML3) and (B) shows the mean 
number of foci per cell. The differences between the cell lines and primary CD34+ cells are 
statistically significant (p < 0.001) (C). The differences among the CML patient samples 
are less clear but statistical analysis shows that the differences within this group are 
statistically significant (p < 0.0059 p< 0.001) suggesting the focus distribution within CML 
samples is heterogeneous. Our sample size is very small and it would be interesting to 
analyse more patient material to confirm the differences. However, this approach is limited 
to patient samples that express the b2a2 breakpoint. p2 I OBCR-ABL focus distribution is 
similar between two of three cell lines (BV173 and KYO-I cells) we tested whilst KCL-22 
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I 
cells express a much higher number of foci relative to the rest of the cell types we have 
tested (p < 0.001). 
B 
Figure 5.6 - strategy to score p2 
1OBCR-ABL 
- positive foci. KCL-22 cells stained with 
anti-p2 I OBCR-ABL antibody and A. represents aZ scan of KCL-22 cell stained for p2 I 
OBCR- 
ABL and (B) red circle (0) indicate the p2 I OBCR-ABL positive foci which were scored. 
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Table 5.1 - Number of foci per cell. Images of BV173, KCL-22, KYO-1, CML CD34+ 1, 
CNffi CD34+ 2 and CML CD34+ 3 cells taken by CLSM were analysed. The number of foci 
perpell was scored from the z-scan images of each cell type. 
Number of p2jOBCR-ABL - positive foci 
n 
KCL-22 KYO-1 BV173 
CNIIL CML 
CD34+ (1) CD34+ (2) 
CML 
CD34+ 
(3) 
1 35 23 13 66 6 
2 41 28 16 84 5 
3 38 12 15 12 3 2 
4 40 25 16 54 4 
5 36 13 18 14 1 1 
6 32 21 5 85 4 
7 29 16 13 10 9 4 
8 32 15 11 5 10 1 
9 26 22 13 48 1 
10 39 14 15 4 11 2 
11 23 21 16 92 0 
12 36 22 11 63 3 
13 25 13 21 73 15 
14 37 11 13 32 4 
15 31 18 11 16 4 4 
16 34 23 14 7 13 1 
17 28 32 16 15 2 
18 19 26 11 9 14 2 
19 17 5 14 19 10 1 
20 34 11 13 11 9 5 
21 12 8 17 9 16 2 
22 14 6 9 99 3 
23 17 9 11 7 15 0 
24 15 11 10 17 1 0 
25 24 10 6 14 14 3 
26 _ 20 11 18 4 3 4 
27 14 18 12 10 5 2 
28 _ 27 16 16 11 0 1 
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29 22 20 11 2 6 2 
30 21 14 9 2 9 1 
31 17 18 6 4 6 1 
32 20 12 8 4 15 9 
33 23 21 5 8 9 4 
34 16 16 10 11 8 5 
35 15 13 12 4 13 5 
36 16 18 9 2 4 4 
37 22 16 6 6 5 7 
38 40 11 17 6 5 4 
39 24 23 13 3 4 2 
40 27 19 11 5 6 5 
41 17 11 16 4 15 0 
42 34 29 10 5 7 1 
43 16 17 18 4 16 2 
44 12 16 11 3 12 3 
45 23 21 18 9 11 6 
46 18 24 30 5 14 5 
47 29 22 29 2 11 2 
48 38 20 25 3 17 3 
49 23 19 16 2 10 1 
50 19 11 26 5 16 5 
51 30 5 20 6 5 3 
52 28 8 19 4 7 4 
53 26 22 16 4 5 1 
54 16 15 13 6 4 2 
55 33 13 15 5 5 10 
56 41 25 16 3 2 4 
57 24 33 11 3 6 3 
58 22 13 13 8 10 2 
59 19 15 17 14 11 3 
60 17 9 11 21 9 4 
61 11 10 14 4 12 1 
62 20 11 16 7 3 0 
63 18 6 11 12 4 1 
64 16 16 14 3 4 4 
65 12 4 13 3 3 2 
66 21 5 17 5 5 6 
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67 23 6 19 5 14 1 
68 29 8 11 9 6 4 
69 31 9 21 12 15 2 
70 15 6 14 5 11 1 
71 15 5 18 3 10 2 
72 21 4 16 7 17 3 
73 40 2 18 7 10 1 
74 32 8 11 4 16 2 
75 19 6 9 6 7 4 
76 13 9 6 5 15 1 
77 29 5 8 6 4 3 
78 34 15 5 5 6 2 
79 19 12 10 4 1 1 
80 15 16 12 10 7 4 
81 12 9 9 6 10 3 
82 38 16 6 3 7 2 
83 36 6 17 4 16 0 
84 21 19 19 3 10 6 
85 22 25 11 6 9 1 
86 16 21 21 7 14 3 
87 36 10 24 5 5 3 
88 39 16 18 5 6 2 
89 29 15 11 7 6 5 
90 45 13 18 6 5 4 
91 38 25 12 4 7 2 
92 21 5 9 4 16 1 
93 29 16 20 9 8 3 
94 32 19 17 15 17 4 
95 40 22 11 22 13 0 
96 31 17 10 5 12 1 
97 19 11 8 8 15 2 
98 26 21 12 13 12 2 
99 16 5 11 4 18 0 
100 12 9 17 4 11 6 
Mean 25.14 14.72 13.85 6.80 8.59 2.80 
SD 8.87 6.87 4.98 4.19 4.66 1.94 
SEM 
(SD/4n) 1 0.89 0.69 1 0.50 1 0.42 0.47 0.19 
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C71 KCL-22 < 0.001 < 0.001 < 0.001 < 0.001 < 0.00 1 
KYO-1 < 0.001 0.458 < 0.001 < 0.001 < 0.001 
BV173 < 0.001 *0 0 0.458 < 0.001 < 0.001 < 0.001 
CMLI < 0.001 01 < 0.001 < 0.00 1 < 0.005 < 0.001 
CML2 < 0.001 <0 < 0.001 < 0.00 1 < 0.005 < 0.001 
CML3 < 0.001 < 0.001 < 0.001 < 0.001 
KCL- c 
22 
KYO-1 BV173 CML1 CML2 CML3 
FigUre 5.7 - Quantiflcation of p2jOBCR-ABL_positive foci in CMEL ceU lines (BV173, 
KCL-22, K-YO-1) and primary CD34+ CML cefls (CML 1. ) CML 2. CML 3). 
(A) Shows the number of foci for single cells, (B) represents the mean number of foci for 
each cell type (+/- SEM) and (C) p-values for the number of foci in the different cell types. 
All the cells type show a statistical difference except the KYO- I and BV 173 cells. 
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5.2.4: Correlation between the mean number of foci and total cellular p2 OBCR-ABL 
Total p2 I OBCR-ABL levels may influence the number of foci. Therefore we measured the 
total amount of p2 IOBCR-ABL expressed the same cell by Image J analysis. The most 
common method used to measure the total levels of p2 I OBCR-ABL is FACS analysis but as 
described in section 5.2.1.2 the anti-BCR-ABL junction specific antibody is not suitable for 
FACS. Alternatively, the image J software measures the integrated density (ID) of the 
immunofluorescent signal of a region of interest (ROI) from a single CLSM image. Table 
5.2 shows that mean density data for BV 173, KCL-22, KYO- 1, CMEL CD34+ 1, 
CMIL CD34+ 2 and CML CD34+ 3. There is a statistically significant correlation between 
total levels of p2 I OBCR-ABL and the number of foci per cell in the CML cell lines 
and patient samples (r = 0.989, p<0.0001) (Figure 5.8). This implies that the 
variation in the number of foci per cell type is directly related to differences in the total 
levels of p2 IOBCR-ABL. 
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Table 5.2 - Integrated density of p2 1OBCR-ABL in different cell types. Images taken by 
CLSM were imported into Image J and the ID was measured. (* units of integrated density) 
ED of p2lOBCR-ABL - positive cell 
n 
KCL-22* KYO-l* BV173* 
CML 
CD34+ (1)* 
CML 
CD34+ (2)* 
CML CD34+- 
(3)* 
1 6066. *99 3263.84 4885.28 4215.84 3792.85 1400.55 
2 6358.48 4252.89 6198.82 2740.00 - 2541.08 - 1144.46 
3 4345.35 10203.77 5387.47 2212.28 2258.09 1381.83 
4 6451.14 7090.46 4990.95 2214.77 3907.08 1460.37 
5 7437.74 10385.18 3162.98 3164.49 2644.23 1363.96 
6 7412.99 9875.52 5025.76 4345.52 3076.46 2019.83 
7 6292.93 3456.18 5140.29 3217.13 2610.22 2263.07 
8 6944.43 4445.23 6346.86 5028.69 2109.50 1911.79 
9 8962.57 4637.58 5008.62 3838.06 3821.74 1606.98 
10 6590.10 7282.80 6322.15 3151.73 2015.58 1313.67 
11 10277.15 10577.53 5510.81 3954.74 1894.81 2204.62 
12 6760.39 10067.87 5114.28 4015.89 4858.16 1692.19 
13 10392.66 3648.53 3286.31 4210.47 2790.45 1803.21 
14 8013.87 4637.58 5149.10 3883.34 2790.45 1634.30 
15 10516.31 4829.92 5263.63 3746.35 3125.64 2115.84 
16 7709.06 7475.15 6470.19 2863.07 2749.86 2034.83 
17 7709.06 10769.87 5131.95 3892.61 4535.87 2638.59 
18 7039.84 10260.21 6445.49 3748.97 3159.02 3190.20 
19 6331.51 3840.87 5634.14 2787.66 3298.22 2341.09 
20 9252.84 4829.92 5237.62 2681.20 3854.29 2589.90 
21 5809.72 5022.27 3409.64 3366.15 2565.96 1494.86 
22 5857.01 7667.49 5272.43 3424.40 2714.25 3358.62 
23 9738.98 2315.34 5386.96 3373.74 2630.75 2135.36 
24 6309.66 1192.34 6593 . 52 3831.32 
2720.59 2124.25 
25 5476.43 4033.22 5255.28 2489.83 3022.41 2578.46 
26 6503.11 3188.63 6568.82 1307-73 2609.73 1543.90 
27 5818.55 4177.68 5757.47 2467.24 2611.88 3301.30 
28 7654.04 4370.02 5360.95 4450.73 1987.26 
- 
2087.19 
29 7362.51 7015.24 3532.98 4165.29 3190.15 
t 
2573.63 
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30 4126.66 10309.97 5395.76 6271.01 4421.01 3136.22 
31 8473.61 9800.31 5510.29 3729.95 3169.25 2489.32 
32 8231.82 3380.97 6716.86 4416.32 2886.26 2523.59 
33 8473.61 4370.02 5378.62 5345.25 4535.25 2339.65 
34 6361.57 4562.37 6692.15 7311.94 3272.40 2184.47 
35 9031.97 7207.59 5880.81 7137.17 3704.62 2308.71 
36 8737.21 10502.32 5484.28 8558.28 3238.39 1669.57 
37 6144.38 9992.66 3656.31 9652.13 2737.67 1827.30 
38 6774.09 3573.32 5519.10 3781.26 4449.90 2235-11 
39 7164.05 4562.37 5633.63 3826.22 2643.74 2339.70 
40 7478.05 4754.71 6840.19 2987.92 2522.98 1970.00 
41 8063.44 7399.93 5501.95 3082.14 5486.33 1646.90 
42 6553.39 2047.79 6815.49 2289.62 3418.62 2026.51 
43 6323.39 1018.60 6004.14 2573.08 3418.62 3079.35 
44 7412.99 3765.66 5607.62 3850.63 3753.80 2826.73 
45 6292.93 2921.07 3779.64 3569.72 3378.02 3046.10 
46 6944.43 3910.12 5642.43 2424.94 5164.04 3410.67 
47 8962.57 4102.47 5756.96 3884.26 3787.19 3189.21 
48 6590.10 6747.69 6963.52 3218.75 3926.38 2910.57 
49 10277.15 3233.54 5625.28 4279.23 4482.45 2042.07 
50 8013.87 9532.76 6938.82 2803.39 3194.13 3297.91 
51 7189.33 3385.82 5115.51 2275.67 3342.42 3292.39 
52 7480.81 4374.87 6429.04 2278.16 3258.92 2965.33 
53 5467.68 10325.75 5617.70 3227.87 3348.76 2385.34 
54 7573.48 7212.44 5221.17 4408.91 3650.58 2297.73 
55 8560.07 10507.16 3393.20 3280.52 3237.90 2560.50 
56 8535.32 9997.50 5255.99 5092.08 3240.05 3159.59 
57 7415.26 3578.16 5370.52 3901.45 2615.43 1876.14 
58 8066.77 4567.21 6577.08 3215.12 3818.31 1702.88 
59 10084.90 4759.56 5238.84 4018.13 5049.18 1588.89 
60 7712.43 7404.78 6552.38 4079.28 3797.42 1738.70 
61 11399.48 10699.51 5741.03 4273.85 3514.43 1945.63 
62 7882.72 10189.85 5344.51 3946.73 5163.42 3222.80 
63 11514.99 3770.51 3516.53 3809.74 3900.57 3089.38 
64 9136.20 4759.56 5379.32 2926.46 4332.79 5849.17 
65 11638.64 4951.90 5493.85 3956.00 3866.55 2481.44 
66 8831.39 7597.13 6700.41 3812.36 3365.83 2165.28 
67 8831.39 10891.85 5362.17 1 2851.04 5078.07 2335.73 
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68 8162.17 10382.19 6675.71 2744.59 3271.91 1994.86 
69 7453.84 3962.85 5864,36 3429.53 3151.14 2372.81 
70 10375.17 4951.90 5467.84 3487.78 6114.49 2993.15 
71 6932.05 5144.25 3639.86 3437.13 4046.78 2118.20 
72 6979.34 7789.47 5502.65 3894.70 4046.78 ' 2137.67 
73 10861.32 2437.32 5617.18 2553.22 4381.97 2859.31 
74 7431.99 1314.32 6823.74 1371.12 4006.19 1861.78 
75 6598.77 4155.20 5485.51 2530.63 5792.21 2567.60 
76 7625.44 3310.61 6799.04 4514.12 4415.35 2721.92 
77 6940.88 4299.66 5987.70 4228.68 4554.55 2489.34 
78 8776.38 4492.00 5591.17 6334.40 5110.62 2454.32 
79 8484.85 7137.22 3763.20 3793.34 3822.30 2258.00 
80 5248.99 10431.95 5625.99 4479.70 3970.59 1515.60 
81 9595.94 9922.29 5740.52 5408.64 3887.08 2236.42 
82 9354.16 3502-95 6947.08 7375.33 39 76.92 1837.85 
83 9595.94 4492.00 5608.84 7200.55 4278.74 2286.64 
84 7483.90 4684.35 6922.38 8621.67 3866.07 2832.13 
85 10154.30 7329.57 6111.03 9715.51 3868.21 3646.60 
86 9859.55 10624.30 5714.51 3844.65 3243.59 3757.94 
87 7266.72 10114.64 3886.53 3889.61 4446.48 3219.98 
88 7896.42 3695.30 5749.32 3051.31 5677.35 3710.46 
89 8286.38 4684.35 5863.85 3145.53 4425.58 4000.95 
90 8600.38 4876.69 7070.41 2353.01 4142.59 2768.59 
91 9185.78 7521.91 5732.17 2636.47 57191.58 2656.55 
92 7675.73 2169.77 7045.71 3914.02 4528.73 2801.93 
93 _ 7445.72 1140.58 6234.36 3633.10 4960.96 2317.75 
94 8535.32 3887.64 5837.84 2488.33 4494.72 2483.44 
95 7415.26 3043.05 4009.86 3947.65 3994.00 2134.96 
96 8066.77 4032.10 5872.65 3282.14 5706.24 2097.24 
97 10084.90 4224.45 5987.18 4342.61 3900.08 2713.68 
98 7712.43 6869.67 7193.74 2866.77 3779.31 2641.81 
99 11399.48 3355.52 5855.51 2339.05 6742.66 3255.03 
100 9136.20 9654.74 7169.04 2341.55 4674.95 2744.49 
Mean 7917.70 5911.18 5599.00 3883.32 3751.29 2429.54 
SD 1565.52 2867.37 952.06 1574.52 976.05 706.83 
_SEM 
156.55 286.74 95.21 157.45 97.61 70.68 
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Figure 5.8 - Total p210 
BCR-ABL and mean number of foci for the different cell types. 
Graph shows the average total levels of p2 I OBCR-ABL and the number of foci 
per cell in the CML cell lines and patient samples. r=0.989, p<0,000 1 (n = 100, 4" 
SEM). 
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5.2.5: Proportion of p2 jOIaCR-ABL in the focal and diffuse regions. 
The images in Figure 5.4 and 5.5 show that p2 IOECR-ABL forms foci as we have described 
but p2 I OBCR-ABL is also present diffusely across the cell. Using Image J we determined the 
proportion of p2 IOBCR-ABL in the foci and in diffusely staining regions of the cell. Analysis 
was performed on images of cells taken in the central plane of the z scan. We measure the 
integrated density (ID) of the whole cell and single foci stained with p2l OBCR-ABL. The 
percentage of p2 IOBCR-ABL in the focal and diffuse areas was calculated using the following 
formulae: 
Percentage of p2 16BCR-ABL 
in foci 
(ID of single foci 
ID of whole cell 
x 100 
Percentage of diffuse 
Percentage of p2 
OCR-ABL 
P2 i oPCR-ABL 
100 - in foci 
We analyzed a single focal plane of 50 cells randomly selected for each cell type using the 
strategy described (Table 5.3) and Figure 5.9 show a large proportion of p2 
I OBCR-ABL is 
distributed within the diffuse region of the different cell types. 
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Table 5.3 - Percentage of p2lolaCR-ABL in foci and diffuse regions. Images from a single 
focal plane taken by CLSM were analysed by Image J. The percentage of p2 I OBCR-ABL in 
the foci and diffusely staining region was determined based on the integrated density 
calculated by Image J. 
BV173 KCL-22 KYO-1 CML CD34+ 
1 
CML CD34+ 
2 
CML CD34+ 
3 
n 
% in 
foci 
% 
diffuse 
% in 
foci 
% 
diffuse 
% in 
foci 
% 
diffuse 
% in 
foci 
% 
diffuse , 
% in 
foci 
% 
diffuse 
%in 
foci 
% 
diffuse 
1 23.65 76.35 22.63 77.37 2.46 97.54 31.92 68.08 44.52 55.48 18.12 81.88 
2 31.56 68.44 38.75 61.25 16.69 83.31 27.95 72.05 44.22 55.78 11.73 88.27 
3 30.88 69.12 37.31 62.69 36.45 63.55 13.18 86.82 0.00 100-00 0.00 100-00 
4 86.56 13.44 34.74 65.26 27.99 72.01 8.78 91.22 19.14 80.86 20.65 79.35 
5 74.02 25.98 40.30 59.70 25.14 74.86 22.01 77.99 17.25 82.75 23.24 76.76 
6 29.95 70.05 29.75 70.25 9.91 90.09 4.37 95.63 35.89 64.11 31.24 68.76 
7 16.84 83.16 24.77 75.23 3.85 96.15 7.66 92.34 31.33 68.67 0.00 100.00 
8 24.11 75.89 35.13 64.87 18.59 81.41 21.17 78.83 11.50 88.50 16.35 83.65 
9 86.61 13.39 26.22 73.78 45.29 54.71 3.71 96.29 40.48 59.52 14.44 85.56 
10 32.89 67.11 34.14 65.86 29.89 70.11 24.08 75.92 51.81 48.19 21.16 78.84 
11 32.43 67.57 32.95 67.05 26.50 73.50 38.09 61.91 41.64 58.36 20.14 79.86 
12 86.88 13.12 43.10 56.90 11.63 88.37 1.99 98.01 44.92 55.08 13.42 86.58 
13 71.37 28.63 40.18 59.82 5.21 94.79 17.92 82.08 50.66 49.34 9.55 90.45 
14 31.63 68.37 44.76 55.24 20.40 79.60 38.66 61.34 5.60 94.40 10.73 T7 89.2, 
15 18.79 81.21 48.70 51.30 46.48 53.52 21.80 78.20 31.68 68.32 23.95 76.05 
16 35.35 64.65 45.98 54.02 31.69 68.31 25.51 74.49 11.14 88.86 0.00 loo. oo 
17 33.93 66.07 45.98 54.02 27.81 72.19 38.96 61.04 32.48 67.52 18.17 81: 83 
18 34.18 65.82 33.85 66.15 1.21 98.79 3.22 96.78 44.61 55.39 11.77 88.23 
19 33.91 66.09 33.89 66.11 6.53 93.47 19.45 80.55 44.39 55.61 18.86 81.14 
20 87.19 12.81 31.98 68.02 9.45 90.55 4.81 95.19 0.21 99.79 20.69 79.31 
21 75.22 24.78 32.69 67.31 26.00 74.00 8.43 91.57 19.39 80.61 23.29 76.71 
22 33.23 66.77 26.74 73.26 33.41 66.59 21.74 78.26 17.52 82.48 31.27 68.73 
23 20.65 79.35 41.70 58.30 29.08 70.92 4.16 95 . 84 36.20 
63.80 0.00 100.00 
24 26.95 73.05 44.98 55.02 3.03 96.97 24.70 75.30 31.52 68.48 16.41 83.59 
25 87.24 12.76 29.73 70.27 7.81 92.19 38.47 61.53 11.77 88.23 14.48 85.52 
26 35.41 64.59 32.21 67.79 1.90 98.10 2.52 97.48 40.58 59.42 0.00 100.00 
27 35.32 64.68 41.58 58.42 15.92 84.08 33.43 66.57 51.96 48-04 20.18 79.82 
28 87.49 12.51 _ 26.29 73.71 43.54 56.46 36.92 63_. 08 41.82 58.18 13.47 86.53 
29 76.09 23.91 26.42 73.58 27.21 72.79 1.67 98.33 45.1.3 54.87 9.59 90.41 
30 34.75 65.25- 22.32 77.68 24.59 75.41 17.51 82.49 50.79 49.21 10.80 89.20 
31 22.42 
28.29 
77.58 
71.71 
17.26 
22.33 
82.74 
77.67 
9.22 
3.31 
90.78 
96.69 
38.40 
f 21.35 
61.60 
78.65 
5.95 
31.85 
94.05 
68.15 
0.00 
0.08 
100.00 
99.92 
87.50 12.50 , 17.26 
82.74 17.85 82.15 25.14 74.86 11.42 88.58 
_ 
18.27 81.73 
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34 36.60 63.40 50.54 1 49.46 44-81 55.19 39.73 61.27 32.67 67.33 11.81 1 88.19 
35 36.68 63.32 30.32 69.68 29.16 70.84 2.90 97.10 44.70 55.30 21.16 78.84 
36 76.99 23.01 26.62 73.38 25.97 74.03 19.05 80.95 10-93 89.07 20.73 79.27 
37 49.87 50.13 26.26 73.74 1.44 98.56 4.54 95.46 40.29 59.71 23.33 76.67 
38 36.21 63.79 46.36 53-64 4.68 95.32 7.96 92.04 51.50 48.50 18.20 81.80 
39 24.12 75.88 35.13 64.87 6.62 93.38 21.39 78.61 41.27 58.73 11.79 88.21 
40 29.59 70.41 19.70 80.30 23.74 76.26 3.88 96.12 44.50 55.50 23.95 76.05 
41 72.56 27.44 29.84 70.16 31.00 69.00 24.32 75.68 50.39 49.61 11.96 88.04 
42 37.75 62.25 23.07 76.93 27.30 72.70 38.24 61.76 4.88 95.12 23.30 76.70 
43 37.98 62.02 22.23 77.77 1.47 98.53 2.20 97.80 31.33 68.67 31,29 68.71 
44 31.77 68.23 29.75 70.25 6.02 93.98 33.13 66.87 10.55 89.45 78.46 21.54 
45 41.23 58.77 24.77 75.23 10.24 89.76 36.64 63.36 32.07 67.93 16.44 83.56 
46 37.61 62.39 35.13 64.87 13.08 86.92 9.71 90.29 44.42 55.58 14.49 85.51 
47 25.75 74.25 26.22 73.78 41.67 58.33 22.71 77.29 44.03 55.97 21.22 78.78 
48 30.83 69.17 34.14 65.86 24.33 75.67 4.93 95.07 2.25 97.75 20.20 79.80 
49 34.29 65.71 32.95 67.05 70.13 29.87 25.74 74.26 18.87 81.13 13,49 86.51 
50 38.86 61.14 44.76 55.24 6.67 93.33 39.10 60.90 16.96 83.04 9.61 90.39 
Mean 44.64 55.36 32.89 67.11 20.29 79.71 19.70 80.30 30.42 69.58 16.67 83.33 
SD 22.87 22.87 8.61 8.61 15.19 15.19 13.05 13.05 16.26 16.26 12.14 12.14 
SEM 3.15 3.23 ý 
1.22 
, 
1.22_ 
, 
2.15 2.15 1.85 1.85 2.30 2.30 1.72 1.72 
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Figure 5.9 - Quantification of p210 
BCR-ABL in the focal and diffuse regions of single 
ceUs. CLSM images were imported into Image J and integrated density was measured for 
all of the single foci and the whole cellular area of a single plane. The percentage of 
p2 I OBCR-ABL in each fraction of was calculated for 50 cells of each cell type (+/- SEM). 
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5.2.6: CMIL CD34+ cells have higher levels of p2joBCR-ABL relative to CML MNC 
There has been recent interest in cell maturation-related differences in p2 I OBCR-ABL 
expression in prunary CML cells because they are thought to be related to the relative 
imatinib-resistance of primitive progenitor cells in CMEL. Using Image J we analysed the 
levels p2 I OPCR-A]BL in the MNC and CD34+ cell fractions. Evidence suggests that more 
primitive CML cells express higher levels of p2 IOBCR-ABL and that levels decrease with 
cellular maturation 45. This may be difficult to quantify by western blot using the anti-BCR- 
A BLJ. L antibody in primary cells due to the presence of ADA 387 and the requirement for high 
cell numbers. Therefore using CLSM we show that the level of p2 I OBCR-ABL is on average 
1.8-fold higher (n = 3) in CMEL CD34 cells relative to CML MNCs (Table 5.4 and Figure 
5.10). 
Table 5.4 - Mean ID of p2jOBCR-ABL 
in CMEL MNCs and CD34+ cells. The levels of 
p210 
BCR-ABL in CML MNCs and CD34+ cells from three individual CML patients 
calculated by Image J. 
M[NC 1 CD34+ 1 MNC 2 CD34+ 2 MNC 3 CD34+ 3 
Mean 2089.83 3883.32 2111.80 3751.29 1410.05 2429.54 
SD 348.08 1574.52 547.60 976.05 543.81 706-83 
SEM 68.26 157.45 111.78 97.61 115.94 70.68 
n 26 100 24 100 22 100 
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Figure 5.10 -Expression of p2 
OBCR-ABL in CML MNCs and CD34+ cells. (Three 
independent CML samples). 
5.2.7: Association of unphosphorylated and phosphorylated CRKL with p2jOBCR-ABL 
in CML ceUs 
To confirm the utility of CLSM as a method for investigating protein complexes in CML 
cells we analysed the association of CRKL with p2 I 
OBCR-ABL 
. This revealed that CRKL, as 
well as p2 I OBCR-ABL, formed distinct foci in the cytoplasm of the CD34+ CMIL cells (Figure 
5.11 A). We used the colocalisation. analysis software which provide the proportion of each 
protein contributing to the complex and the proportion of unbound protein 
310 quantify the 
proportion p2 1013CR-ABL complexed with CRKL in BV173 cells (Figure 5.11 B). 31 cells 
were analysed and we found that 20% (± 0.35) of total CRKL is complexed with 56% (± 
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0.65) p2 I OBCR-ABL (Table 5-5). Therefore, the distributions of CRKL and p2 IOBCR-ABL were 
not identical. Rather, foci of CRKL could be coincident, overlapping, touching or separate 
1OBCR-, ", BL andCRKLf (Figure 5.11 A). This distribution of p2 OCi suggests that the 
association of these proteins may be in a state of dynamic equilibrium. Since it is well 
established that CRKL is highly phosphorylated in CML and binds to p2 I OBCR-ABL, we next 
analysed the association between phosphorylated CRKL (pCRYL) and p2 I OBCR-ABL in 
BV 173 cells with CLSM (Figure 5.12 A and Table 5.6). Unexpectedly we found only a 
small proportion, 14% (±0.25) of pCRKL in complex with 37 % (±-0.69) of p2 I OBCR-ABL 
(Figure 5.12 B). Colocalisation was concentrated in the foci with very minor componet 
complexing in the diffusely staining regions. Since 60% of p2 IOBCR-ABL colocalises with 
total CRKL, 40% does not and 86% of pCRKL is not complexed with p2 IOBCR-ABL, this 
result indicates various possible mechanisms: (1) that CRKL could possibly bind to 
p210 
BCR-ABL irrespective of its phosphorylation status and/or (2) CRKL phosphorylation is 
not dependent on p2 1013CR-ABL and CRKL complex formation and/or (3) p2 I OBCR-ABL does 
not phosphorylate all of the cellular CRKL. 
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Figure 5.11 - SubceHular distribution and colocalisation of p2 IOBCR-ABL and CRKL in 
BV1 73 cells. BV 173 cells were air dried, fixed in 2% PFA and permeabilised in 0.2 % 
triton in PBS and blocked in 5% FBS/3% BSA. Anti-BCR-ABL and anti-CRK-L or 
matched isotype control (IgG) were incubated with the cells for I hour at room 
temperature. After three washes cells were incubated with AF 488 and AF 564, and washed 
and mounted with VectaShield plus DAPI. All cells were analysed using the CLSM. (A) 
The distribution of p2 I OBCR-ABL (green) and CRKL (red) foci can be separate, close 
together, partially overlapping and completely overlapping (yellow). (B) The proportions of 
colocalisation (colocalisation coefficient = 1) were analysed for 31 cells as described in 
Chapter 2: Figure 2.4 Percentages of complexed and uncomplexed CRKL and p2 I OBCR- 
ABL 
are shown in the graph. 
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Table 5.5 - Percentage of p2 
OBCR-ABL and CRKL complexed and uncomplexed. 
Images of CRKL and p2 I OBCR-ABL were taken by CLSM for co-localisation. An image in a 
single focal plane was analysed by co-localisation software by Ziess . 
N 
Colocalisation (Bound) Uncomplexed 
CRKL BCR-A-BL CRKL BCR-ABL 
1 16.70 33.60 83.30 66.40 
2 21.10 44.10 78.90 55.90 
3 17.80 43.00 82.20 57.00 
4 10.80 32.70 89.20 67.30 
5 9.50 28.70 90.50 71.30 
6 23.10 23-90 76.90 76.10 
7 17.20 50.90 82.80 49.10 
8 12.70 24.00 87.30 76.00 
9 6.00 47.20 94.00 52.80 
10 4.80 36.20 95.20 63.80 
11 5.10 82.50 94.90 17.50 
12 10.80 67.50 89.20 32.50 
13 11.40 69.10 88.60 30.90 
14 11.40 69.10 88.60 _ 30.90 
15 18.70 81.60 81.30 18.40 
16 18.40 57.50 81.60 42.50 
17 17.80 56.50 82.20 43.50 
18 14.80 44.70 85.20 55.30 
19 12.20 74.20 87.80 25.80 
20 16.10 16.40 83.90 83.60 
21 35.50 31.40 64.50 68.60 
22 21.60 23.90 78.40 76.10 
23 26.50 32.50 73.50 67.50 
24 26.80 21.80 73.20 78.20 
25 32.70 32.10 67.30 67.90 
26 41.50 67.80 58.50 32.20 
27 29.60 31.80 70.40 68.20 
28 31.30 30.00 68.70 70.00 
29 36.80 30.40 63.20 69.60 
30 45.80 57.90 54.20 42.10 
31 18.20 18.80 81.80 81.20 
Average 20.09 43.93 79.91 56.07 
SD 10.65 19.47 10.65 19.47 
SEM 0.35 0.65 0.35 0.65 
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Figure 5.12 - Subceflular distribution and colocalisation of p2jOBCR-AI9L and pCRKL in 
BVI 73 cefls. BV 173 cells were air dried, fixed in 2% PFA and permeabilised in 0.2 % 
triton in PBS and blocked in 5% FBS/3% BSA. Anti-BCR-ABL and anti-phosphoCRKL or 
matched isotype control (IgG) were incubated with the cells for I hour at room 
temperature. After three washes cells were incubated with AF 488 and AF 564, washed and 
mounted with VectaShield plus DAPI. All cells were analysed using CLSM. (A) The 
distribution of p2 I OBCR-ABL (green) and pCRKL (red) and colocalisation (yellow) is shown 
in the Z-section. (B) The proportions of colocalisation (colocalisation coefficient = 1) was 
analysed for 25 cells as described in Chapter 2: Figure 2.4. Percentages of complexed and 
uncomplexed pCRKL and p2 I OBCR-ABL are shown in the graph. 
Overlav 
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Table 5.6 - Percentage of p2 
1OBCR-ABL and pCRKL complexed and uncomplexed. 
Images of pCRKL and p2 I OBCR-ABL were taken by CLSM for co-localisation. An image in a 
single focal plane was analysed by co-localisation software by Ziess. 
Colocalisation (Bound) Uncomplexed 
n 
CRKI, BCR-A-BL pCRKL 
BCR-ABL 
(%) 
1 19.3 27.1 80.7 72.9 
2 9.4 12.4 90.6 87.6 
3 13.9 49.1 86.1 50.9 
4 13.6 58.2 86.4 41.8 
5 16.2 68.8 83.8 31.2 
6 14.8 46 85.2 54 
7 19.7 70.5 80.3 29.5 
8 6.8 25.6 93.2 74.4 
9 18.8 20 81.2 80 
10 8.3 43.1 91.7 56.9 
11 14.7 48.3 85.3 51.7 
12 20.6 38.3 79.4 61.7 
13 27.9 32.5 72.1 67.5 
14 15 16.5 85 83.5 
15 12.6 27.6 87.4 72.4 
16 13.3 22.2 86.7 77.8 
17 22.4 23.2 77.6_ 76.8 
18 24.1 19.6 75.9 80.4 
19 5.7 19.2 94.3 80.8 
20 12 45.6 88 54.4 
21 9.4 45.1 90.6 54.9 
22 9.1 43.9 90.9 56.1 
23 14.8 61 85.2 39 
24 7.5 44 92.5 56 
25 5.3 25.1 94.7 74.9 
Average 14 37 85 62 
SD 5.9 16.6 5.9 16.6 
SEM 0.25 0.69 2.5 0.69 
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5.2.8: Protein complexes of p2jOBCR-ABL and CRYCL with CBL and GRB2 
The colocalisation analysis has also shown that large proportion of CRYL (Figure 5.11), 
BCR-ABL 
pCRKL (Figure 5.12) and p2 10 remain uncomplexed. To test if this is unique to 
unphosphorylated and phosphorylated CRKL or common to other p2 IOBCR-ABL binding 
partners we analysed the cellular distribution of GRB2 and CBL with p2 IOBCR-ABL and 
CRKL. We found that 20% (+/- 0.28, n--26) of GRB2 colocalised. with 18% (+/- 0.29, 
n=26) of p2 I OBCR-ABL (Figure 5.13 A and Table 5.7) and 10% (+/- 0.083, n=33) of CBL 
. '1- lOBCR-ABL wiua 29% (+/- 0.4 1, n--3 3) of p2 (Figure 5.13 B and Table 5.8) colocalised. Also, 
63% (+/- 0.61, n--30) of CRKL with 38% (+/- 0.36, n=30) of GRB2 (Figure 5.13 C and 
Table 5.9) and 34% (+/- 0.48, n=24) of CRKL with 48 % (+/- 0.76, n=24) of CBL (Figure 
5.13 D and Table 5.10) colocalised. These data imply that low levels of p2 I OBCR-ABL 
remains in complex with other partner proteins but the amount of CRKL in complex with 
other adaptor proteins is relatively high. 
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Figure 5.13 - Colocalisation and quantification of p2 jOBCR-ABL and CRKL associated 
protein complexes. BV173 cells were air dried, Rxed in 2% PFA and permeabilised in 0.2 
% triton in PBS and blocked in 5% FBS/3% BSA. Anti-BCR-ABL/anti-GRB2 (A), anti- 
BCR-ABL/anti-CBL (B), anti-CRKL/anti-GRB2 (C), anti-CRKL/anti-CBL (D) or matched 
isotype control (IgG) were incubated with the cells for I hour at room temperature. After 
three washes cells were incubated with AF 488 and AF 564, washed and mounted with 
VectaShield plus DAPI. All cells were analysed using CLSM. The proportions of 
colocalisation was analysed for > 24 cells for each protein association as described in 
Figure 2. Percentages of complexed and uncomplexed proteins are shown in the graphs. 
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Table 5.7 - Percentage of p2 
1OBCR-ABL and GRB2 complexed and uncomplexed. Images 
of GRB2 and p2 I OBCR-ABL were taken by CLSM for co-localisation. An image in a single 
focal plane was analysed by co-localisation software by Ziess. 
n Colocalisati n (Bound) Uncomplexed 
GRB2 BCR-ABL GRB2 (%) BCR-ABL 
1 7.6 6.1 92.4 93.9 
2 26.1 23.8 73.9 76.2 
3 11.5 9.8 88.5 90.2 
4 23.8 18.9 76.2 81.1 
5 35.5 26.7 64.5 73.3 
6 20 13.7 80 86.3 
7 19.8 17.6 80.2 82.4 
8 19.4 15.8 80.6 84.2 
9 29.4 23.7 70.6 76.3 
10 17.9 15 82.1 85 
11 19.1 18.4 80.9 81.6 
12 29.4 35.4 70.6 64.6 
13 26.6 35.1 73.4 64.9 
14 28.4 28.6 71.6 71.4 
15 17.5 15.9 82.5 84.1 
16 10.4 9 89.6 91 
17 15.8 11.1 84.2 88.9 
18 12 5.8 88 94.2 
19 26.8 23.6 73.2 76.4 
20 11.6 10.4 88.4 89.6 
21 20.1 21.5 79.9 78.5 
22 19.8 21 80.2 79 
23 27.4 14.7 72.6 85.3 
24 29.6 20.2 70.4 79.8 
25 26.1 18.2 73.9 81.8 
26 11.7 12.9 88.3 87.1 
27 27.1 19 72.9 81 
Average 20 18 80 82 
SD 7.3 7.7 7.3 7.7 
SEM 0.28 0.29 0.28 0.2 
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Table 5.8 - Percentage of p2 
1OBCR-ABL and CBL complexed. and uncomplexed. Images 
of CBL and p2 I OBCR-ABL were taken by CLSM for co-localisation. An image in a single 
focal plane was analysed by co-localisation software by Ziess. 
n 
Colocalisati n (Bound) Uncomplexed 
CBL (%) BCR-ABL CBL (%) BCR-A. BL 
1 7.4 20 92.6 80 
2 6.6 33.3 93.4 66.7 
3 10 26.1 90 73.9 
4 12.3 37.9 87.7 62.1 
5 12.9 44.2 87.1 55.8 
6 9.2 23.1 90.8 76.9 
7 14 11.3 86 88.7 
8 6.8 32.4 93.2 67.6 
9 6.2 17.5 93.8 82.5 
10 5.3 15.9 94.7 84.1 
11 8.8 35.1 91.2 64.9 
12 11.6 43.9 88.4 56.1 
13 8.3 55.9 91.7 44.1 
14 8.1 41.2 91.9 58.8 
15 9 23.9 91 76.1 
16 8.6 20.7 91.4 79.3 
17 15.1 21.1 84.9 78.9 
18 9.3 39 90.7 61 
19 8.6 35 91.4 65 
20 8.3 14 91.7 8 
21 8.7 25.7 91.3 74.3 
22 8.5 17.9 91.5 82.1 
23 9 50.1 91 49.9 
24 9.1 7.6 90.9 92.4 
25 14.8 14.8 85.2 85.2 
26 11 6.6 89 93.4 
27 16.4 13.3 83.6 86.7 
28 9.8 20.9 90.2 79.1 
29 13.3 49.7 86.7 50.3 
30 7.2 30.1 92.8 69.9 
31 7.2 42.3 92.8 57.7 
32 7.5 22.7 92.5 77.3 
33 12.3 51.9 87.7 48.1 
34 11.1 37.3 88.9 62.7 
Average 10 29 90 71 
SD 2.7 13.5 1 2.7 13.5 
SEM 0.08 0.41 1 0.08 0.41 
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Table 5.9 - Percentage of CRKL and GRB2 complexed and uncomplexed. Images of 
CRKL and GRB2 were taken by CLSM for co-localisation. An image in a single focal 
plane was analysed by co-localisation. software by Ziess. 
n Colocalisation (Bound) Uncomplexed 
CRK-L (%) GRB2 CRKL (%) GRB2 (%) 
1 22.4 26.3 77.6 73.7 
2 45.5 31.9 54.5 68.1 
3 47.4 50.6 52.6 49.4 
4 38.8 40.8 61.2 59.2 
5 64.9 49.1 35.1 50.9 
6 42.8 34.3 57.2 65.7 
7 81.4 36.8 18.6 63.2 
8 57.6 38.7 42.4 61.3 
9 46.4 29.1 53.6 70.9 
10 71.3 51.3 28.7 48.7 
11 61.9 56.3 38.1 43.7 
12 70.6 46.6 29.4 53.4 
13 56.4 28.5 43.6 71.5 
14 58.4 36 41.6 64 
15 37.7 20.7 62.3 79.3 
16 61.5 27.1 38.5 72.9 
17 76.1 37.8 23.9 62.2 
18 82.2 47.5 17.8 52.5 
19 61.9 32.6 38.1 67.4 
20 77.6 54.8 22.4 45.2 
21 57 38.6 43 61.4 
22 62.9 36.7 37.1 63.3 
23 67.1 45.8 32.9 54.2 
24 71.6 39.2 28.4 60.8 
25 44.8 14.9 55.2 85.1 
26 49 36.2 51 63.8 
27 60 26.8 40 73.2 
28 95.7 38.1 4.3 61.9 
29 94.2 31.5 5.8 68.5 
30 98.9 57.6 1.1 42.4 
31 89.3 20.7 10.7 79.3 
Average 63 38 37 62 
SD 1.84 1.08 1.84 1.08 
SEM 0.6 0.4 __+ 0.6 0.4 
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Table 5.10 - Percentage of CRK-L and CBL complexed and uncomplexed. Images of 
CRKL and CBL were taken by CLSM for co-localisation. An image in a single focal plane 
was analysed by co-localisation software by Ziess. 
n Colocafisation (B und) Uncomplexed 
CRKL (%) CBL (%) CRKL (%) CBL (%) 
1 15.6 69.7 84.4 30.3 
2 37.8 88.9 62.2 11.1 
3 36.1 86.5 63.9 13.5 
4 33.6 60.5 66.4 39.5 
5 20.7 76.7 79.3 23.3 
6 29.3 46.6 70.7 53.4 
7 42.3 49.8 57.7 50.2 
8 22.8 57.4 77.2 42.6 
9 20.4 56.7 79.6 43.3 
10 13.9 30.8 86.1 69.2 
11 35.7 67.6 64.3 32.4 
12 30.4 26.3 69.6 73.7 
13 35.8 36.4 64.2 63.6 
14 31.3 40.9 68.7 59.1 
15 36.5 28.7 63.5 71.3 
16 19.6 26.3 80.4 73.7 
17 60.8 49.9 39.2 50.1 
18 31.4 28.2 68.6 71.8 
19 47.7 38.2 52.3 61.8 
20 43.9 34 56.1 66 
21 58.9 34.6 41.1 65.4 
22 35 35.4 65 64.6 
23 37.2 36.9 62.8 63.1 
24 37.2 52.9 62.8 47.1 
25 35.9 36.5 64.1 63.5 
26 29.5 56.9 70.5 43.1 
Average 34 48 66 52 
SD 1.14 1.82 1.14 1.82 
SEM 0.47 0.67 0.47 0.67 
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5.2.9: Summary of p2jOBCR-ABL and CRKL - associated protein complexes 
Figure 5.14 summaries the clata for the proportion of p2 IOBCR-ABL complexed with CRKL 
(A), pCRKL (B), GRB2 (C), CBL (D) and the proportion of CRKL complexed to GRB2 
(E) and CBL (F). The data indicates that only a small proportion of partner protems are 
complexed to p2 IOBCR-ABL but higher proportions of GRB2 and CBL are complexed to 
CRKL in BV 173 cells. 
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Figure 5.14 - Summary of p2 
IOBCR- 
ABL 
_ and CRKL-associated protein 
complexes. 
The proportion of protein complexed is 
represented by: 
ýý 
and the 
proportion of protein uncomplexed is 
represented by: 
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5.3 Discussion 
A central role in determining abnormal cell function in CML including 
abnonnalities in signalling, proliferation, adhesion and gene expression is attributed to 
multimolecular complex formation with p2 I OBCR-'ýBL. The focal arrangement of p2 I OBcR- 
ABL reported here implies a higher order of organisation than simply random distribution in 
the cytosol. Since proteins generally interact with other proteins in order to perform 
essential roles in important cellular functionS388 , it is likely that different arrangements of 
p210 BCR-ABL will have an impact on downstream signalling events and degrees of 
dysregulation of signalling pathways such as the RAS 
312,76,313,206,312,314 
, JAK-STAT 
315,316,317,318 
and the P13K 
281,319,320,213 
Pathways which have been linked to CML pathology. 
We used the junction specific anti-BCR-ABL antibody which recognises the b2a2 
(e I 3a2) breakpoint of p2l OBCR-ABL to detect p2 IOBCR-ABL by CSLM. The b2a2 and b3a2 
(el4a2) are the two major breakpoints in CM[L 
83. Our data show that p2 10 
BCR-ABL is 
expressed as foci in the cell lines tested, both myeloid and lymphoid, and in primary CD34+ 
CML cells. However, greater numbers of foci could be scored in cell lines, particularly in 
the KCL-22 cells, than in primary CD34 + cells, whereas a diffuse distribution characterised 
mononuclear CML cell populations (Figures 5A-5.7). The mean number of foci varies 
between the cell types tested and coffelates with the total levels of p2 
IOBCR-ABL (Figure 
5.8). Further analysis of the foci indicates that a higher proportion of p2 I 
OBCR-ABI, is present 
in the diff-usely stained regions which may also have an important role in abnormal protein 
complexes and signaling in CMIL (Figure 5.9). There has been recent interest in cell 
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maturation-related differences in p2 IOBCR-ABL expression in primary CMI cells because 
they are thought to be related to the relative imatinib-resistance of primitive progenitor cells 
in CML. Evidence suggests that more primitive CML cells express higher levels of 
p210 
BCR-ABL 
and that levels decrease with cellular maturation 
163,45 
. We have shown that 
CD34+ CML cells express on average 1.8-fold higher levels of p2 1OBCR-ABL in comparison 
to MNCs (Figures 5.10). Thus, p2 IOBCR-ABL is distributed in foci in CD34+ cells but is 
diffusely distributed in MNCs. This difference between NNC and CD34+ cells confirms 
that focus formation is not a technical artefact. Moreover, Deng et al (2004) 389 reported 
that fixation tends to make foci of MLL-5 protein more diffuse. One interesting speculation 
is that focus formation by p2 lO: 
BCR-ABL 
renders it less accessible to the actions of imatinib 
than a diffuse distribution. Alternatively, complexed p2 I OBCR-ABL may be more stable than 
diffuse p2 IOBCR-ABL by association with SHP-2 phosphatase 
390 
, although we could not 
detect a high degree of colocalisation of p2 IOBCR-ABL and SHP-2 in preliminary experiments 
(data not shown). 
The association of CRYL with p2 IOCR-ABL and CRKL phosphorylation in CML has 
received considerable attention recently due to its value in monitoring clinical 
responsiveness and resistance to the p2 IOBCR-ABL protein tyrosine kinase inhibitor, imatinib 
191,190. In this regard, it has been shown that normal cells contain little phosphorylated. 
CRKL whereas CRKL is predominantly phosphorylated in CML. The mechanism of 
CRKL phosphorylation is not certain but it is known that the SH3 domain on CRKL binds 
to the proline rich region on p2 I OBCR-ABL 
217 
and the tyrosine, 207 residue on the SH3 
domain is essential for CRKL phosphorylation in p2 IOBCR-ABL_Positive cells 
236. CLSM has 
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revealed that only a small portion of CRKL and p2 I OBCR-ABL foci colocalise completely 
whilst other foci partially overlap, touch or are separate. This unexpected distribution of 
p2 IOBCR-ABL and CRKL suggests the association between the proteins maybe in a state of 
dynamic equilibrium (Figure 5.11). 
We have also shown that the percentage colocalisation of pCRKL and p2 IOBCR-ABL 
is low (Figure 5.12) which implies various potential mechanisms of CRKL 
phosphorylation in CMIL: (1) that CRKL binds to p2 IOBCR-ABL irrespective of its 
phosphorylation status and/or (2) CRKL phosphorylation does not depend on p2 
IOBCR-ABL 
and CRKL complex formation and/or (3) p2l OCR-ABL does not phosphorylate all the 
cellular CRKL. The first mechanism is supported by other studies which have reported that 
IOBCR-ABL d CRy CRKL phosphorylation may not depend on the direct interaction of p2 an 'L 
236,237 
and the lack of CRKL phosphorylation does not prevent it binding to p2 
1()BCR-ABL 
212,213,214 BCR-ABL 
. Overall the association 
between p2 10 bind and CRKL phosphorylation 
may not be as tight as previously believed. 
The low levels of colocalisation between p2 IOPCR-ABL and CRKL or pCRKL was 
I OBCR-ABL andCRy unexpected therefore we calculated the proportion of p2 "L in CoMpleX 
with other adaptor proteins. We examined the colocalisation of CBL and GRB2 because 
they have been shown to complex with p2 I OBCR-ABL and CRKL. CBL can bind p2 
IOBCR-ABL 
213,214 Cpý 206,213 IOBCR-ABL and . directly and also acts as a linker between p2 and 
CRKL. 
GRB2 binds p2 IOBCR-ABL directly via the tyrosine 177 residue 
391,207 
and CRKL indirectly 
374 
. Alternatively 
GRB2 may bind to ABL in a similar way to CRKL and CBL Figure 5.13 
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(A-D) shows a large proportion of protein still remains uncomplexed when the 
colocalisation of p2 1 OBcR-ABL - GRB2 (A), p2 1 
Ccp'-ABI'- CBL (B), CRKL - GRB2 (C) 
and CRKL - CBL (D) was analysed implying that this pattern of association is not unique 
"_L/ CRy 
OCR-ABL 
_ Cp 'y to p2 p ýL complexes (all the complexes analysed are summarised in 
Figure 4.14). 
In summary, we believe that our results support the use of CLSM as an alternative 
approach to the investigation of multimolecular protein complexes in CML and how their 
composition may change with disease stage, cellular maturation and exposure to therapeutic 
agents like imatinib and new generation tyrosine kinase inhibitors. 
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CHAPTER 6- FACTORS AFFECTING PROTEIN 
COMPLEXES IN CAM 
6.1: Introduction 
The success of any CML therapy is a fine balance between disease eradication and 
myeloablation. The only curative therapy for CML is an allogeneic stem cell transplant but 
this treatment is limited by the lack of suitable donors and severe side effects which effect 
126 
older patients who are unable to tolerate the side effects of the therapy . In recent years 
targeted therapy has revolutionised the treatment of CML. Deregulated p2 IOBCR-ABL/ABL 4ý? 
kinase is the main feature of CML 
192,364 
therefore targeting this activity to manage the 
disease using Imatinib 149has proved to be effective in CML patients. Prior to the 
development of Imatinib the best option for the patients who were not suitable for 
allogeneic stem cell transplantation was IFN-a. IFN- a has been shown to have differential 
effects between normal and CMEL cells 
392,393. preViOUSIY, in our laboratory we have shown 
that patients in CMIL CP have lower self renewal capacity than CML BC and Imatinib or 
IFN -a both reduce the self renewal capacity of CMIL BC cells to the level exhibited by 
CML CP cells 394 . These 
fmdings suggest that IFN -a and Imatinib suppress CML cell 
proliferation rather than causing then to undergo apoptosis. 
Imatinib (CGP571418B, ST1571 or Glivec), a 2-phenylaminopyfimidine derivative 
is a small molecule tyrosine kinase inhibitor which Wgets p2 IOBCR-ABL and c-ABL 
149, 
C_ 
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. Kit , and PDGFR 
150,151 (refer to Chapter 1: Figure 1.6). The drug is orally administered, 
has a half life of 12-14 hours and a single daily dose of > 400mg maintains the plasma 
152 
concentration at 1.46pM Imatinib is very well tolerated by patients. The most frequent 
side effect identified were haematological suppression (neutropenia, thrombocytopenia, 
ananemia) followed by raised liver enzymes and peripheral oedema. 153. Based on this study 
400mg daily is the standard dose of Imatinib. A small number of patients suffer from bone 
mineral defects '54and heart failure 155 . The drug is not suitable to take during pregnancy 
156 
. Imatinib has been shown to be more effective then IFN 
157,158 
. Intolerances to Imatinib 
are associated with skin inflammation, elevated transaminases (indicator of liver damage), 
fluid retention 
144,145,159 
or transient cytopenia 160 all of which can become reasons for 
terminating Imatinib therapy. 
Monitoring patients is an important aspect of patient survival. Patients on Imatinib 
are monitored on three different levels, haematological, cytogenetic and molecular. 
Haematological. responses are monitored every two weeks until a response is achieved and 
then monitoring take takes place every three months. Cytogenetic monitoring is carried out 
on bone marrow aspirates every 6 months until a complete cytogenefic response is achieved 
and then every 12 months. If a cytogenetic response is achieved then molecular response 
should be monitored, and this is commonly carried out by quantitative PCR. Refer to 
Chapter 1: Table 1.4 which summarises the three different stages of monitoring (recently 
reviewed and updated by 17) . The IRIS study has shown that up to 
87% of patients achieve 
a complete cytogenetic response and many patients who achieve a molecular response have 
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a low or undetectable level of the BCR-ABL transcript. Recently, an update of this study 
has supported the data and shown that the rate of a haematological remission is 98%, of 
major cytogenetic response is 92%, of complete cytogenetic remission is 87% and of 
160,161 
progression free survival is 84% 
Disease progression to accelerated phase or blast crisis occurs as a consequence of 
resistance to therapy. Imatinib is not as effective in advanced stages of CML compared to 
CP. Since the introduction of Imatinib the median survival of BC patients has only 
increased from 2 months to 7.5 months with very few patients surviving for longer 159 . 
Patients not in CP have poor survival rates even if the Imatinib dose has been increased to 
800mg daily 144,145. Many patients who achieve a complete cytogenetic response require 
further monitoring on a molecular level by quantitative PCR which will provide 
information about the levels of residual disease present 
395,396 
. Even though CP patients 
respond well to Imatinib the rate of BCR-ABL reduction after 24 months begins to lessen 
which may be associated with the presence of residual disease after therapy. Recent studies 
have suggested that *the residual disease maybe present in quiescent stem cells which could 
be the cell fraction which is resistant to Imatinib therapy 
45,163 
. The major cause of 
resistance is the development of mutations in the kinase domain preventing h-natinib from 
mteractmg with p2 1OBCR-ABL 
164,165 Increasing the dose of Imatinib to 800mg from 400mg 
may help to restore response but not all mutations will respond 
144,145 
. Lahaye et al 
'66used 
sequencing analysis to show that approximately 50% of imatinib resistant patients have 
mutations of p2 IOBCR-ABL. Other mechanisms that have been identified as causes of 
211 
Chapter 6- Factors affecting protein complexes in CML 
resistance are genomic amplification of BCR-ABL or BCR-ABL independent mechanisms 
167 169 170,171 
such as loss of functional p53 168, SRC activation or chromosomal changes 
The success of Imatinib therapy and the attempt to improve prognosis of CML 
patients who are resistant/non-responsive to Imatinib has resulted in the development of the 
next generation of tyrosine kinase inhibitors (refer to Chapter 1: Table 1.3 which 
summarises some of the new tyrosine kinase inhibitors in clinical trials for CML). Nilotinib 
172 and Dasatinib 173 have been through clinical phase I and H trails. Both drugs are active 
against all known imatinib resistant p2 IOBCR-ABL mutants except T315I mutation. The 
results from the phase II trails of Dasatinib which is a dual ABL and SRC inhibitors, has 
meant the drug has been approved for clinical use in the US and EU. The phase HI trails for 
the drug will provide information about effective dosages. NM-0457 is drug one of the few 
drugs in phase Il which is active against the T3151 mutation. The ongoing clinical trials 
may generate interesting information and novel therapies which alone or in combination 
have the potential to ftu-ther improve the therapy for CML patients. 
Imatinib targets the tyrosine kinase of ABL and reduces phosphorylation of 
p210 
BCR-ABL 
and many downstream target proteins involved in CML 
397,398,3", 400. The 
subcellular localisation. of p2 I OBCR-ABL may be influenced by the changes in tyrosine kinase 
activity. The localization of normal ABL is nuclear and cytoplasmic 62 '63 and it can shuttle 
between the two compartments due to the presence of the NLS and NES 64. In contrast 
p210 
BCR-AIBL is located exclusively in the cytoplasm even though the protein expresses the 
NLS and NES regions 83,63 which suggests that NLS is inactive or NES predominates. in 
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the cytoplasm p2 I OBCR-ABL is closely associated with f-actin via the actin binding domain 
on the c-terminal of p2 i oBCR-ABL 
384,67. 
p2 IOBCR-ABL also complexes and phosphorylates 
other focal adhesion proteins 226. Interestingly, nuclear ABL is reported to induce apoptosis 
61 
and cytoplasmic p2 lOBCR-ABL inhibits apoptosis, via signaling pathways such as the P13K 
pathWay 
385,386. 
p2 IOBCR-ABL does not translocate to the nucleus in CML but inhibition of the 
tyrosine kinase activity by Imatinib cause p2 I 
OCR-ABL to translocate to the nucleus. The 
protein only remains in the nucleus when the cells are co-treated with Imatinib and 
leptomycin which is a drug that blocks nuclear export. This shift in location demonstrate 
the integfity of the NLS and NES293. 
The importance and complexity of protein signaling in CML has already been 
discussed in previous chapters. Some protein complexes in CML have been suggested to be 
dependent on tyrosine phosphorylation. In the case of CRKL, it is well established that in 
Ph-hegative cefls the protein is not phosphorylated 
215,216,217,234 
which may prevent CRKL 
and ABL from complexing in non-CMEL cells. CBL is also tyrosine phosphorylated in a 
227, M 
range of different leukaemic cells such as CML BC, AML, Ph- T and B -ALL 
Nishihara et al 397 have shown that there is a change in levels of phosphorylated p2 I CýCR- 
ABL 
, CBL and CRKL within minutes of treatment with 
30 microM (prn) Imatinib in the TF- 
I BCR-ABL cell line. They also demonstrated by co-immunoprecipitation that complex 
formation between p2 OBCR-ABL and CRY.. L, p2 
OBCR-ADL and CBL, and CBL and CRY. L in 
these cells was reduced within 30 minutes or less post treatment with 30gm imatinib but 
total protein levels of p2 I 
OBCR-ABL, CRKL and CBL remained unchanged. Gaston et a, 
391 
also demonstrated that there was a reduction in CBL co-immunoprecipitating with p2 I 
OBcR- 
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ABL 
when 32D cells transfected with p2 IOBCR-ABL were treated with 10pm imatinib. They 
imply that the reduction in complexed p2 IOPCR-ABL and CBL could be due to the inhibition 
of the tyrosine kinase activity of p2 IOBCR-ABL as a result of which CBL remains 
uriphosphotylated and unable to bind to p210 
BCR-ABL 
. They also suggest that the small 
proportion of p210 
BCR-ABL 
and CBL still in complex after imatinib treatment is a result of 
indirect coupling via adaptor proteins such as GRB2 and unphosphorylated CBL. In this 
chapter we have investigated further the effects of imatinib on complex formation in Ph+ 
cell lines. 
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6.2: Results 
6.2.1 - Imatinib and the subceHular distribution of p2lOBcR-"L 
6.2.1.1 - Imatinib promotes nuclear transport of p210 
BCR-ABL 
When we treated BV 173 and CD34+ CML cells with I pM Imatinib for 16 hours the 
p210 
BCR-ABL 
positive foci translocated to the nucleus since they co-localised with the 
nucleus, stained with DAPI. This translocation was more prominent in BV173 cell lines 
compared with pnmary CD34 CNIL cells (Figure 6.1). Using the image J software we 
analysed the density of the p2 I 6WR-ABL signal wbich is Present in the area stained with 
DAPI (Table 6.1). The data are summarised in Figure 6.2 which demonstrates that that 
p210 
BCR-ABL located in the DAPI stained regions of treated cells was 2.1 -fold and 2.5 -fold 
higher relative to untreated cells in BV 173 and CD34+ CML cells, respectively. 
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BV173 cells 
CNM CD34+ 
Figure 6.1 - Effects of Imatinib on the p2jOBCR-ABL positive foci. BV 173 and CML 
CD34+ cells were treated with I gM Imatinib for 16 hours. Treated and untreated cells were 
air dried, fixed in 2% PFA and permeabilised in 0.2 % triton in PBS and blocked in 5% 
FBS/3% BSA. Anti-BCR-ABL or matched isotype control (IgG) were incubated with the 
cells for I hour at room temperature. After three washes cells were incubated with AF 488, 
washed and mounted with VectaShield plus DAPI. All cells were analysed using CLSM. 
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Table 6.1 - Percentage of p2lOBcR-ABLimatinib treated and untreated cells. The 
integrated density of p2 IOBCR-ABL was measured for the total cell and in the nuclear stained 
region (DAPI). The percentage of p2 IOBCR-ABL in the nucleus pre - and post - therapy was 
calculated for BV 173 cells and CD34+ cells. SD = standard deviation, SEM = standard 
error of mean, n (number of cells) = 50. 
Cell number 
% of nuclear BCR-ABL (BV173 
cells) Levels of nuclear BCR-AB (CD34+ CML cells) 
Untreated (UT) Treated (T) Untreated (UT) Treated (T) 
1 45.36 45.51 42.66 60.78 
2 37.73 54.14 34.92 57.73 
3 21.11 60.33 32.09 69.57 
4 25.55 38.97 37.60 53.99 
5 27.86 77.76 52.54 60.73 
6 15.49 51.05 59.86 68.10 
7 39.50 59.59 71.24 56.99 
8 28.22 47.59 49.78 76.81 
9 33.00 34.46 34.15 95.51 
10 38.50 43.09 52.87 54.72 
11 35.09 58.56 36.13 72.86 
12 42.03 41.10 47.41 59.14 
13 44.10 60.33 33.47 66.02 
14 31.33 33.20 31.28 53.04 
15 24.65 57.83 45.56 63.12 
16 54.80 85.57 51.20 74.54 
17 19.00 55.75 49.70 87.49 
18 35.58 57.27 21.09 81.12 
19 46.13 63.16 25.76 94.17 
20 19.91 74.88 34.92 53.33 
21 53.03 45-99 19.52 59.35 
22 69.47 80.61 25.00 78.27 
23 72.31 84.74 26.61 63.21 
24 52.89 52.97 17.90 75.04 
25 57.46 92.71 23.96 76.65 
26 28.89 93.22 24.07 39.76 
27 20.82 88.76 19.08 87.44 
28 34.34 86.24 24.51 98.41 
29 30.44 69.10 40.38 86.28 
30 43.25 62.45 33.53 67.34 
31 29.00 90.41 24.21 72.34 
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32 48.61 83.49 31.94 85.75 
33 46.11 92.62 33.08 95.46 
34 28.00 75.34 43.82 34.89 
35 20.23 63.71 49.17 77.43 
36 29.74 86.89 34.98 65.99 
37 17.20 60.55 23.12 76.45 
38 52.16 87.33 32.78 83.33 
39 31.51 56.56 23.86 53.05 
40 30.28 80.20 23.63 70.09 
41 17.78 95.29 23.80 46.43 
42 19.64 57.21 23.82 48.59 
43 17.58 63.82 37.65 93.88 
44 43.17 70.56 42.64 55.34 
45 16.52 83.36 43.48 67.99 
46 12.60 45.67 17.72 72.54 
47 20.62 94.89 17.71 76.01 
48 35.93 98.43 27.05 75.74 
49 25.11 61.40 61 . 4( 16.65 97.44 
50 35.88 57 . 8: 57.82 17.02 79.68 
Mean 34.11 67.25 67 V 33.74 70.40 
tive to UT 1.00 1.7 1.00 2.09 
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Figure 6.2 - Levels of p2jOBCR-ABL in the nuclear regions on BV173 and CD34+ CML 
cells. Levels of p2 10 BCR-ABL in the DAPI stained regions on the untreated and treated cells. 
The mean expression of p2 I OBCR-ABL is shown relative to untreated cells for both cell types, 
50 cells were analysed (n) and the SEM is calculated. p values correspond to the 
probabilities for the data sets indicated (Wilcoxon rank sum test). 
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6.2.2 - Effects of Imatinib on protein complexes 
To analyse the effects of Imatinib on protein complexes we treated K562 cells with 
Imatinib and performed IP experiments on treated and untreated cells. Then using western 
blot we analysed the, total levels of each protein and their association with p2 IOBCR-ABL. 
6.2.2.1 - Levels of p2jOBCR-ABL after Imatinib therapy. 
K562 cells were treated with I ýLM Imatinib for up 24 hours and the levels of p2 ()BCR-ABL 
were analysed at 0,4,8,16 and 24 hours. Cells were lysed in conventional lysis buffer and 
westem blotted to detect the levels of p2 
IOBCR-ABL. Our data suggest that p2 10 
BCR-ABL 
protein levels remain unchanged during the course of Imatinib therapy (Figure 6.3: A and 
B) which is in agreement with other studies implying that Imatinib reduces phosphorylation 
of p2 I OBCR-ABL but not the amount of total protein. 
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Figure 6.3 - Levels of p2jOBCR-ABL after Imatinib therapy. (A) Levels of p2l 
oBCR-ABL 
after Imatinib treatment. 107 K562 cells treated and untreated with Imatinib were lysed in 
conventional lysis buffer and were separated on 6% and 12 % polyacrylamide gel and 
transferred onto a nitrocellulose membrane. Membranes were blocked for I hour at room 
temperature and probed with anti-ABL and anti-actin antibodies overnight at 4'C. Actin is 
used as a loading control. (B) Using densitometry the levels of p2 IOBCR-ABL were measured. 
Levels of p2 1013CR-ABL were corrected for variations in loading control, actin. This 
represents the mean +/- SEM of 5 repeat experiments. The p values represent the 
probability relative to untreated (0 hours) cells which was calculated using a paired t-test. 
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6.2.2.2 - Effects of Imatinib on the p2jOBCR-ABL and CBL complex 
CBL is tyrosine phosphorylated in CML BC, AML, Ph- T and B -ALL' - p2 I 
OBCR-ABL is 
complexed with CBL via the SH2 domain on ABL but the interaction is dependent on the 
phosphorylation of CBL. Our data in chapter 4 indicate that CBL and p2 I 
OBCR-ABL 
complex in primary CD34+ cells from CML patients . K562 cells were treated with I ýM 
Imatinib for up 24 hours and the levels of p2 IOBCR-ABL were analysed at 0,4,8,16 and 24 
hours. Cells were lysed in conventional lysis buffer and an ABL IP was performed to 
analyse the complex between p2 lOBcR-ABL/ABL and CBL by western blot analysis. The 
data show that total CBL levels remain unchanged (Figure 6.4 A and B) but the levels of 
CBL complexed to p2 IOBCR-ABL/ABL are significantly reduced after 8 hours of treatment 
with Imatinib and levels of CBL complexes with p2 
IOBCR-ABL continue to remain low at 24 
hours of Imatinib therapy (Figure 6.5 A and B). 
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Figure 6.4 - Levels of CBL after Imatinib therapy. (A) Levels of CBL after Imatinib 
treatment. 107 K562 cells treated and untreated with Imatinib were lysed in conventional 
lysis buffer and were separated on 8% and 12 % polyacrylamide gel and transferred onto a 
nitrocellulose membrane. Membranes were blocked for I hour at room temperature and 
probed with anti-CBL and anti-actin antibodies overnight at 4'C. Actin is used as a loading 
control. (B) Using densitometry the levels of CBL were measured. Levels of CBL were 
corrected for variations in loading control, actin. This represents the mean +/- SEM of 5 
repeat experiments. The p values represent the probability relative to untreated (0 hours) 
cells which was calculated using a paired t-test. 
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Figure 6.5 - Levels of CBL complexed to p2jOBCR-ABL /ABL after Imatinib therapy. (A) 
Levels of CBL after Imatinib treatment. 107 K562 cells treated and untreated with Imatinib 
were lysed in conventional lysis buffer and IP of ABL was preformed. Lysates were 
separated on 8% polyacrylamide gels and transferred onto a nitrocellulose membrane. 
Membranes were blocked for I hour at room temperature and probed with anti-CBL 
antibodies overnight at 4'C. (B) Using densitometry the levels of CBL were measured. 
Levels of CBL complexed were corrected for variations in p2 IOBCR-ABL pulldown during 
the IP for each time point. This represents the mean +/- SEM of 5 repeat experiments. The 
p values represent the probability relative to untreated (0 hours) cells which was calculated 
using a paired West. 
224 
Chapter 6- Factors affecting protein complexes in CML 
6.2.2.3 - Effects of Imatinib on the p2jOBCR-ABL and CRIKL complex 
Many independent groups have reported that CRKL is a major tyrosine phosphorylated 
protem in CML cell lines and primary cells. Ph- cell lines and primary cells lack 
phosphorylated CRKL but do express CRKL protein. These differences between CMEL and 
normal cells has meant the levels of phosphorylated CRKL have been exploited as an 
indirect indicator of Imatinib response. CRKL complexes with p2 IOBCR-ABL in Ph' cell lines 
and in chapter 4 we show that the CRYL and p2 IOBCR-ABL complex in CML CD34+ cells 
from patients . K562 cells were treated with I pM Imatinib 
for up 24 hours and the levels of 
p2 IOBCR-ABL were analysed at 0,4,8,16 and 24 hours. Cells were lysed in conventional 
lysis buffer and an ABL IP was performed to analyse the complex between p2 IOBCR-ABL 
and' CRKL by western blot analysis. The data shows that total CRKL levels remain 
unchanged (Figure 6.6 A and B) but the levels of CRKL complexed to p2 I OBcR-ABL /ABL is 
significantly reduced after 8 hours of treatment with Imatinib with a ftu-ther reduction at 16 
hours of therapy and 24 hours of Imatinib therapy (Figure 6.7 A and B). 
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Figure 6.6 - Levels of CRK-L after Imatinib therapy. (A) Levels of CRKL after Imatinib 
treatment. 107 K562 cells treated and untreated with Imatinib were lysed in conventional 
lysis buffer and were separated on 12 % polyacrylamide gel and transferred onto a 
nitrocellulose membrane. Membranes were blocked for I hour at room temperature and 
probed with anti- CRKL and anti-actin antibodies overnight at 4'C. Actin is used as a 
loading control. (B) Using densitometry the levels of CRKL were measured. Levels of 
CRKL were corrected for variations in loading control, actin. This represents the mean 
SEM of 5 repeat experiments. The p values represent the probability relative to untreated (0 
hours) cells which was calculated using a paired t-test. . 
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Figure 6.7 - Levels of CRKL complexed to p2jOBCR-ABL /ABL after Imatinib therapy. 
(A) Levels of CRKL after Imatinib treatment. 107 K562 cells treated and untreated with 
Imatinib were lysed in conventional lysis buffer and IP of ABL was performed. Lysates 
were separated on 12% polyacrylamide, gels and transferred onto a nitrocellulose 
membrane. Membranes were blocked for I hour at room temperature and probed with anti- 
CRKL antibodies overnight at 4'C. (B) Using densitometry the levels of CRKL were 
measured. Levels of CRKL complexed were corrected for variations in p2l 013CR-ABL 
pulldown during the IP for each time point. This represents the mean +/- SEM of 5 repeat 
experiments. The p values represent the probability relative to untreated (0 hours) cells 
which was calculated using a paired t-test. 
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6.2.2.4 - Effects of Imatinib on the p2jOBCR-ABL and GRB2 complex 
GRB2 is a SH2/SH3 adaptor protein of 27 kDa that acts as a direct molecular link between 
tyrosme kinase receptors and RAS pathway. GRB2 SH2 domain binds to tyrosine residue 
177 on p160 
BCR 
of p210 
13CR-ABL in Vivo and in vitro . GRB2 and p2 10 
BCR-ABL 
complex in 
primary CD34"- CML cells (see chapter 4). K562 cells were treated with I gM Imatinib for 
up to 24 hours and the levels of p2 IOBCR-ABL were analysed at 0,4,8,16 and 24 hours. 
Cells were lysed in conventional lysis buffer an ABL IP was perfonned to analyse the 
complex between p2 IOBCR-ABL/ABL and GRB2 by western blot analysis. Data show that 
total GRB2 levels (Figure 6.8 A and B) and GRB2 bound to p2 IOBCR-ABL remain 
unchanged (Figure 6.9 A and B) even after 24 hours of Imatinib therapy. 
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Figure 6.8 - Levels of GRB2 after Imatinib therapy. (A) Levels of GRB2 after Imatinib 
treatment. 10 7 K562 cells treated and untreated with Imatinib were lysed in conventional 
lysis buffer and were separated on 12% and 15 % polyacrylamide gel and transferred onto a 
nitrocellulose membrane. Membranes were blocked for I hour at room temperature and 
probed with anti- GRB2 and anti-actin antibodies overnight at 4'C. Actin is used as a 
loading control. (B) Using densitometry the levels of GRB2 were measured. Levels of 
GRB2 were corrected for variations in loading control, actin. This represents the mean 
SEM of 5 repeat expenments. The p values represent the probability relative to untreated (0 
hours) cells which was calculated using a paired t-test. 
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Figure 6.9 - Levels of GR_B2 complexed to p2jOBCR-ABL /ABL after Imatinib therapy. 
(A) Levels of GRB2 after Imatinib treatment. 107 K562 cells treated and untreated with 
Imatinib were lysed in conventional lysis buffer and IP of ABL was performed. Lysates 
were separated on 15% polyacrylamide gels and transferred onto a nitrocellulose 
membrane. Membranes were blocked for I hour at room temperature and probed with anti- 
GRB2 antibodies overnight at 4'C. (B) Using densitometry the levels of GRB2 were 
measured. Levels of GRB2 complexed were corrected for variations in p2 10 BCR-ABL 
pull-down during the IP for each time point. This represents the mean +/- SEM of 5 repeat 
experiments. The p values represent the probability relative to untreated (0 hours) cells 
which was calculated using a paired t-test. 
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6.3 - Discussion 
The main characteristic feature of p2 IOBCR-ABL in comparison with normal c-ABL is 
the deregulated tyrosine kinase activity '92 and change in subcellular location. Abnormal 
signalling in CML results in deregulated cellular proliferation 193 and decreased adherence 
of leukaernic cells to the bone moffow stroma 
37 
and the effect p2 IOBCR-ABL has on 
94,195,292 
apoptosis is not entirely clear-cut '. Protein complexes are important in CML and 
actiyate many signalling cascades which are responsible for the abnormalities in CML. 
Tberefore understanding the effects of Imatinib on protein complexes between p2 I OBCR-ABL 
and CBL, CRKL and GRB2 may provide further information about the biology of CML 
and-response to therapy. Imatinib, a small tyrosine kinase inhibitor, has proved to be an 
effective therapy for those patients unsuitable for a stem cell transplant, including many 
elderly patients and patients who do not have a matched donor 54. The drug is mostly 
effective in CP CML Patients and recent updates of the IRIS study have shown 84% of CP 
160,161 
patients have a progression free survival when treated with Imatinib 
In chapter 5 the data shows that p2 IOBCR-ABL is expressed in distinct foci in CML 
cell lines and in CD34+ cells from CML patient samples. The distribution of foci was used 
to devise methods to quantify the levels of p2 10 
BCR-ABL 
per cell either by scoring individual 
foci and/or measuring integrated density by Image J. When we treated BV 173 and CMEL 
CD34+ cells with Imatinib the p2 IOBCR-ABL_PoSitive foci translocated to the nucleus in 
comparison to the untreated cells where the foci were expressed predominantly in the 
cytoplasm (Figures 6.2,6.3 and Table 6.3). p2 I 
OBCR-ABL is located exclusively in the 
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cytoplasm even though the protein expresses the NLS and NES regions 
83,63but ABL can 
shuttle between the nucleus and cytoplasm 61,62 .A previous study has shown that tyrosine 
kinase inhibition by Imatinib, activates the nuclear localization signal of p2 I OECR-ABL and 
causes p2 I OBCR-ABL to localise in the cytoplasm. When the nuclear export signal was 
inhibited by Leptomycin B it caused apoptosis of the cell but when the nuclear export 
signal is not inhibited, p2 IOBCR-ABL does not remain in the nucleus and will translocate back 
into the cytoplasm 293. We can speculate from our data and that of Vigneria and Wang 293 
that activation of the ABL tyrosine, kinase in CML inhibits or inactivates the nuclear 
localisation region on p2 IOBCR-ABL which prevents the oncogenic protein from moving 
between cellular compartments like its normal counterpart ABL. Induction of apoptosis by 
nuclear p2 I OBCR-ABL maybe a strategy that can be exploited for therapy to target only the 
p2 I OBCR-ABL_Positive cells although the mechanism of this apoptosis is not known. 
The abnormal tyrosine kinase is also important for downstream target proteins 
which bind to p2 IOBCR-ABL. p210 
BCR-ABL 
_ CBL and p2 I OBCR-ABL - CRKL dissociate after 8 
hours of imatinib treatment and continue to further dissociate. However GRB2 remains 
complexed with p2 IOBCR-ABL through the 24 hour treatment period. Imatinib had no effect 
on the total protein levels of p2 I OPCR-ABL, CBL, CRKL and GRB2 over 24 hours (Figures 
6.3 - 6.8). We have previously described in detail the background to the association of 
p2 I OBCR-ABL with CBL, CRKL and GRB2 in chapters 1,4 and 5. However it is interesting 
213,214 CL 215,216,217 378,379 that- the CBL and CRK '234 but not GRB2 '380 are phosphorylated. only 
in cells of leukaemic origin (ie. CML, ALL, AML) whilst GRB2 is phosphorylated in non- 
leukaemic cells. Chapter 4 shows that CRKL and CBL do not complex with ABL in 
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normal cells from donors of non-leukaemic origin but GRB2 does form complexes in 
normal cells. In addition CBL, CRKL and GRB2 complex with ABL in cells of leukaemic 
origin which are Ph negative. This data implies that the associations of p2 I OBCR-ABL _ CBL 
and p2 I OBCR-ABL _ CRý are dependent on abnormal tyrosine kinase activity. However the 
p210 
BCR-ABL 
- GRB2 complex appears to be independent of tyrosine kinase activity. 
Furthermore we have observed (Chapter 4) that associations of GRB2 with ABL and BCR 
are present in all cell types, CMIL, leukaemic (Ph-) and non-leukaemic cells types. These 
observations also may indicate that complex formation with GRB2 may be relatively 
unimportant in the pathogenesis of CMIL. 
This study has provided new information about the action of Imatinib on the 
proteins involved in CML and p2 10 
BCR-ABL 
and has strengthened our conclusions about 
protein complexes described in chapter 4. 
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CHAPTER 7- SIGNIFICANCE OF THE RESULTS AND 
FUTURE WORK 
7.1: significance of the results 
7.1.1 - General discussion 
The associations between p2 IOBCR-ABL and adaptor protein CBL, CRKL and GRB2 
can activate the RAS and P13K pathway in many different ways. CRKL may affect cell 
adhesion 
401,402 
and we hypothesise that the association between CRKL and CD34 
241,240 
and p2 I OBCR-ABL 
217,213 links CRKL to adhesion and proliferation defects in CML. Figures 
7.1 demonstrates the various mechanisms that the adaptor proteins CBL, CRKL and GRB2 
can complex with p2 16BCR-ABL. 
The altered protein interactions and changes in enzyme activity are likely to affect 
cell function. The functional abnormalities that have been described in CML include 
defective adhesion and dysregulated progenitor cell proliferation. Studies have suggested 
P13K as a key regulator of progenitor proliferation in normal haemopoiesis and CML. First, 
inhibitors of P13K, wortmannin and LY294002, differentially suppress normal and CML 
cell proliferation in vitro in the same way as the therapeutic agents IFN-a and Imatinib 
393,403 
. Second, the effects of wortmannin and 
LY294002 coffelate with the effects of IIFN-a 
and imatinib in individual patients. Moreover, imatinib reduces P13K activity in CMEL cells 
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which, together with the finding in our laboratory that imatinib resistant cell lines respond 
to wortmannin and LY294002, demonstmtes that P13K is downsitream of p2 jOBCR-ABL 
285 
Third, normal and CML progenitor cells respond differently to G-CSF in vitro. G-CSF 
recruits SHIP which hydrolyses the 5'-phosphate from PIP3, a lipid substrate of P13K, and 
blocks one ann of the P13K signalling cascade. Other studies have shown that deletion of 
SHIP results in a myeloproliferative disorder in a knock out mouse model4o4and that SHIP 
protein levels may be increased or decreased in CML cells 
405,406 
. PTEN, another PIP3 
phosphatase, functions in the same way as SHIP and has been suggested to function as a 
tumour suppresser gene by negative regulation of the P13K pathway, but little is known 
about its involvement in CML 
407 
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Figure 7.1 - Mechanisms of association between p2jOBCR-ABL and CBL, CRKL and 
I OBCR-ABL _Cp , yL G"2. p2 " _SOS and p2 
loBCR-ABL 
- GRB2 can activate RAS signalling 
pathway. p2 I OBCR-ABL -CRKL, p2 I 
OBCR-ABL 
-CBL and indirect association between 
p2 I OBCR-ABL -CBL via CRKL and GRB2 can activate the PUK pathway. The downstream 
activation of either the RAS or P13K pathways require appropriate activation many 
intermediate signalling proteins. 
Similarly activation of the RAS pathway affects the cell function. The complex 
between p2 I OBCR-ABLand GRB2 recruits SOS which causes activation of RAS signalling. 
p185 
BCR-ABL 
which lacks tyrosine 177 was shown to transform fibroblasts but not 
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haemopoietic cells in culture which implies that RAS activation maybe be an important 
mechanism in the transformation of haernopoietic cells 260 . RAS is involved in anti- 
apoptosis signals because it is required for anti-apoptotic effect when cytokines are 
removed408 and RAS inhibition leads to the induction of apoptosis 409 and inhibition of 
proliferation 
68,275 
7.1.; - Detection of p2 IOBCR-ABL /ABL protein and associated protein complexes 
p2 IOBCR-ABL forms a complexes with a wide range of cytoplasmic and cytoskeletal 
proteins which have been described in CML cell lines and p2 IOIBCR-ABL transduced cells 
(Chapter 1: Figure 1.7 and Table 1.6). Due to the large number of proteins that complex 
with p2 I OBCR-ABL it is likely that some associations are more important than others in 
disease pathogenesis. The protein complexes mediate the oncogeneic effect of p2 IOBCR-ABL 
but the associations have only been identified in cell lines and p2 I OBCR-ABL transduced cells. 
The advantages of using cell lines rather than primary CML cells is they are easily 
accessible, yield high cell numbers rapidly and can be transduced with mutant variants of 
p210 BCR-ABL to determine the role of specific molecular motifs but they are not 
representative of the in vivo scenano 362 .A major obstacle that has prevented the analysis 
of p2 IOBCR-ABL protein complexes in primary cells from CML patients has been the 
presence of an activity that degrades p2 IOBCR-ABL and ABL specifically upon lysis. The 
204,410,205 
ADA was first described in 1987 . Specialised. 
lysis techniques have been described 
which involve the use high temperature conditions 
410,205,103 but these conditions prevent 
functional studies such as co-IP and kinase assays. 
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To inhibit the activity it was important to identify the properties and the cellular 
source of the degradative activity. Our data shows that the degradative activity targets ABL 
kinases only (p2 IOBCR-ABL and ABL) (Chapter 3: Figure 3.4), that it is present in normal 
and leukaemic cells (Chapter 3: Figure 3.5 and 3.6) and the immature cells (CD34+) 
express lower concentrations of the activity compared to mature cells (MNCs). However 
selecting CD34+ cells is not enough to detect p2 IOBCR-ABL efficiently from primary cells 
(Chapter 3: figure 3.7 and 3.8). To identify the cellular source three target candidates were 
selected based on their cellular roles and pre-treating cells with chloroquine allowed 
detection of p2 1013CR-ABL and ABL in primary CMEL cells (Chapter 3: Figure 3.11). This 
implied that the degradative activity was associated mainly if not completely with cell 
lysosomes. Chloroquine, a lysosome inhibitor, has major disadvantages because it requires 
incubation of cells under non-physiological conditions for 24 h before the effect is maximal 
which reduces cell viability and tyrosine phosphorylation (Chapter 3: Figure 3.12). 
Understanding the action of chloroquine provided the rationale for the experiment with 
high pH lysis buffer which allowed recovery of p2 IOBCR-ABL and ABL (Chapter 3: Figure 
3.1ý) and did not affect the tyrosine phosphorylation in K562 cells (Chapter 3: Figure 
3.14). p2 I OBCR-ABL and ABL recovery from CMEL CD34+ cells was optimal when the cells 
were lysed in 1.25% 10 M NaOH in cold lysis buffer. 
Using the high pH lysis assay we showed that p2 IOBCR-ABL complexes with CBL, 
CRKL and GRB2 in primary CP CMI CD34+ cells (Chapter 4: Figure 4.7) and BC CML 
cells (Chapter 4: Figure 4-8) which confirms the findings in the literature based on cell 
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line work. The presence of ADA also prevented the analysis of ABL related protein 
complexes in normal and CML cells but from cell line work the literature is unclear (refer 
to Chapter 4: Table 4.1). Interestingly in CML CBL, CRKL and GRB2 bound to p21013cR- 
ABL and ABL in K562 cells (ýChapter 4: Figure 4.6) which raised questions about the 
association of ABL and the adaptor proteins in leukaernic and normal cells. KGla and 
HL60 cells originate from patients with AML and are p2 IOBCR-ABL -negative and ABL- 
positive. These co-IP experiments strengthened our finding that normal ABL complexes 
with CBL, CRKL and GRB2 even in non-CMEL cells (Chapter 4: Figure 4.9). The high 
pH lysis assay allows the association of ABL with CBL, CRKL and GRB2 to be analysed 
in primary CD34+ cells from non-leukaemic: patients. Surprisingly, GRB2 and BCR bound 
to nonnal ABL but CBL and CRKL (except patient A, who had a CRKL and ABL 
complex) did not (Chapter 4: Figure 4.10 and Table 4.2). 
Even though the high pH lYsis assay has only mainly been confu-matory of 
published findings for the association of p2 IOBCR-ABL in CML with the adaptor proteins, the 
assay has provided new information about ABL-related protein complexes (Chapter 
4: 
Table 4.3). In CML we speculate that if there are any differences between cell lines and 
primary cells they are likely to be detected further downstream of the adaptor proteins 
where the associations become more complex. 
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7.1.3 - The subcellular distribution of p2joý"-ABL and associated protein complexes 
The subcellular distribution of p2l OBCR-ABL and its associated adaptor proteins 
supplement our co-11P data. One advantage of microscopy is the low cell numbers required 
in comparison to co-IP. The development of a junction specific anti-BCR-ABL antibody 
which recognises the b2a2 (el3a2) breakpoint of p2 IOBCR-ABL specifically without 
IOBCR-ABL recogmsing normal ABL has allowcd dctection of p2 in selcctcd paticnts. 
Interestingly, p2 lOBCR-ABL is expressed as foci in the cell lines tested, both myeloid and 
lymphoid, and in primary CD34+ CMIL cells. However, the number of foci between the 
different cell types varied (Chapter 5: Figures 5.4-5.7), there was a correlation between 
the total levels of p2 IOBCR-ABL (Chapter 5: Figure 5.8) and there was a higher proportion 
of p210 BCR-ABL present in the diffusely stained regions suggesting that this may also have 
an important role in abnormal protein complexes and signalling (Chapter 5: Figure 5.9). 
There has been recent interest in cell maturation-relatcd differences in p2 
IOBCR-ABL 
expression in primary CML cells as primitive cells may be imatinib-resistance and express 
higher levels of p2 I OBCR-ABL 
35,163,45. We have shown that CD34+ CMIL cells express on 
average 1.8-fold higher levels of p2 IOBCR-ADL in comparison to MNCs (Chapter 5: Figures 
5.10). Thus, p2 I OBCR-ABL is distributed in foci in CD34+ cells but is diffusely distributed 
MNCs. 
The association of CRKL with p2 I OPCR-ABL and CRKL phosphorylation in CML has 
received considerable attention recently due to its value in monitoring clinical 
responsiveness and resistance to imatinib In this regard, it has been shown that 
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normal cells contain little phosphorylated CRKL whereas CRKL is predominantly 
phosphorylated in CML. The mechanism of CRKL phosphorylation is not certain but it is 
known that the SH3 domain on CRKL binds to the proline rich region on p2 I OBCR-ABL 
217 
and the tyrosine 207 residue on the SH3 domain is essential for CRKL phosphorylation in 
p210 
BCR-ABL 
-positive cells 
236. The CLSM data implies that only a small proportion of total 
CRKL and total p2 I OBCR-ABL complex but closer examination of the foci indicates that a 
I OBCR-ABL fi small portion of CRKL and p2 oc colocalise completely whilst other foci 
partially overlap, topCh or are separate. (Figure 5: Figure 5.11). This distribution pattern 
may be important in understanding the role of CRKL and other proteins. When we analysed 
the colocalisation of p2 10 
IBCR-ABL 
with other adaptor proteins we also found only small 
amounts of each protein were in complex (Chapter 5: Figure 5.12 and Chapter 5: Figure 
5.13 (A-D). 
BCR ABL 
7.1.4 - Effects of Imatinib on localisation of p210 - and 
integrity of protein 
complexes 
Imatinib has improved CML therapy significantly particularly in CP 160. We 
reasoned that Imatinib might influence protein complex formation and treated 
BV 173 and 
CML CD34+ cells with Imatinib. Then using CLSM we analysed the distribution of 
p210 
BCR-ABL_Positive foci. Interestingly, the p210 
BCR-ABL foci translocated to the nucleus 
(Chapter 6: Figures 6.2,6.3 and Table 6.3). Normal c-ABL can shuttle between the 
nucleus and cytoplasm but p2 
I OBCR-ABL is located exclusively in the cytoplasm. Imatinib 
can activate nuclear localisation p2 
lCjBCR-ABL and when trapped in the nucleus promotes 
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apoptosis of the cell but when the NES is not inhibitedý p2 IOPCR-ABL does not remain in the 
nucleus and will translocate back into the cytoplasm 
293 
. 
Many protein complexes in CML are dependent on phosphorylation therefore the 
dissociation of p2 IOBCR-ABL and CBL and p2 1OBCRý-ABL and CRKL was not unexpected. 
However it was more interesting that the p2 IOPCR-ABL and GRB2 complex was not affected 
by Imatinib (Chapter 6: Figures 6.3 - 6.8). This also supports and strengthens our 
hypothesis in chapter 4, that the associations of GRB2 with p2 IOBCR-ABL and ABL is 
present in all cell types potentially because GRB2 is phosphorylated in these cells thus 
nlk IOBCR-ABL capable of forming the SH2 mediated complex with p2 or ABL even in the 
presence of Imatinib. 
7.1.5 - Final conclusion 
In conclusion this study has developed novel and alternative methods to analyse 
protein complexes particularly in primary CML cells from patient material. The data show 
that p2 I OBCR-ABL complexes with adaptor proteins in primary CML cells, that not all the 
adaptor proteins complex with normal ABL in non-leukaemic cells. Also, the 
inhibition of 
the tyrosine kinase activity dissociates some protein complexes but not others. Finally the 
assays developed have answered and also raised some important questions about protein 
complexes in CML. 
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7.2: Future work 
7.2.1 - Further applications of high pH lysis 
The ability to IP p2 I O: 
BCR-ABL from primary CML cells has been an important 
fmding. It also provides opportunity to further validate the model of p2 IOBCR-ABL associated 
signalling in CML and identify difference amongst different case, disease states and treated 
CML patients. Also there is the possibility of developing a direct kinase assay to measure 
p2 1013CR-ABL kinase activity which may prove technically difficult. However, an indirect 
kinase assay which uses phosphorylation of CRKL 191"" as a measure of p2 IODCR-ADL 
function has been developed and a direct method of measuring kinase assay may be more 
powerful and specific for clinical and research purposes. 
Surprisingly, ABL complexes with the adaptor proteins in a similar way to p2 I O"cR- 
ABL and some of the complexes are leukaemia specific. Using the high lysis assay ftu-ther 
analysis of p2 IOBCR-ABL, ABL and BCR associated complex in CML and non-CML cells 
may elucidate signalling pathways that are specific to CML. 
7.2.2 - Proteomics analysis in CMIL 
We have focused on the associations of p2 IOBCR-ABL with adaptor proteins in CMI, 
but as discussed, the p2ldE'CR-ABL associated signalling network is very complex and 
involves many different Proteins. Thus, a detailed study which analyses a wide range of 
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proteins is still required. We have resolved high molecular weight bands from whole cells 
lysate from CML cells using a commercially available native page western blot system 
411,412,413 (Invitrogen) that was adapted from blue native page protocols . We now intend to 
apply a proteomics approach to analyse the composition of these high molecular weight 
bands which may reveal new binding partners of p2 10 
BCR-ABL 
. Also, this approach will 
answer questions about heterogeneity of complex formation in CML. 
7.2.3 - Role of CRKL in CMIL 
CLSM microscopy is a useful tool to visualise and quantify total levels of proteins 
and protem colocalisation. An approach to understanding the role of CRKL would be to use 
siRNA to knockdown the CRKL and measure changes in cell functions such as 
proliferation and adhesion between normal and CML cells. CRKL has been implicated in 
adhesion and migration 
401,402 
and migrates to focal adhesions when SRC activity is 
nik 
402 240 
, bnomial . The association 
between CRKL and CD34 is of particular interest 241, as 
CD34 mediates binding between normal progenitor cells 29 which reduces proliferation 414 
suggesting it may have a role in regulating cell kinetics via its association with CD34. We 
have preliminary data showing knockdown of CRKL protein using siRNA in normal (A) 
and- CML (B) CD34+ cells (Figure 7.2) 48 hours after siRNA treatment Our preliminary 
data for the effects of siRNA knockdown on proliferation using the colony replating assay 
is still premature and so inconclusive. Effects of imatinib or the new tyrosine kinase 
inhi . bitors, in combination with CRKL siRNA may add further to understand the cellular 
functions of CRKL. 
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Figure 7.2 - CRK-L knockdown using ARNA. CD34 + cells were isolated ftom normal (A) 
and CML (B) cells. CRKL siRNA was used to knock down CRKL protein and CRKL 
expression was analysed at 0,24,28 and 72 hours after siRNA treatment by FACS 
analysis. 
7.2.4 - Abnormal centrosomes in CMIL 
Further preliminary data shows that p2 I 
OBCR-ABL associated with centrosomes 
stained with pericentrin antibody (data not shown) suggesting that p2 10 
BCR-ABL 
may be 
directly linked to the centrosomal abnormalities in 
CNlL415,416 
. The involvement of CD34 
in cell aggregation 
29,414 
, association with 
CRKL 240'24' and possible association with 
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centrosomes with p2 I OB 
CR-ABL 
suggests that p2 IOBCR-ABL expression may disrupt the 
balance between symmetrical and asymmetrical division in CML. Previous work in our 
laboratory has demonstrated that position of the centrosome relative to notch and CD 164 
(makers of cell polarity) can be used to predict if a cell may divide symmetrically or 
asyrnmetrically 414 . Based on the data 
from our laboratory and others, using CLSM, the 
junction specific p2 IOBCR-ABL antibody and IP we may be able to elucidate possible 
mechanisms of abnormal cell division in CML. 
7.2.5 - Therapy and protein complexes in CMEL 
Using the high pH lysis assay we can determine if Imatinib or the new tyrosine kinase 
inhibitors affects protein complexes in primary CML cells like the cell line data. This 
analysis may provide ftirther information about the biological action of different drugs used 
in CML. Also, we can determine if targeting complexes which do not dissociate in response 
to therapy improve patient prognosis. 
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Detection in Primary Chronic Myeloid Leukaemia 
Cells of p2 I OBCR-ABL I in Complexes with Adaptor 
Proteins CBL, CRKL, and GRB2 
Hetall Patel, Stephen B. Marley, and Myrtle Y. Gordon* 
Department of Haematology, Faculty of Medicine, Imperial College, Hammersmith Campus, London, UK 
Chronic myeloid leukemia (CML) arises as a consequence of the expression of a chimeric fusion protein, p2lOBCR-ABLI, 
which is localized to the cytoplasm-and has constitutive protein tyrosine kinase activity. Extensive publications report that 
p2lOBCR-ABL. 1 complexed with multiple cytoplasmic proteins can modulate several cell signaling pathways. However, while 
altered signaling states can be demonstrated in primary CML material, most of the reported analytical work on complexed 
proteins has been done in cell lines expressing p2lOBCR-ABLI. This has been necessary because primary hemopoietic cell 
lysates contain a degradative activity which rapidly and permanently destroys p2 I OBCR-ABL 1, precluding accurate p2 I OBCR- 
ABIL I quantification by Western blotting or investigation of coimmunoprecipitating proteins in primary cells. This degradative 
activity has proven intractable to inhibition by conventional protease inhibitors. We show here that the degradative activity in 
primary cells is associated With cell lysosomes and is most likely to be an acid-dependent hydrolase. By iysing primary hemo- 
poietic cells at high pH, we have demonstrated substantial inhibition of the p2 I OBCR-ABL I -degradative activity and now 
report, to the best of our knowledge, the first published demonstration by coirnmunoprecipitation of the association between 
p2 I OBCR-ABL I and cytoplasmic effector proteins in primary CML material. 0 2006 Wiley-Liss, Inc. 
INTRODUCTION 
Chronic myeloid leukemia (CML) is a myelo- 
proliferative -disorder which arises as a result of the 
acquisition of a 09,22) by a primitive hemopoietic 
cell (Nowell and Hungerford, 1960). This translo- 
cation brings two genes, Abelson murine leukemia 
virus (ABLI) and the breakpoint cluster region 
(BCR), into juxtaposition to form the characteristic 
Philadelphia. (Ph) chromosome and results in the 
synthesis of a chimeric protein, p2lOBCR-ABLI, 
with constitutively activated protein tyrosine 
kinase activity. The resultant clinical outcome is 
an unregulated expansion of the myeloid series. 
There is no overt maturational block in the neo- 
plastic clone at this chronic phase stage but, if the 
disease is managed purely by controlling the white 
cell count, the ultimate acquisition of further 
genetic lesions will permit the emergence of an 
overt acute leukemic phase, blast crisis, which is 
generally chemorefractory and fatal We Klein 
et al., 1982; Heisterkamp et al., 1982; Shtivelman 
et al., 1985)., 
The ABLI and BCR proteins are ubiquitously 
expressed in nonmalignant cells (Laneuville, 1995) 
and appear to have multiple cellular regulatory 
functions. BCR carries a serine threonine kinase 
and several tyrosine phosphorylation sites, can 
modulate actin polymerization through RAC via 
0 2006 Wiley-Uss, Inc. 
GTP-ase activity (Diekmann et al., 1991), activates 
the transcription factor NFKB by driving GTP 
substitution for GDP on RHO (Montaner et al., 
1998), and may influence the RAS pathway 
through interaction with the adaptor protein 
growth factor binding protein 2 (GRB2) (Ma et al., 
1997). BCR knockout mice are viable (Voncken 
et al., 1995). The ABLI protein is predominantly 
nuclear, with some plasma membrane and f-actin- 
associated expression (Van Etten et al., 1989; 
McWhirter et al., 1993; Laneuville, 1995; Van 
Etten, 1999) although a cytoplasmic ABLI distri- 
bution has been noted in primary hemopoietic 
cells (Wetzler et al., 1993). The expression of nu- 
clear localization and exit motifs on ABLI suggest 
a trafficking role for the protein, and three SRC 
domains carry tyrosine phosphorylation sites 
potentially allowing complexing with adaptor pro- 
tems such as GRB2 or CT10 regulator of kinase- 
like (CRKL) via their SH2 domains. Functionally, 
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ABLI would appear to modulate cell cycle regula- 
tion, effects of genotoxic stress, and response to 
integrin signaling (Van Etten, 1999). ABLI knock- 
out mouse survival is severely impaired (Schwartz- 
berg et al., 1991; Tybulewicz et al., 1991). 
By contrast to ABL1, pZ10BCR-ABL1 distribu- 
tion is restricted to cytoplasmic f-actin-associated 
focal adhesions. The protein tyrosine kinase of the 
ABLI component of the molecule is constitutively 
activated and in cell lines p210BCR-ABL1 binds 
the adaptor proteins GRB2 (Pendergast et al., 1993; 
Gishizky et al., 1995), CRKL (Oda et al., 1994; Sal- 
gia et al., 1995; Sattler et al., 1996), casitas B-cell 
lymphoma (CBL) (Sattler et al., 1996), and Src-ho- 
mologous and collagen gene (SHC) (Pelicci et al., 
1995) as well as f-actin. The list of p210BCR-ABL1 
substrates is extensive (Deininger et al., 2000; Steel- 
man et al., 2004; Marley and Gordon, 2005). Expres- 
sion of p210BCR-ABL1 has been shown to alter cell 
adhesion (Gordon et al., 1987), inhibit apoptosis 
(Bedi et al., 1994), and modulate cell signaling path- 
ways responsible for proliferation and transforma- 
tion (Cortez et al., 1995). It follows that the abnor- 
mal cell function and protein complexity in CML 
may be linked in some way and, further, that varia- 
tions in complex formation may contribute to clini- 
cal heterogeneity that has been observed among 
CML patients (Gordon et al., 2003). 
The association of p210BCR-ABL1 with intra- 
cellular signaling intermediates has been described 
principally in Ph' cell lines but. it remains for these 
findings to be confirmed or refuted in primary 
CML cells. This has been limited by the presence 
of a proteolytic activity in myeloid cells which rap- 
idly degrades p145ABLI and p210BCR-ABL1 pro- 
teins upon cell lysis. This was first noted in 1987 
(Maxwell et al., 1987) as an inhibitor of protein 
kinase function. In 1991, it was reported that high 
concentrations of degradative enzymes hindered 
attempts to detect the kinase activity of p210BCR- 
ABLI protein in chronic phase patients. (Guo 
et al., 1991). The degradative activity was not pre- 
vented by any of the conventional protease inhibi- 
tors used in preparation of cell lysates, thus com- 
promising attempts to quantify p210BCR-ABL1 or 
to describe its protein-protein interactions or ki- 
nase activities directly in primary hemopoietic 
cells. Activity is lower in the CD34' cell fraction, 
where a regime using boiling lysis buffer can per- 
mit detection of p210BCR-ABL1 from primary 
cells by Western blotting (Schleuning et al., 1999; 
Barnes et al., 2005) but boiling precludes immuno- 
precipitation by disrupting protein complexes. 
However, abrogation of the p210BCR-ABL1 deg- 
radative activity by a method that maintains pro- 
tein-protein interactions would permit immuno- 
precipitation of intact p2lOBCR-ABLI from pri- 
mary CML hemopoletic material to confirm the 
associations between p210BCR-ABLI and cell sig- 
naling moieties implied by studies of cell line mod- 
els. This would allow the dynamics of protein asso- 
ciations during therapy to be studied as well as 
functional aspects of p2lOBCR-ABLI such as tyro- 
sine kinase activity. 
We identified cell lysosomes as the most likely 
source of the degradative activity, as a prelude to de- 
veloping a suitable technique for its inhibition. We 
show here that in a high pH milieu, the degradative 
activity in CML chronic phase peripheral blood 
cells can be abrogated sufficiently to allow confident 
quantification of p210BCR-ABL1 levels and suc- 
cessful immunoprecipitation of p2lOBCR-ABLI 
with coimmunoprecipItation of associated proteins. 
We believe that this is the first demonstration of 
reliable immunoprecipitation of p21OBCR-ABL1 
from chronic phase CML cells and that it represents 
a step forward in the investigation of CML pathoge- 
nesis, permitting direct biochemical studies of pri- 
mary leukemic cells. 
MATERIALS AND METHODS 
Cells for Study 
The K562 CML cell line, BaF3 cells transfected 
with p2lOBCR-ABLI and KBM5 cells (Beran 
et al., 1993) (provided by Professor Beran, M. D 
Anderson center, Houston) were grown in the labo- 
ratory. Hemopoletic cells from newly diagnosed 
CML patients or from hernatologically normal 
donors were obtained from excess material from 
leukaphereses taken for clinical purposes. All 
patients and donors gave informed consent in ac- 
cordance with local Ethics Committee guidelines. 
Reagents and Antibodies 
Monoclonal mouse anti-c-ABL, rabbit anti-CBL, 
rabbit anti-CRKL and mouse anti-Grb2, protein A/G 
agarose beads, c-ABL-conjugated agarose beads, and 
ExactacruzTm IP matrix were supplied by Autogen 
Bioclear (Calne, United Kingdom). HRP-conjugated 
swine anti-rabbit, rabbit anti-mouse, and rabbit anti- 
goat antibodies were supplied by Dako (Glostrup, 
Denmark). ZVAD, lactacystin, and chloroquine were 
supplied by Sigma (Poole, United Kingdom). 
Cell Separation 
Mononuclear cells (MNQ were separated from 
leukapheresis samples by density gradient centrif- 
Genes, Chromosomes &Canter DOI 10.1002/gcc 
IMMUNOPRECIPITATION OF p2lOBCR-ABLI 
ugation (Lymphoprep, Axis-Shield, Oslo, Norway) 
and washed three times in Ca 2+ /Mg+'-free PBS 
(Gibco, Paisley, United Kingdom) before lysis. 
CD34' cells were purified from CML or normal 
leukaphereses MNC using immunomagnetic 
beads following the manufacturer's recommenda- 
tions (Stem Cell Technologies, Grenoble, France). 
Conventional Cell Lysis 
Cells were washed twice in Ca2'/Mg'-free PBS. 
The cell pellet was manually dispersed and then 
vigorously resuspended in 200 gl ice-cold standard 
lysis buffer (1% Triton X-100 (Sigma, Poole, 
United Kingdom), 150 mM NaCl, 1 MM MgC12, 
10% glycerol (Invitrogen, Paisley, United King- 
dom), 20 mM Tris C& pH 8 and -a proprietary prote- 
ase inhibitor cocktail (Complete TM tablets, Roche, 
Mannheim, 'Germany), per 107 cells. The lysate 
was incubated on ice for 10 min, and then the cells 
were sheared by rapid expulsion through a 21-g 
needle. The crude lysate was centrifuged at 4'C 
for 3 min at 13,000 rpm. For Western blotting, the 
lysates were mixed with an equal volume of load- 
ing buffer (2.3% sodium dodecyl sulfate (SDS), 
10 mM DL-DTT (DTT), 0.01% bromophenol 
blue (all Sigma, Paisley, United Kingdom), 10% 
glycerol, and 62.5 mM Tris C& pH 6.8) and boiled 
for 5 min at 100'C. For immunoprecipitation cells 
were lysed as described above and the unboiled, 
cleared lysate was used immediately for immuno- 
precipitation without addition of loading buffer. 
High pH Lysis to Abrogate Anti-p2l OBCR-ABL I 
Degradative Activity 
Cells were washed and pelleted as described 
above. For p21OBCR-ABL1 quantification by 
Western blot, cells were lysed in 200 pl per 107 
cells of high pH lysis buffer (1% Triton X-100 
(Sigma), 150 mM NaCl, 1 MM MgC12,10% glYC- 
erol (Invitrogen), 20 mM Tris @ pH 8, and a propri- 
etary protease inhibitor cocktail (Complete TM tab- 
lets), as follows: Immediately before lysis, 1.25% 
(2.5 pl per 107 cells) of 10 M NaOH was added to 
the lysis buffer. The high pH lysis buffer was 
added immediately to the cell pellet which was 
vigorously dispersed. After 10 min incubation on 
ice, the lysate was sheared and centrifuged at 
13,000 rpm for 3 min. The supernatant was mixed 
with an equal volume of loading buffer and boiled 
for 5 min at 100'C for Western blotting. For immu- 
noprecipitation, cells were lysed as described 
above and the unboiled, cleared lysate was used 
immediately for immunoprecipitation without ad- 
dition of loading buffer. 
High pH Agarose Bead Immunoprecipitation 
of p2 I OBC R-ABL I 
1123 
Cells were lysed in high pH lysis buffer as de- 
scribed above. The cleared, unboiled lysate was 
dispersed in 2 ml of ice-cold RIPA buffer (150 mM 
NaCl, l% Triton X-100,0.1% SDS, 10 mX1 Tris @ 
pH8.0 and protease inhibitors as per high pH lysis 
buffer) containing 1: 50 of primary antibody for I hr 
at 4'C. Protein A/G agarose beads were added at 100 
ýd packed volume/I 07 input cell number. Where pre- 
conjugated beads were used, the primary antibodN 
step was omitted. Following I hr of gentle agitation 
at 4'C, the beads were removed by centrifugation 
and washed four times in I ml of ice-cold RIPA 
buffer, suspended in 50 pl of loading buffer per 107 
of input cell number and boiled for 5 min and then 
Western blotted to detect protein complexes. 
High pH Exactacruz TM Immunoprecipitation 
of p2 I OBCR-ABL I 
ExactaCruz TM (Santa Cruz Biotechnology, Wilt- 
shire, United Kingdom) was also used to immuno- 
precipitate p21OBCR-ABL1 from K562 cells and 
primary cells. The Exactacruz TM matrix was pre- 
pared as per the manufacturer's protocol. In brief, 
for 107 cells lysed in 200 pl high pH lysis buffer, 
antibody-matrix complex was formed by incubating 
100 pl of IP matrix and 10 gg/ml anti-c-ABL or 
mouse IgG in 500 pl of Ca 2+ /Mg+'-free PBS for 2 hr 
at 4'C. The matrix was washed twice with cold 
Ca 2+/Mg"-free PBS and then incubated with cell 
lysate for I hr at VC. After two washes in 500 pl 
cold Ca 2+ /Mg++-free PBS, the matrix was suspended 
in 80 V1 of loading buffer and boiled for 5 min and 
then Western blotted to detect protein complexes. 
Western Blotting 
Protein lysates and colored molecular weight 
markers (Bio-Rad, Hemel Hempstead, United 
Kingdom) were run in parallel on 6.5-8% SDS- 
PAGE minigels (37.5: 1 acrylamide: bisacrylamide; 
Bio-Rad, Hemel Hempstead, United Kingdom) 
and then transferred to polyvinylidenedifluoride 
membranes (Immobilon TM , Sigma, Poole, United Kingdom) using a semi-dry transfer system (Bio- 
Rad, Hemel Hempstead, United Kingdom). The 
membranes were blocked with 1-5% milk (NIarvel 
milk powder, obtained from local retailer) in TBS- 
Tween, stained overnight at 4'C with monoclonal 
antibodies to proteins of interest, washed 4X in 
TBS-Tween, stained for 30 min at 20'C with 
HRP-conjugated secondary antibodies in 1-5% milk 
in TBS-Tween, washed 4X again in TBS-Tween 
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and visualized by chemilurninescence (ECL, Amer- 
sham Biosciences, Little Chalfont, Bucks, United 
Kingdom) on Kodak Biomax MR film (Sigma, Poole, 
United Kingdom). 
Assay of Anti-p2 I OBCR-ABL I Degradative Activity 
To demonstrate anti-p2lOBCR-ABLI degrada- 
tive activity in MNC, p2 1 OBCR-ABL 1 -positive 
K562 cells were used as a reporter. Intact K562 
cells and MNC were mixed and then colysed with 
conventional lysis buffer. For lysate mixing experi- 
ments, MNC were mixed 1: 1 with K562 cells and 
colysed at 200 pl lysis buffer per 107 cells for 
10 min on ice as described earlier. The cleared 
lysate was added to equal volumes of loading 
buffer, boiled for 5 min, and then Western blotted 
to detect intact p2lOBCR-ABLI. 
Inhibition of Potential Intracellular Sources 
of Anti-p2 I OBCR-ABL I Degradative Activity 
Ten million MNC were incubated for 24 hr at 
37'C, 5% C02 in 25 cm 2 tissue culture flasks (VWR, 
Poole, United Kingdom) containing 5 ml ct-MEM 
(Gibco, Paisley, United Kingdom) with 15% FCS 
and with or without the caspase inhibitor ZVAD, 
the proteosome inhibitor lactacystin or the lysosome 
inhibitor chloroquine. The cultured MNC were 
counted, viability was checked by trypan blue dye 
exclusion and then the cells were washed 3X in 
Ca2'/Mg"-free PBS before undergoing standard 
lysis and the unbolled lysate assayed for anti- 
p210BCR-ABL1 degradative activity. 
RESULTS 
Anti-p2 I OBCR-ABL I Degradative Activity is 
Expressed in Normal and Malignant Myeloid Cells 
Both p145ABLI and p2lOBCR-ABLI are readily 
detectable in lysates of the Ph' K562 cell line, but 
not in primary CML cell lysates, which expresses a 
potent degradative activity that degrades p21OBCR- 
ABL1 and p145ABL1 as shown in cell lysates from 
two patients (A and B) by conventional Western 
blotting (Fig. 1A). In Figure 1B, p145ABLI and 
p21OBCR-ABL1 are detected in the control K562 
cell lysate (Lane 1). CNIL MNC and K562 cells 
were mixed and colysed in boiling lysis buffer which 
removed the degradative activity (Lane 2). How- 
ever, both p21OBCR-ABL1 and p145ABL1 were 
degraded completely when CNIL MNC: KS62 cell 
mix was colysed in cold lysis buffer (Lane 3). Similar 
results were seen with MNC from normal peripheral 
blood progenitor cells (PBPQ (Fig. 10 and normal 
bone marrow (Fig. I D) where there was degradation 
14' 
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3 
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Figure 1. p2lOBCR-ABLI-degradative activity is present in MNC 
from different tissues and is inactivated by heat. K562 and CML MNC 
cells from two patients (A and B) were lysed in standard lysis buffer and 
Western blotted using an anti-ABLI antibody for the detection of 
p2lOBCR-ABLI andp145ABLI (A). MNC derived from (B) CMLor (C) 
normal PBPC or from (D) normal bone marrow were mixed with equal 
numbers of K562 cells and lysed in boiled or unboiled lysis buffer. 
Lysates were Western blotted and probed with an anti-ABL I antibody 
for the presence of p2 I OBCR-ABL I and p 145ABL 1. Lane 1: K562 con- 
trol incubated with unboiled lysis buffer only. Lane 2: K562: MNC mix 
colysed in boiling lysis buffer, Lane 3: K562: MNC mix colysed in 
unboiled lysis buffer. 
of p21OBCR-ABLI and p145ABLI. Degradation of 
p21OBCR-ABL1 occurs within 60 sec of exposure to 
lysed primary cells (data not shown). 
CD34"' Cell Enrichment Reduces But Does Not 
Abrogate Anti-p2 I OBCR-ABL I Activity 
It has been proposed (Maxwell et al., 1987; Guo 
et al., 1991) that the degradative activity is present 
only in mature myelold cells. Therefore, we rea- 
soned that it may be possible to detect p21OBCR- 
ABLI in isolated CD34' cell fractions. However, 
analysis of conventional lysates of CD34' CML 
cells did not demonstrate any recovery of 
p21OBCR-ABL1 (data not shown), suggesting that 
degradative activity was present in these cells as 
well as more mature MNC. When graded numbers 
of MNC were mixed with K562 cells and then 
colysed the p21OBCR-ABL1 signal was degraded 
even at 1: 16 (MNC: K562) dilution (Fig. 2A) while 
colysing K562 cells mixed with CD34' cells (Fig. 
2B) diluted out at 1: 8 (CD34': K562) or 1: 16 
(CD34': K562) allows detection of p21OBCR-ABL1 
showing that CD34' cells had less activity com- 
pared with MNC. This experiment was repeated 
three times with similar results. The data show 
that while CD34' cells contain less degradative ac- 
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Figure 2. CD34* purification is not sufficient to abrogate anti- 
p2lOBCR-ABLI activity. Unboiled lysates of normal PBPC (A) MNC or 
(B) CD34+ cells were mixed with K562 cells serially in two-fold dilu- 
tions and colysed in cold lysis buffer for 10 min on ice. The cleared 
lysate was mixed with an equal volume of loading buffer and boiled for 
5 min at 100'C. Lysate were Western blotted and probed with anti- 
ABLI for p2lOBCR-ABLl. Final dilution ratios of primary MNC: K562 
cells are shown. Last lane is K562 lysate-only control diluted 1: 1 with 
lysis buffer only. 
tivity than MNCs, it is at a level that still precludes 
immunoprecipitation of primary p2lOBCR-ABL1. 
Additional experiments on primary cells used 
CD34' cells. 
Inhibition of Cellular Organelles or Caspase 
Cascades Indicates that p2 I OBCR-ABL I 
Degradative Activity is Located 
in MNC Lysosomes 
We investigated the cellular source of the degra- 
dative activity present in NINC as a prelude to 
attempting to identify and specifically inhibit its 
action. Three candidate targets were the caspase 
cascade, proteosomes, and lysosomes, inhibited by 
ZVAD, lactacystin, and chloroquine, respectively. 
It has been suggested that TP53-induced erythroid 
differentiation requires the caspase cascade which 
results in the cleavage of p21OBCR-ABL1 and 
p145ABLL This cleavage can be inhibited when 
K562 cells are pretreated with caspase inhibitor, 
ZVAD (Di Bacco and Cotter, 2002). Proteosomes 
(Adams, 2003; Posthuma et al., 2004) and lyso- 
somes (Hatch et al., 1993) were targeted as they 
are natural cellular reservoirs of enzymatic activ- 
ities. We exposed NINC to a range of concentra- 
tions of these agents for 24 hr and then assayed 
the cells for p2lOBCR-ABLI-degradative activity. 
Figure 3A shows that incubation with ZVAD did 
not reduce degradative activity in NINC, suggest- 
ing that the activity was not a component of the ap- 
optotic caspase cascade. Similarly, inhibition of 
proteosomes with lactacystin (Fig. 3B) did not reduce 
degradative activity of NINC lysates. However, the 
dose-response series for chloroquine (Fig. 3C) showed 
that, after 24 hr incubation with high levels, the 
p2lOBCR-ABLI-degradative activity in NINC was 
Lactacystm 
- I'l 
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Figure 3. The p2lOBCR-ABLI clegraclative activity in MNC is asso- 
ciated with lysosomes. To determine the cellular source of the 
p2 I OBCR-ABL I -clegraclative activity, normal PBPC MNC and K562 cells 
were cultured for 24 hr in the presence or absence of (A) the caspase 
inhibitor ZVAD and (B) the proteosome inhibitor lactacystin or (C) the 
lysosome inhibitor chloroquine. The treated cells were lysed and 
cleared lysate was mixed with equal volumes of loading buffer and 
boiled for 5 min at I OO'C. Lysates were then assayed by Western blot- 
ting for degradation of K562-derived p2 I OBCR-ABL 1. 
substantially inhibited. Densitometry analysis showed 
that 5 mM chloroquine treatment results In 87% re- 
covery of p2lOBCR-ABLI in relation to control K562 
derived p2lOBCR-ABLI levels. Shorter term incuba- 
tion with chloroquine was markedly less effective 
(data not shown). The effect of chloroquine indicates 
that the degradative activity is likely to be mainly, if 
not entirely, located within lysosomes of intact MNC. 
Tyrosine Phosphorylation of Proteins in K562 Cells 
is Reduced by 5 nM Chloroquine Treatment 
Although the use of chloroquine indicates a pos- 
sible solution to the difficulties in immunoprecipi- 
tating p210BCR-ABL1 from primary CML cells, it 
required 24-hr incubation under nonphysiological 
conditions before its effect was maximal. Chloro- 
quine treatment over 24-hr substantially reduced 
the culture medium pH, raising concerns that the 
observed reduction in degradative activity was as a 
result of reduced lysis efficiency or cell viability. 
However, there was no reduction in cell viability in 
chloroquine-treated cultures at 24 hr, and actin 
yields from chloroquine-treated and untreated 
MNC cultures were comparable (data not shown). 
However, chloroquine has an effect on the tyrosine 
phosphorylation levels. Untreated K562 cells and 
K562 cells pretreated with chloroquine were lysed 
with standard lysis buffer and tyrosine phosphoryla- 
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Figure 4. High chloroquine concentrations severely effect the tyro- 
sine phosphorylation of p210BCR-ABL I and downstream target pro- 
teins. K562 cells were lysed in cold lysis buffer without NaOH (Lane: 
A), with 1.25% IQ M NaOH (Lane: B) and cells pretreated with 5,50, 
and 500 itM and 5 mM chloroquine (Lanes C-F). The lysates; were then 
Western blotted using anti -phosphotyrosi ne antibody to determine the 
level of total phosphorylation in cells. Actin was used as a loading control. 
tion levels were analyzed by Western blotting 
(Fig. 4). Chloroquine at low concentrations has no 
significant effect on the phosphorylation pattern 
(Lane C-E) but when cells are treated with chloro- 
quine concentrations (5 mM) required to inhibit the 
degradative activity the tyrosine phosphorylation is 
significantly reduced (Lane F). This further confirms 
that chloroquine is not a suitable agent for inhibiting 
the p2 1OBCR-ABL I -associated degradative activity. 
Chloroquine acts to abrogate lysosome function 
by increasing the internal pH of the lysosome 
(Hatch et al., 1993) suggesting that chloroquine 
may be mimicked by high pH conditions. High pH 
lysis (Lane B) does not significantly effect the 
phosphorylation of p21OBCR-ABL1 and lower mo- 
lecular weight proteins in comparison to the stand- 
ard lysis (Lane A). This finding suggests that high 
pH lysis may mimic effects of chloroquine without 
affecting the protein tyrosine kinase activity. 
1.25% 10 M NaOH Results in Optimal Recovery of 
p2 I OBCR-ABL I from Primary CD34+ CML Cells 
To optimize the yield of p210BCR-ABL1 from 
primary cells, CML CD34' cells were lysed in lysis 
buffer containing increasing concentrations of 
NaOH. About 1.25% of 10 M NaOH in cold lysis 
buffer permitted maximal recovery of p210BCR- 
ABLI at levels comparable to those of boil-lysed 
control samples. When cells were lysed in lysis 
buffer containing 1.25% 10 M NaOH the levels of 
p210BCR-ABLI recovered was 90% relative to 
p2lOBCR-ABL1 levels recovered from cells lysed 
in boiling lysis buffer (Fig. 5). When cells were 
lysed in 10 M NaOH at concentrations higher than 
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Figure S. Increasing lysis buffer pH results in abrogation of 
p2lOBCR-ABLI-degradative activity in mononuclear cell lysates. CML 
CD34' cells were lysed at 4ýC in cold lysis buffer containing 0- 10% 10 
M NaOH. The lysates were then Western blotted to determine the 
effects of increasing pH on p2 I OBCR-ABL I -clegraclative activity. As a pos- itive control, mixed cells were boil-lysed in lysis buffer without NaOH. 
1.25% recovery of p21OBCR-ABLI was compro- 
mised by the effects of extreme pH on the Western 
blotting system. These data and Figure 4 (Lane B) 
confirm that high pH lysis using 1.25% NaOH in 
cold lysis buffer inhibits the degradative activity 
without affecting tyrosine phosphorylation. 
High pH Lysis Permits Immunoprecipitation 
of p2l OBCR-ABL I and Detection of 
Complex Formation 
While good yields of p2lOBCR-ABLI were re- 
covered from K562 cells or CML CD34' cells im- 
munoprecipitated on agarose beads using the high 
pH immunoprecipitation methodology, nonspecific 
IgG fragments comigrated with the target protein 
in the initial experiments. These artifactual bands 
were somewhat reduced but not sufficiently elimi- 
nated by standard means such as preclearing of 
lysates, mismatching of antibody species for pri- 
mary and secondary targets, and use of IgGI-spe- 
cific primary and secondary antibodies (data not 
shown). The Exactacruz TM matrix IP system uses 
a gel matrix rather than an agarose bead to pull 
down the primary antibody target. Target protein 
release is achieved by boiling but this does not result 
in release of immunoglobulin fragments. Using the 
Exactacruz TNI system and high pH immunoprecipi- 
tation methodology on K562 cell lysates, we demon- 
strated substantial coimmunoprecipitation of CBL, 
CRKL, and GR132 with p21OBCR-ABL1 in K562 
cells (Fig. 6A) and BaF3 cells transfected with 
p210BCR-ABL1 (Fig. 6B). The p21OBCR-ABL1 as- 
sociated protein complexes were also analyzed in 
KBM5 cells, a CML cell line that lacks normal 
ABL1 (Beran et al., 1993) (Fig. 6Q. This result con- 
firms that the high pH approach combined with 
ExactaCruz TNI matrix is compatible with successful 
immunoprecipitation and can be applied to investi- 
gation of primary cells. 
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Figure 6. Coimmunoprecipitation of p2lOBCR-ABLI and partner proteins from K562, p2lOBCR-ABLI transfected BaF3 cells, KBMS cells using high pH lysis with ExactaCruz-rm immunoprecipitation. 2x 107 K562, BAF3. p2 10, and KBMS cells were lysed with high pH lysis buffer. Total lysates, IgG-only Vs and ABL I ll'*s were Western blotted for ABIL I, CBL, CRKL, and GPB2, respectively. 
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Figure 7. Coimmunoprecipitation of p2lOBCR-ABL I and CBL, CRKL and GRB2 from CML chronic 
phase CD34+ cells using high pH lysis with FxactaCruZTM immunoprecipitation. About 2.5 x 107 CML 
CD34+ cells were lysed with high pH lysis buffer. K562 control lysates, CML CD34+ total lysates, ABL I IP's, 
and IgG-only IP's were Western blotted for c-ABL I, CBL, CRKL, and GRB2 respectively. 
Immunoprecipitation of Primary Chronic Phase 
CIVIL Cell p2l OBCR-ABL I 
Application of the high pH lysis and Exacta- 
Cruz TM methodology to chronic phase CML 
CD34' cells demonstrated the coimmunoprecipita- 
tion of p21OBCR-ABLI and the adaptor proteins 
CBL, CRKL, and GRB2 in three individual CML 
patients (Fig. 7). Thus, CBL, CRKL, and GRB2 
associates with p210BCR-ABLI in primary chronic 
phase CML cells as well as in p210BCR-ABL1 cell 
lines. 
DISCUSSION 
A characteristic feature of CML is the presence 
of the Ph chromosome. This abnormality arises as 
a result of a characteristic genetic rearrangement 
where a section of the breakpoint cluster region 
(BCR) gene on chromosome 22 and ABL1 gene on 
chromosome 9 translocate to form a fusion gene, 
BCR-ABLI (de Klein et al., 1982; Heisterkamp 
et al., 1982; Shtivelman et al., 1985). This fusion 
gene encodes for a protein of the molecular weight 
1127 
of 210 kDa, p210BCR-ABLI, which has been 
shown to complex with various cytoplasmic and 
cytoskeletal proteins in cell line models or cells 
transduced to express p2lOBCR-ABLl. There is a 
lack of information about these associations in pri- 
mary CML cells because lysis of hemopoletic cells 
releases a degradative activity that destroys 
p21OBCR-ABL1 and ABL1 thereby preventing 
detection of p210BCR-ABL1 and associated pro- 
tein complexes in CML by immunoprecipitation. 
The degradative activity is not a unique feature of 
CML as we have shown in Figure 1, since it was 
also present in MNC from normal PBPC and nor- 
mal bone marrow. Boiling the lysate prior to incu- 
bation with the K562 lysate removed the degrada- 
tive activity in all samples. Therefore, the degrada- 
tion of p21OBCR-ABL1 in CML MNC is as a 
result of a heat sensitive activity common to nor- 
mal as well as neoplastic primary hemopoietic ma- 
terial. Although the degradative activity can be 
substantially destroyed by boiling, this step pre- 
cludes immunoprecipitation experiments to inves- 
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tigate complexes in primary cells. It has been 
reported that the degradative activity was present 
mainly in mature cells containing a high concentra- 
tion of degradative enzymes which prevents detec- 
tion of p21OBCR-ABL1 using a protein kinase 
assay (Maxwell et al., 1987; Guo et al., 1991). How- 
ever, selection of CD34' cells did not remove the 
degradative activity completely, although CD34' 
cells contain a lower concentration of degradative 
enzymes compared with MNC. 
To identify the cellular source of the degradative 
activity three target candidates were selected 
based on their cellular roles. The caspase cascade 
(Di Bacco and Cotter, 2002), proteosomes (Adams, 
2003; Posthuma et al., 2004) and lysosomes (Hatch 
et al., 1993) were candidates inhibited by ZVAD, 
lactacystin, and chloroquine, respectively. Inhibi- 
tion of the caspase cascade using ZVAD prevented 
cleavage of p21OBCR-ABL1 and p145ABLI associ- 
ated with TP53-induced erythrold differentiation 
in K562 cells (Posthuma et al., 2004). Proteosomes 
(Adams, 2003; Posthuma et al., 2004) and lyso- 
somes (Hatch et al., 1993) were targeted as they 
are natural reservoirs of enzymatic activities. Fig- 
ures 3A and 3B suggest that ZVAD and lactacystin 
have no effect on the recovery of p21OBCR-ABL1 
suggesting that the caspase cascade and proteo- 
somes are not involved in the degradation of 
p21OBCR-ABL1. However, when cells are treated 
with 5 mM chloroquine for 24 hr prior to lysis there 
is significant inhibition of the degradative activity 
resulting in p21OBCR-ABL1 recovery (Fig. 3C), 
which implies that degradative activity is associ- 
ated mainly if not completely with cell lysosomes. 
A disadvantage to using chloroquine is that it 
requires incubation of cells under nonphysiological 
conditions f6r 24 hr before the effect is maximal. 
Also, while chloroquine can be used to inhibit the 
degradative activity, it reduces the tyrosine phos- 
phorylation of p21OBCR-ABL1 and lower molecu- 
lar weight proteins which may affect protein com- 
plexes. Chloroquine acts on lysosomes by increas- 
ing the internal pH within them (Hatch et al., 
1993). This mechanism of chloroquine action pro- 
vided the rational for the experiment with high pH 
lysis buffer which allowed recovery of p21OBCR- 
ABLI and did not effect the tyrosine phosphoryla- 
tion in K562 cells. p21OBCR-ABL1 recovery from 
CML CD34. ' is optimal when cells are lysed in 
1.25% 10 M NaOH in cold lysis buffer. Thus the 
p2lOBCR-ABLI-degradative activity can be abro- 
gated by high pH which further supports the iden- 
tity of the activity as a lysosome-associated acid- 
dependent hydrolase. 
Many publications have shown in cell lines and 
transduced cells that p2l0BCR-ABLl complexes 
with adaptor proteins CBL, CRKL, and GRB2. 
It has been suggested that tyrosine phosphoryla- 
ted CBL complexes with the SH2 domain on 
p2lOBCR-ABL1 but deletion of the SH2 domain 
of p210BCR-ABL1 does not inhibit the association 
which implies that CBL can interact with 
p2l0BCR-ABLl via other mechanisms (Bhat et A, 
1997). It has been proposed that an alternative 
mechanism by which unphosphorylated CBL and 
p2l0BCR-ABL1 associate may be via adaptor pro- 
tein GBR2 (Gaston et al., 2004), which has been 
shown to activate RAS signaling (Pendergast et al., 
1993; Puil et al., 1994). CRKL is an adaptor protein 
related to the CRK oncogene of the avian viral sar- 
coma virus (ten Hoeve et al., 1993). It has been 
demonstrated that CRKL is tyrosine phosphoryl- 
ated in a number of CML cell lines and primary 
CML cells. However, all of the published litera- 
ture suggests that CRKL is not phosphorylated in 
p2 IOBCR-ABL1 -negative cell lines and normal 
primary cells (Nichols et al., 1994; Oda et al., 
1994; ten Hoeve et al., 1994; ten Bosch et al., 
1998). The SH2 domain of GRB2 binds to the ty- 
rosine residue 177 on BCR in p2l0BCR-ABLl 
expressing cells. Data in this report also suggest 
that defective binding of GRB2 to p2lOBCR- 
ABLI will reduce the transforming potential of 
cells (Pendergast et al., 1993). Indirect binding of 
GRB2 to p2l0BCR-ABLl via SHC through its 
SH2 domain has also been implicated in RAS acti- 
vation (Rozakis-Adcock et al., 1992). Thus, there 
remain some uncertainties about the precise 
details and consequences of p2l0BCR-ABLl- 
associated protein interactions that need to be 
evaluated in primary CML cells as well as in cell 
lines. 
In summary, we have successfully shown that the 
complexes between p2l0BCR-ABLl and CBL, 
CRKL, and GRB2 in primary CML cells can be 
demonstrated by the high pH lysis methodology 
and ExactaCruz TM immunoprecipitation kit. These 
complexes have been identified in three different 
chronic phase CML patients. To our knowledge this 
is the first reported demonstration of the coimmu- 
noprecipitation of primary chronic phase CNIL cell 
p2lOBCR-ABLI. Using this methodology, it is now 
possible to verify further that the complex inter- 
actions between p2l0BCR-ABLl and intracellular 
signaling proteins reported for Ph' cell lines hold 
true in primary CNIL cells and to determine disease 
stage- or treatment-related changes in those inter- 
actions. 
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To the editor: 
Conventional Western blotting techniques will not reliably quantity p21011CR-ABLI levels in CIVIL 
mononuclear cells 
We read with interest the paper by Copland et al, ' in which they 
used quantitative reverse transcriptase-polymerase chain reaction 
(RTLPCR) and Western blotting to demonstrate that the transcript 
and protein levels of p2 I OBCR-ABLI are elevated in primitive chronic 
myeloid leukemia (CML) progenitors relative to more mature cells. 
The work adds substance to the growing body of evidence for 
increased p2 JOBCR-ABLI activity in the putative CML stem cell, 
which also provides a partial rationale for the failure of treatments 
such as imatinib to achieve complete eradication of disease in vivo. 
We note that the RT-PCR-based quantitative data and patterns 
of CrkL phosphorylation that Copland et all report support the 
hypothesis that p2 I OBCR-ABLI activity is enhanced in more primitive 
cell populations. However, their Western blotting method uses a 
conventional lysis buffer to lyse cells in the cold, which is standard 
procedure. It has been known since 19871 that such lysis of CML 
mononuclear cells (MNCs) releases a degradative activity that very 
rapidly and selectively destroys p2l OBCR-ABLI and c-ABL but does 
not degrade other proteins. 3 This activity has been reported to be 
primarily restricted to the mature cell compartments '2-4 
hence its 
influence is commensurately greater in MNC lysates. It is entirely 
predictable therefore that Copland et all could not recover a 
p2 JOBCR-ABLI signal or a 210-kDa phosphotyrosine signal from a 
CML MNC blot and that the signal recovered is greater from 
CD34+CD38- cells than CD34+ cells. CD34+ cell fractions 
typically contain up to 5% contaminating mature cells that 
would elicit some signal degradation, while double-sorted 
CD34+CD38- populations would be expected to contain fewer 
contaminating cells. 
Furthermore, while Copland et a12 could not recover any 
p2joBCR-ABLI signal from CML MNCs, Guo et all showed that use 
of an extremely toxic nerve agent and a boiling lysis medium 
permitted routine p2 JOBCR-ABLI recovery from CML MNCs. We 
have recently published data showing that the degradative activity 
is probably an acid-dependent hydrolase and can be neutralized by 
a high-pH lysis regimen to allow accurate determination of 
p210 BCR-ABLI protein levels. This has the further advantage of 
permitting coirnmunoprecipitation studies, and so, for the first 
time, investigation of p2 I OBCR-ABL '-protein complexes in pri- 
mary cells from CML patients is now possible. 3 These com- 
plexes play an important role in CML pathogenesis, and the 
amount of p2 I OBCR-ABL I present will be a significant contributory 
factor. The degradation of p2 I OBCR-ABL I by MNC components of 
primary cell lysates is therefore a critical variable. Future 
Western blotting experiments should take account of this 
inhibitory activity. 
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Response: 
Conventional Western blotting techniques will not reliably quantify p2l 0 BCR-ABL 
We welcome the opportunity to respond to the comments of Patel et 
al. We were aware of the selective rapid degradation of p2 I OBCR-ABL 
and c-ABL after lysis of total mononuclear cells (MNCs), which has 
been reported previously' and makes assessment of p2loBCR-ABL 
and c-ABL protein levels in mature cell compartments difficult. In 
order to overcome this, we used multiple techniques to assess 
BCR-ABL expression in chronic myeloid leukemia (CML) cells. 
First, we measured BCR-ABL transcripts using real-time quan- 
titative reverse transcriptase-polymerase chain reaction (RT-PCR). 
This showed that, compared with total MNCs, BCR-ABL tran- 
scripts were significantly increased in both CD34+ and 
CD34+CD38- populations (P = . 
016 and P= . 
031, respectively). 
We then developed a novel flow cytometry assay to measure CrKL 
phosphorylation (P-CrKL), as a marker of BCR-ABL activity in 
CML cellS. 2 This confirmed that P-CrKL was significantly in- 
creased in CD34'CD38- populations compared with total CD34+ 
populations. The P-CrKL assay was then validated by Western 
blotting using a method previously described. 3 and comparing 
MNCs, CD34+ cells, and CD34+CD38- cells. Once again the 
levels were lowest in MNCs-we are not aware that the degrada- 
tive activity should affect P-CrKL. This Western blotting technique 
has also been used for the detection of BCR-ABL, c-ABL, and 
P-Tyrosine (P-Tyr) in BCR-ABL-transduced CD34+ cord blood 
samples cultured for up to 12 days (Ravi Bhatia, City of Hope 
National Medical Center, Duarte, CA; personal communication, 
October 15,2006). By 12 days, these cultures contain differentiated 
cells equivalent to an MNC preparation, and we therefore felt 
confident using this technique for assessment of BCR-ABL and 
P-Tyr in our experiments. In addition, another group has also 
successfully developed a flow cytometry assay for measuring total 
P-Týr in MNCs and CD34+ CML cells to predict response to 
imatinib treatment. 4,5 
Based on the combination of techniques used, we do believe 
that BCR-ABL levels are very significantly lower in MNCs than in 
CD34+ and CD34+CD38- populations. However, we would 
disagree with the statement that BCR-ABL levels would be 
expected to be lower in the CD34+ compared with CD34+CD38- 
population due to degradative activity. First, all the CD34+ selected 
CML samples we used were more than 95% CD34+ after magnetic- 
activated cell sorting using the CLINIMACS system (Miltenyi 
Biotec, Bisley, United Kingdom). This was confirmed by flow 
cytometry after cell sorting, and in some cases the samples were 
more than 98% purified for CD341 cells. Therefore, we believe that 
the degradative activity from contaminating mature myeloid cells 
in these samples would be negligible. Further, in the report by 
Maxwell et al, ' they found that enriching blast cells by Ficoll- 
Hypaque gradient cenuifugation in blast crisis CML samples was 
sufficient to detect p2 I OBCR-ABL kinase activity. 
We would be concerned by the results of Patel et al, 6 who failed 
to detect BCR-ABL protein expression in CD341 CML cells. This 
has never been an issue in our experience. While we find their 
description of a novel method to overcome the degradative activity 
of total MNCs using high pH to inhibit an, as yet, unidentified 
acid-dependent hydrolase interesting, because of the increased 
degradative activity in total MNCs, we would wish to see it 
validated in total MNCs as well as CD341 cells. 
We would like to thank Patel et al for highlighfing the 
importance of the degradative activity of total MNCs on BCR- 
ABL, c-ABL, and P-Tyr levels and will keep this in mind for future 
Western blotting experiments. 
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To the editor: 
Update on fact . or V Leiden association with venous thromboembolism in the LITE Study 
In a previous article, ' we reported population-based findings from 
the Longitudinal Investigation of Thromboembolism Etiology 
(LITE) on factor V Leiden and risk of venous thromboembolism 
(VTE). We used a nested case-control design (301 new WE cases 
and 630 controls through 1998) from the prospective Atherosclero- 
sis Risk in Communities (ARIC) Study and Cardiovascular Health 
Study (CHS). The odds ratio, overall, for risk of VTE for carriers of 
factor V Leiden was 3.67 (95% Cl, 2.20-6.12). 1 
We recently extended LITE to additional cases and controls 
through 2002. In the process, we discovered and corrected an error 
in the original selection of controls for ARIC that had caused us to 
oversample participants who had died into the control group for our 
earlier report. Compared with our published report, the updated 
sample of 502 cases and 1021 controls yielded an almost identical 
odds ratio for factor V Leiden of 3.46 (95% Cl, 2.20-5.43). 
Genotype distributions and other odds ratios for factor V Leiden 
Leukemia (2007), 1-13 
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Subcellular distribution of p2l OBCR-ABL in CML cell lines and primary CD34 + CML cells 
H Patel, SB Marley, L Greener and MY Gordon 
Department of Haernatology, Faculty of Medicine, Imperial College, Hammersmith Campus, London, UK 
We analyssid the subcellular distribution of p2jCjSCFt-ABL protein 
using a junction-specific anti-BCR-ABL monoclonal antibody 
and confocal laser scanning microscopy (CLSM). Our studies 
have shown that p210BC"113L Is arranged In discrete foci In the 
cytoplasm of cell lines and primary CD34+ cells but not 
mononuclear cells suggesting the foci may be a feature of 
Immature chronic myelo. ld leukaernia cells. We have devised a 
strategy to score the foci and found the mean number of foci 
varies between the cell types. The number of foci per cell is 
directly related to the level of p2l 0801-ABL expression. CLSM 
was also used to analyse the distribution and colocalization of 
CT10 regulator-like (CRKL) p2l OSCR-ABL. CRKL-p2l 08CR-ASL foci 
were completely or partially associated, touching or separate In 
different regions of the same cell. We also analysed the 
distribution of phosphorylated CRKL (pCRKL) with p210Bc"Em- 
and unexpectedly found- only a small proportion of pCRKL In 
complex with p21013c"Em-. The foci distribution and high kn(Ws of 
uncomplexed p2l()Pcpýmm-, pCRKL and CRKL protein suggested 
the possibility of a dynamic equilibrium. Imatinib promoted 
nuclear transport of p2108c"BL-posltive foci. It also disrupted 
complex formation between p2lOBcwAE"- and casitas B-cell 
lymphoma and CRKL but not between 
ýpgj 
0SCR-ML and GR132. 
Our'observations of the CRKL and p2l 05CR-ASL Complex may be 
Important for understanding the function of CRKL. 
Leukemia advance online publication, 6 December 2007; 
doi: 10.1038/sj. leu. 2405057 
Keywords: p2l OBCR-ABL; CML; confocal microscopy; CRKL 
Introduction 
p2l OBCR-ABL has a central role in chronic myeloid leukaemia 
(CMQ. This fusion protein arises due to a translocation that 
brings the Abelson murine leukaemia virus (ABL) and breakpoint 
cluster region (BCR) genes into juxtaposition to form the 
characteristic Philadelphia (Ph) chromosome. First described 
by , Nowell and Hungerford in 1960,1 the chimeric protein 
product p2 I OBCR-ABL has constitutively activated tyrosine kinase 
actiVitY2 resulting in unregulated expansion of the myeloid 
s enes. 
The p2l OBCR-ABL fusion protein forms intracellular complexes 
with multiple protein partners in cell lines, as demonstrated by 
immunoprecipitation (IP) and western blotting. ' These ob- 
servations have evoked a model in which p2l OBCR-ABL recruits 
signalling enzymes and adaptor molecules into multimolecular 
complexes and activates them. ' Until recently, few studies had 
investigated these complexes in primary CML cel Is'" 1 because 
it was difficult to carry out IP and western blotting studies of ABL 
Proteins in primary cells. These cells contain a proteolytic 
activity that rapidly and selectively degrades p145 
ABL and 
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p2 1 OBCR-ABL when the cells are lysed in a conventional manner. 
Recently, we developed a method for inhibiting the proteolytic 
degradation by high-pH lysis that maintains protein integrity and 
allows IP studies of p 145 
ABLand 
p2 I 0BCR-ABL in primary cells for 
the first time. 
12 
CT10 regulator like (CRKL) protein was first cloned by ten 
Hoeve in 1993 13 on chromosome 22. The gene encodes for a 
39kDa protein that is found most abundantly in haemopoietic 
tissue. 
14 Ph- cell lines and primary cel 
IS4,15-18 lack phospho- 
rylated CRKL (pCRKL) but do express CRKL rotein. CRKL 
complexes with p2l OBCR-ABL in Ph' cell lines'fand we have 
shown CRKL and p2l OBCR-ABL complex in primary CD34 ' cells 
by co-IP using the high-pH lysis assay. 
12 Levels of CRKL phos- 
phorylation can be used as an indirect marker of p2l OSCR-ABL 
function in response to therapy by western blot" and 
fluorescence-activated cell sorting assay. 
20 
Many questions remain about the composition of the protein 
complexes in primary CML cells. In particular, it is not known if 
the complexes incorporate all of the implicated proteins all of 
the time, if their composition can be modified or what 
implications changes may have on intracellular signalling or 
cell function. Confocal laser scanning microscopy (CLSM) can 
be used to analyse colocalized proteins in single cel IS2 ' but 
studies of proteins colocalized with p2l OBCR-Alk have been 
confounded by the lack of an antibody that specifically 
recognizes the fusion proteins. Instead, antibodies to ABL or 
BCR have been used although these detect the normal cellular 
proteins as well. Studies were conducted by Wetzler et al. 22 and 
Skourides et A8 which demonstrated that the p2l OBCR-Al3L/ABL 
protein is distributed in punctuate structures in the cytoplasm. 
The study by Wetzler et al . 
22 analysed the differences between 
the subcellular distribution of p2l OOCR-ABL , normal ABL and 
normal BCR in various cell lines, and Skourides et A8 
demonstrated a similar cytoplasmic distribution of p2l OBCR-ABL/ 
ABL in transfected haeml )oietic and fibroblast cells. They C 
further showed that p2l 0 
BC7-ABL/ABL 
and adaptor proteins such 
as growth factor-binding protein (GR132), src homologous and 
collagen gene and casitas B-cell lymphoma (CBQ colocalize 
with p2 I OBCR-ABL in transfected fibroblast cells. The recent avail- 
ability of a P21 
OBCR-ABL antibody that recognizes the b2a2 junc- 
tion sequence (Cell Signalling Technologies, MA, USA) means 
that the specific distribution of p2l 
013CR-ABL can be visualized. 
Here, we used this antibody to show that p2l 
015CR-ABL protein 
forms distinct foci in the cell cytoplasm that are variously 
associated with CRKL- We also show that imatinib, a small 
molecule tyrosine kinase inhibitor, changes the subcellular 
distribution of the p2l 
OBCR-ABL and prevents it from forming 
complexes with some partner proteins, confirming previous 
observations that imatinib treatment causes nuclear transport of 
p2l OBCR-ABL in CML cells lines. 
23,24 
OBCR-ABL Our study provides a detailed description of p2l 
distribution in primary CML patient cells at different matu- 
ration levels and in various CML cell lines. We describe 
detailed approaches to determine and quantify the sub- 
Subcellular dLsWWfm of p2lOBcR"4"- 6H 
NW et al 
cellular distribution and protein-protein interactions in single 
CML cells. 
supplemented with 15% FCS for up to 16 h. Treated 
and untreated cells were used for immunofluorescence and 
western blot. 
Materials and methods 
Cells for study 
CML cell lines KCL-22 (myeloid), KYO-1 (myeloid) (kindly 
provided by Professor Junia Melo, Imperial College, Faculty of 
Medicine, UK), BV173 (lymphoid) and K562 (myeloid) were 
grown in the laboratory in RPMI-1 640 medium (Gibco, Paisley, 
UK) supplemented with 10% fetal calf serum (FCS) (BioSera, 
East Sussex, UK) and 1% penicillin and streptomycin (Gibco). 
Haemopoietic cells from newly diagnosed CML patients with 
known b2a2 junctions were obtained from excess material from 
leukapheresis taken for clinical purposes. All patients and 
donors gave informed consent in accordance with local ethics 
committee guidelines. 
Cell separation 
Mononuclear cells (MNCs) were separated from leukapheresis 
samples by density gradient centrifugation (Lymphoprep, Axis- 
Shield, Oslo, Norway), harvested from the interface and washed 
three times in Hanks' balanced salt solution (Gibco). CD34' 
cells were purified from MNC using MiniMACS immunomag- 
netic bead technology following the manufacturer's recommen- 
dations (Miltenyi Biotec Ltd, Bergisch Gladbach, Germany). 
Cell treatment 
BVI 73 and CD34 + CML cells were incubated with I gm 
imatinib (kindly provided by Prof. Junia Melo, Imperial College, 
Faculty of Medicine, UK) in Alpha MEM medium (Gibco) 
Immunofluorescence 
CML cell lines, primary CML MNCs and CML CD34' cells 
were re-suspended in Alpha MEM medium (Gibco) at 106 cells 
per ml and 30VI aliquots were air-dried on to glass microscope 
slides (VWR, Leicestershire, UK) and fixed in 2% paraformalde- 
hyde (PFA) in phosphate-buffered saline (PBS) for 10min at 
room temperature. For intracellular staining cells were permea- 
bilized using 0.2% Triton X-100 (Sigma, Poole, UK) in PBS for 
10min at room temperature. Non-specific sites were blocked 
using 5% fetal bovine serum (FBS) (Biosers, Ringmer, UK)/3% 
bovine serum albumin (BSA; PAA laboratories, Linz, Austria) in 
PBS (blocking solution) for 1 h. p2l OBCR-Aft was labelled using 
0.5 pg ml-1 mouse anti-BCR-ABL (b2a2 junction-specific) anti- 
body (Catalogue number L99H4, Cell Signalling Technology), 
anti-ABL (Santa Cruz Biotechnology, Wiltshire, UK) or mouse 
immunoglobulin G (IgG)2, isotype-negative control (BID Bios- 
ciences Pharmingen, Oxford, UK) in blocking solution for 1 h. 
After four 5min washes in 3% FBS/1% BSA in PBS (wash 
solution), cells were incubated with 1 [igml-' donkey anti- 
mouse Alexa Fluor 488 in blocking solution for Ih in the dark. 
Four 5 min washes in wash solution were repeated and slides 
were mounted in VECTASHIELD containing 4,6-diamidino-2- 
phenylindole (DAPI; Vector Laboratories, Burlingame, CA, 
USA). 
For dual staining cells were treated as previously described 
except both primary and secondary antibodies were incubated 
together. Additional antibodies used were 0.5pgml-' anti- 
GRB2, anti-CRKL and anti-CBL (all from Autogen Bioclear, 
Caine, UK). 
a 
Figure I Strategy to score p2l 0 
BCR-ABL 
-positive foci. KCL-22 cells stained with anti-p2l 
OBCR-ABL antibody. (a) Z scan of a KCL-22 cell stained for 
p2l OBCR-ABL and (b) circles (0) indicate the p2l 
OBCR-ABL_PoSi tive foci scored. 
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Figure2 Measurement of colocalization coefficient. Ziess LSM 510 meta software was used to measure the colocalization coefficient. (a) Region 
of interest (ROO was selected, U histogram generated for the ROI, (c) threshold can be set automatically or manually (MFI of ROI +2 (standard deviation)) and A table of results generated by the software. 
Immunostained cells were analysed by a Zeiss Meta 512 
confocal microscope (Carl Zeiss, Jena, Germany) using an argon 
and HeNel laser to view the Alexa Fluor 488 and 594 
secondary conjugates. 
Strategy for Scoring P21 OBCR-ABL ositive foci 
OBCR-AX -- To quantify the number of p2l positive foci we devised 
the scoring system depicted in Figures 1a and b. After acquiring 
the Z scan images of CML cells using confocal microscopy the 
distinct p2 I OBCR-ABL foci in each section were scored. Any 
diffuse green signal on the images was considered as back- 
ground staining and not included in the count. We define a 
focus by the following criteria: 
(1) high intensity of staining around a point represents a focus. 
(2) Staining has to clearly stand out from the background. 
(3) Any irregular elongated foci were considered as one focus. 
Scoring from the Z scans eliminates the possibility of counting 
any of the foci more than once. 
Strategy of scoring percentage of p2 I 
eCR-ABL in foci 
The percentage of p2l OBCR-ABL in the foci was scored using 
Image). 25 Confocal images were uploaded into Imagej and the 
integrated density (ID) was measured for the whole cell followed 
by the ID for single foci. The_ rcentages of p2l 
OBCR-ABL in the 
foci and diffused p2l OBCR 
M 
were calculated using the 
following formulae: 
Percentage of p2l 013CR-Al3L in foci 
(E ID of single foci 
X100 IDofwholecell 
) 
Percentage of diffuse p2l OBCR-ABL =I 00 - Percentage of p2 I oBCR-ABL 
in foci 
Measurement of the colocalization coefficient 
Colocalization analysis was performed on randomly selected 
cells (n>20) using Zeiss LSM 510 meta software. The 
colocalization coefficient, defined by Manders et a/. 26 is 
calculated where I indicates complete colocalization while 0 
indicates no colocalization. The intensity of the pixels does not 
affect the calculation as the pixel intensity in a certain channel is 
normalized by the total number of pixels and pixels with zero 
intensity are considered as background. Briefly, the region of 
interest (ROI) is selected (Figure 2a), which generates a scatter 
diagram of the number of red pixels against the number of green 
pixels (Figure 2b). To accurately determine the proportion of 
yellow signal a threshold, which is automatically calculated by 
the software at the mean fluorescence intensity (MFI) of ROI +2 
standard deviations (Figure 2c). The software generates the 
colocalization coefficient (proportion of protein complexed) for 
each signal (Figure 2d). 
Western blotting 
2+ Preparation of cell lysate: cells were washed twice in Ca 
Mg+ +-free PBS. The cell pellet was manually dispersed and 
then vigorously re-suspended in 200 VI ice-cold lysis buffer 0% 
Triton X-1 00 (Sigma), 150 mm NaCl, 1 MM MgC12,101/6 glycerol 
(Invitrogen, Paisley, UK), 20mm Tris (pH 8) and a proprietary 
protease inhibitor cocktail (Complete tablets, Roche, Man- 
nheim, Germany), per 107 cel Is. The lysate was incubated on ice 
for 10 min, and then the cells were sheared by rapid expulsion 
through a 21 -gauge needle. The crude lysate was centrifuged at 
4 OC for 3 min at 13 000 r. p. m. For western blotting, the lysates 
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Figure 3 Specificity of anti-BCR-ABL (junction-specific) antibody. K562 cells express the b3a2 breakpoint and BV173 cells express b2a2 
breakpoint. (a) K562 and BVI 73 cells were lysed in lysis buffer on ice for 10 min and cleared lysate was separated on 6% gels and probed with 
anti-c-ABL and anti-BCR-ABL (junction-specific) and anti-mouse HRP- N K562 and BV173 cells were air-dried, fixed in 2% PFA and 
permeabilized in 0.2% Triton in PBS. Blocked in 5% FBS/3% BSA and anti-c-ABL, anti-BCR, anti-BCR-ABL (+) or matched isotype control OgG) 
was incubated for Ih at room temperature. After three washes cells were incubated with either AF 488 or AF 564 and washed and mounted with 
VectaSheild plus D. API. All cells were analysed using the CLSM. 
were mixed with an equal volume of loading buffer (2.3% 
sodium dodecyl sulphate (SIDS), 10mm DL-DTT QTT), 0.01% 
bromophenol blue (all Sigma, Paisley, UK), 10% glycerol, and 
62.5mm Tris (pH 6.8) and boiled for 5min at 100'C and 
Kaleidoscope prestained molecular weight markers (Bio-Rad, 
Hemel Hempstead, UK) were run in parallel on 6 and 10% SDS- 
polyacrylamide gel electrophoresis minigels (37.5: 1 acrylami- 
de: bisacrylamide; B io-Rad) at 100 V and transferred to 0.45 Am 
polyvinylidenedifluoricle membranes Ommobilon, Sigma) by a 
semi-dry transfer system (Bio-Rad). Membranes were blocked 
with 1% milk (Marvel milk powder, Nestle, Croydon, UK) in 
Tris-buffered saline (TBS)-Tween and anti-BCR-ABL (junction- 
specific) antibody (1: 1000), anti-ABL or anti-actin were incu- 
bated overnight at 4'C. Membranes were washed four times in 
TBS-Tween for 5 min, stained for 30 min at room temperature 
with appropriate horseradish peroxiclase (HRP)-conjugated 
secondary antibodies diluted at 1: 1000 in 1% milk, washed 
four times in TBS-Tween for 5 min and visualized by chemi- 
luminescence (ECL, Amersham Biosciences, Piscataway, NJ) on 
Kodak Biomax MR film (Sigma). 
manufacturer's protocol. In brief, for 10' cells lysed in 200PI 
lysis buffer (as described for western blot protocol), antibody- 
matrix complex was formed by incubating 100pl of IP matrix 
and lopgml-' anti-c-ABL or mouse IgG in 500pl of Ca 2 +/ 
Mg ' '-free PBS for 2h at 4 'C. The matrix was washed twice 
with cold Ca 2 +/Mg+ +-free PBS and then incubated with 
cell lysate for 1h at 4'C. After two washes in 500pl cold 
Ca 2 +/Mg + +-free PBS, the matrix was suspended in 80pl of 
loading buffer and boiled for 5min and then western blotted 
to detect protein complexes. 
Statistical analysis 
Statistical significance of unpaired data was analysed by the 
Mann-Whitney U-test and paired data were analysed by the 
Wilcoxon test using SSPS 14.0 (Chicago, IL, USA, 2005). A 
value P<0-05 was considered significant. Correlation M was 
estimated by Pearson's correlation coefficient. 
Results 
Immunoprecipitation 
ExactaCruz (Santa Cruz Biotechnology) was also used to 
immunoprecipitate p2l 013CR-AI3L from imatinib-treated K562 
cells. The ExactaCruz matrix was prepared as per the 
Specificity of the junction-specific BCR-ABL antibody 
The BV173 cell line expresses p210 
BCR-ABL 
with the b2a2 
(el 3/a2) breakpoint while K562 cells express p2l 0 
OCR-AOL 
with 
the b3a2 (e14/a2) breakpoint. We have used these cell lines to 
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Figure4 Subcellular distribution of p2l OBCR-ABL in CML cell lines. (a) 
BVI 73, (b) KCL-2 2 and (c) KYO- I cel Is that express p2l OBCR-ABL with 
the b2a2 breakpoint were air-dried on to glass slides. Dried cells were 
fixed in 2% PFA and permeabilized in 0.2% Triton in PBS, blocked in 
5% FBS/3% BSA and incubated with anti-BCR-ABL or matched isotype 
control OgG) for 1h at room temperature. After three washes cel Is were 
incubated with AF 488 and washed and mounted with VectaShield 
plus DAPI. All cells were analysed using CLSM. 
confirm the specificity of the junction-specific BCR-ABL anti- 
body by western blotting and immunofluorescence (Figure 3). 
The results show that p2l OBCR-ABL and pl 45 ABL proteins were 
detected in both cell lines by the anti c-ABL antibody and anti- 
BCR antibodies but only p2l OBCR-ABL is detected in BVI 73 cells 
by the anti-BCR-ABL antibody, using western blotting (Figure 3a) 
and immunofluorescence microscopy (Figure 3b). 
Subcellular distribution of P2 1 OBCR-ABL in CML cells 
The results in Figure 3b suggested a degree of subcellular 
localization of p2l OBCR-ABL since areas of high-intensity staining 
were visible in the BVI 73 cells. To investigate this pattern 
further we used CLSM on the BVI 73, KCL-22 and KYO-1 cell 
lines, all of which express p210 
BCR-ABL 
with the b2a2 break- 
point. The results in Figures 4a, b and c clearly show that a 
Multifocal distribution of p2l OBCR-ABL could be discerned in all 
three cell lines, myeloid as well as lymphoid. Next we 
investigated the distribution of p2l OBCR-ABL in primary CD34' 
and mononuclear CML cells. Three independent CML samples 
(CML 1, CML 2 and CML 3) were analysed. The CD34+ cells 
exhibited clear foci (Figure 5a), like the cell lines, but more 
diffuse staining characterized the MNCs (Figure 5b). This 
observation indicates that the distribution of p2l OBCR-ABL may 
be related to cellular maturation. 
Figure 5 Subcellular distribution of p2l OBCR-ABL in primary chronic 
myeloid leukaemia (CML) cells. Three CML patients (CML 1, CML 2 
and CML 3) with the b2a2 breakpoint were selected and (a) CD34+ 
cells (CML CD34' 1, CML CD34' 2 and CML CD34 ' 3) and (b) 
MNC (CML MNC 1, CML MNC 2 and CML MNC 3) cells from each 
patient were air-dried on to glass slides. Dried cells were fixed in 2% 
PFA and permeabilized in 0.2% Triton in PBS, blocked in 5% FBS/3% 
BSA and incubated with anti-BCR-ABL or matched isotype control 
OgG) was incubated for 1h at room temperature. After three washes 
cells were incubated with AF 488 and washed and mounted with 
VectaShield plus DAPI. All cells were analysed using CLSM. 
Quantification of p2 I OBCR-ABL in CML cell lines and 
primary cells 
To quantify the observed differences in the number of foci per 
cells observed in cell lines and primary CD34' CML cells we 
used the scoring system described in 'Materials and methods' 
(Figure 1). Altogether 100 cells of each cell line and 100 primary 
CD34+ cells per patient (n=3) were scored in this manner. 
Figure 6a shows the number of foci per cell in the CML cell lines 
(KCL-22, KYO-1, BV173) and in three primary CD34+ CML 
samples (CML 1, CML 2 and CML 3) and Figure 6b shows the 
mean number of foci and total levels of p2l OBCR-ABL per cel 1. 
There is a statistically significant difference between the number 
of foci per cell in cell lines and primary CD34 + cells (P<0.001; 
Figure 6c). The variation between CML patient samples is 
smaller but analysis shows that the differences within this group 
are still statistically different (P<0.005, P<0.001) suggesting 
the focal distribution among CML samples is heterogeneous. 
We measured the total amount of p2 I OBCR-ABL expressed in each 
of the cell types by Image) analysis (Figure 6b). There is a 
statistically significant correlation between total levels of 
p2l OBCR-ABL and the number of foci per cell in the CML cell 
lines and patient samples (r=0.989, P<0.0001). This implies 
that the variation in the number of foci per cell type is directly 
related to differences in the total levels of p2 1 OBCR-AIBL 
(Figure 6b). p2l OBCR-ABL focal distribution is similar between 
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Figure 6 Quantification of p2 I OB(-K-AI3L_poSitive foci in CML cell lines (BV1 73, KCL-22, KYO-1) and primary chronic myeloid leukaemia (CML) 
cells (CML 1, CML 2 and CML 3). A total of 100 cells from each cell type were scored for p2l OBCR-ABL-positive foci as described in Figure 1. 
(a) Number of foci for single cells, (b) mean number of foci for each cell type (± s. e. m. ) Q2 and mean total density of the for each cell types 
and (c) table of the P-values for the different cell types. All the cell types show a statistical difference except for KYO-1 and BV1 73 cells. 
BV173 and KYO-1 cells but KCL-22 cells express many more 
foci relative to all the cell types we have tested (P<0.001). 
Using lmagej25 to measure the ID of the whole cell and for 
all foci stained with p2l 013CR-AI3L, we show that the greater 
part of p2l OBCR-ABL for all the cell types is diffused rather than 
in the foci (Figure 7a). Using the same method we scored the 
levels of p2l 013CR-ABL in the MNC and CD34ý- cell fractions of 
the three CML patients analysed in Figure 5. We found 
that levels of p2l OBCR-ABL in the CD34+ cell fraction were 
50.37% on average higher than levels in the MNC fraction 
(n=3). Since focus formation is directly related to the 
p2l 013CR-ABL expression levels and the levels are lowest in 
MNC, it appears that focus formation requires a threshold 
amount of protein in the cell. 
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Figure 7 Quantification of p2l OBCR-ABL in the focal and diffused regions on single cells. Confocal images were imported into Imagel and ID was 
measured for (a) all foci and for the whole cell. Percentage of p2l OBCR-ABL in each fraction was calculated for 50 cells for each cell type. (b) Using 
Imagej we measured the total density of mononuclear cells (MNC) and CD34' cell fractions for three chronic myeloid leukaemia (CML) patients. 
Association of CRKL with p2 I OBCR-ABL in CML cells 
To confirm the utility of CLSM as a method for investigating 
protein complexes in CML cells we analysed the association of 
CRKL with p2l OBCR-ABL. This revealed that CRKL, as well as 
p2 I OBCR-ABL' formed distinct foci in the cytoplasm of the 
CD34' CML cells (Figure 8a). Using the colocalization analysis 
software we quantified the proportion p2l OBCR-ABL complexed 
with CRKL in BVI 73 cells (Figure 8a). From 31 cells analysed 
we found that 20.08% (±0.35) of total CRKL is complexed 
with 43.93% (± 0.65) p2l OBCR-ABL . Therefore, the distributions of CRKL and p2l OBCR-ABL were not identical. Rather, foci of 
CRKL could be coincident, overlappiný touching or separate 
(Figure 8b). This distribution of p210 
CR-ABL 
and CRKL foci 
suggests that the association of these proteins may be in a state 
of dynamic equilibrium. Since it is well established that CRKL is 
highly phosphorylated in CML and binds to p210 
BCR-ABL 
, we 
next analysed the association between pCRKL and p2 1 
OBCR-ABL 
in BV1 73 cells with CLSM (Figure 9a). Unexpectedly, we found 
only a small proportion, 14.01% (± 0.25) of pCRKL in complex 
with 31.32% (± 0.69) of p2l 013CR-ASL (Figure 9b). Colocalization 
was concentrated in the foci with very minor complexing in the 
diffusely staining regions. Since 44% of p2l OBCR-ABL colocalizes 
with total CRKL, 56% does not and 86% of pCRKL is not 
complexed with p2l OBCR-ABL, this result indicates various 
possible mechanisms: (1) that CRKL could possibly bind to 
p2l OBCR-ABL irrespective of its phosphorylation status and/or (2) 
CRKL phosphorylation is not dependent on p2l 
OBCR-AB' and 
CRKL complex formation and/or (3) p2l 
OBCR-ABL does not 
phosphorylate all of the cellular CRKL. 
The colocalization analysis has also shown that large 
proportions of CRKL (Figure 8), pCRKL (Figure 9) and 
p2 I OBCR-ABL remain uncomplexed. To test if this is unique to 
unphosphorylated and phosphorylated CRKL or common to 
other p2l OBCR-ABL binding partners we analysed the cellular 
distribution of GR132 and CBL with p2l OBCR-ABL and CRKL. We 
found that 21.12% (±0.28, n=26) of GRB2 colocalized 
with 18.22% (±0.29, n=26) of p2l OBCR-ABL (Figure loa) and 
9.77% (±0.083, n=33) of CBL colocalized with 28.89% 
(±0.41, n=33) of p2l OBCR-ABL (Figure lob) colocalized. Also, 
63.00% (±0.61, n=30) of CRKL colocalized with 37.52% 
(±0.36, n=30) of GR132 (Figure 100 and 33.82% (±0.48, 
n=24) of CRKL colocalized with 48.20%o (±0.76, n=24) of 
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Figure 8 Subcellular distribution and colocalization of p2l OBCR-AB' and CT10 regulator like (CRKL) in BV1 73 cells. BVI 73 cells were air-dried, 
fixed in 2% PFA and permeabilized in 0.2% Triton in PBS and blocked in 5% FBS/3% BSA. Anti-BCR-ABL and anti-CRKL or matched isotype 
control OgG) were incubated with the cells for 1h at room temperature. After three washes cells were incubated with AF 488 and AF 564, and 
washed and mounted with VectaShield plus DAPI. All cells were analysed using the CLSM. (a) The distribution of p2 I OBCR-IIL (green) and CRKL 
(red) foci can be separate, close together, partially overlapping and completely overlapping (yellow). N Colocalization coefficient was analysed 
for 31 cells as described in Figure 2. Percentages of complexed and uncomplexed CRKL and p2l OBCR-ABL are shown in the graph (*P= <0.0001). 
CBL (Figure 10d) colocalized. These data imply that low levels 
of p2l OBCR-ABL are found in complex with CBL, and GRB2 and 
the proportion of CRKL in complex with these proteins is greater 
than the amount of CRKL complexed with p2l OBCR-ABL. 
Imatinib treatment on p2 I OBCR-A6L -positive foci and 
associated protein complexes 
When we treated BVI 73 and CD34 + CML cells with 1 gm 
imatinib for 16h the p2l OBCR-ABL_PoSiti ve foci translocated 
to the nucleus since they colocalized with the nucleus, 
stained with DAPI. This translocation was more prominent in 
BV1 73 cell lines compared with primary CD34 ' CML cells 
(Figure 11). Using the Imagej software we analysed the 
density of the p2l OBCR-ABL signal that is present in the area 
stained with DAPI. This analysis indicated that p2l 013CR-ASL 
located in the DAPI-stained regions of treated cells was 
2- and 2.5-fold higher relative to untreated cells in BV173 
and CD34' CML cells, respectively. Moreover, our IP and 
western blot analysis on K562 cells treated with imatinib 
has shown that the p2l OBCR-ABL -CBL an OBCR-A8L AX21 -CRKL BcRý complexes dissociate but the p210 L--GRB2 complex 
remains intact even after 24h of imatinib treatment (unpub- 
lished data). 
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Figure 9 Subcellular distribution and colocalization of p2 1 OBCR-ABL and phosphorylated CRKL (pCRKL) in BV173 cells. BV173 cells were 
air-dried, fixed in 2% PFA and permeabilized in 0.2% Triton in PBS and blocked in 5% FBS/3% BSA. Anti-BCR-ABL and anti -phosphoCRKL or 
matched isotype control OgG) were incubated with the cells for 1h at room temperature. After three washes cells were incubated with AF 488 and 
AF 564, washed and mounted with VectaShield plus DAPI. All cells were analysed using CLSM. (a) The distribution of p210BcR-ABL (green) and 
pCRKL (red) and colocalization (yellow) is shown in the Z section. N Colocalization coefficient was analysed for 25 cells as described in Figure 2. 
Percentages of complexed and uncomplexed pCRKL and p2l OBCR-ABL are shown in the graph (**P=0.002; *P= <0.0001). 
Discussion 
A central role in determining abnormal cell function in CML 
including abnormalities in signalling, proliferation, adhesion and 
gene expression is attributed to multimolecular complex formation 
with p2l OBCR-ABL . The 
focal arrangement of p2l OBCR-ABL reported 
here implies a higher order of organization than simply random 
distribution in the cytosol. Since proteins generally interact with 
other proteins to perform essential roles in important cellular 
functionS, 27 it is likely that different arrangements of p210 13CR-AI3L 
will have an impact on downstream signalling events and degrees 
of dysregulation of signalling pathways such as P13 kinase, RAS 
and JAK-STAT linked to CML pathology. 
We used the junction-specific anti-BCR-ABL antibody that 
recognizes the b2a2 (el 3a2) breakpoint of p2 I OBCR-ABL to detect 
p2l OBCR-ABL by CSLM. The b2a2 and b3a2 (el4a2) are the two 
major breakpoints, in CML 2' and there is literature which 
suggests that expression of certain breakpoints has varied 
prognos iS29,30 and duration of chronic phase (reviewed by Mills 
et al . 
31 while other published data found no significance 
between breakpoint expression and prognosiS32). We cannot 
contribute to this controversy until a b3a2-specfic antibody is 
available. Previously, others have shown that p2l ORCR-ABL 
forms punctuate focus-like structures in the cytoplasm 
of p2l OBCR-ABL -positive cells. 
8,22 Our data show a similar 
distribution of p2l OBCR-AB' but the advantage of our study is 
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FigurelO Colocalization and quantification of p2l OBCR-ABL and CT1 0 regulator like (CRKL)-associated protein complexes. BV1 73 cells were air- 
dried, fixed in 2% PFA and permeabilized in 0.2% Triton in PBS and blocked in 5% FBS/3% BSA. Anti -BCR-AB Uanti-G RB2 (a), anti-BCR-ABUanti- CBL (b), anti -CRKVanti -G RB2 (c), anti -CRKUanti -CB LA or matched isotype control (IgG) were incubated with the cells for 1h at room temperature. After three washes cells were incubated with AF 488 and AF 564, washed and mounted with VectaShield plus DAPI. All cells were 
analysed using CLSM. Colocalization coefficient was analysed for >, 24 cells for each protein association as described in Figure 2. Percentages of 
complexed and uncomplexed proteins are shown in the graphs (*P<0.005; **P<0.009). 
that we detect p2l OBCR-AELexclusively without detecting normal 
ABL or BCR. We also describe detailed approaches to quantify 
levels of p2l 013CR-ABL and complexing partner proteins in 
different cell types and primary CML cells at different levels of 
maturation. We show p2l OBCR-ABL is expressed as foci in the cell 
lines tested, both myeloid and lymphoid, and in primary 
CD34' CML cells. However, greater numbers of foci were 
scored in cell lines, particularly in the KCL-22 cells, than in 
primary CD34+ cells. In contrast a diffuse distribution 
characterized MNC populations (Figures 3,4,6 and 7) and this 
correlates with the cellular levels of p2l OBCR-ABL. 
There has been recent interest in cell maturation-related 
differences of p2l O11CR-ABL expression in primary CML cells 
because they are thought to be related to the relative imatinib 
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Figurell Effects of imati nib on the p2l OBCR-A[3 L-positive foci. BVI 73 and chronic myeloid leukaemia (CML) CD34 ' cells were treated with I gm imatinib for 16 h. Treated and untreated cells were air-dried, fixed in 2% PFA and permeabilized in 0.2% Triton in PBS and blocked in 5% FBS/3% BSA. Anti-BCR-ABL or matched isotype control OgG) were incubated with the cells for 1h at room temperature, After three washes cells were incubated with AF 488, washed and mounted with VectaShield plus DAPI. All cells were analysed using CLSM. 
resistance of primitive progenitor cells in CML. Evidence 
suggests that more primitive CML cells express higher levels of 
p2l OBCR-ABL and that levels decrease with cellular maturation. 33 
The CLSM comparison of primary CD34 ' and mononuclear 
CML cell populations revealed a further difference that is likely 
to be related to cellular maturation. Thus, p2 1 OBCR-ABL is 
distributed in foci in CD34' cells but is diffusely distributed 
in MNCs. We show that CMIL CD34 + cel Is have 41.96-46.18% 
higher levels of p2l OBCR-ABL relative to MNC cells from the same 
CMIL patients (Figure 7b). This difference between MNC and 
CD34+ cells confirms that focus formation is not a technical 
artefact. However, to further confirm that the staining is not an 
artefact of the protocol we used the same method to stain and 
analyse F-actin distribution, which is diffuse (data not shown). 
Moreover, Deng et a 1.34 report that fixation tends to result in 
dispersion of foci of MLL-5 protein. One interesting speculation 
is that focus formation by p2l OBCR-AB' renders it less accessible 
to the actions of imatinib than a diffuse distribution. Alter- 
natively, complexed p2 1 OBCR-ABL may be more stable than 
diffuse p2l OBCR-ABL by association with SHP-2 phosphatase . 
35 
Our preliminary observation suggests that p2l OBCR-ABL and 
SHP-2 may associate within the foci in CD34-'- CMIL cells 
(unpublished data). 
The association of CRKL with p2l OBCR-ABL and CRKL phos- 
phorylation in CML has received considerable attention recently 
due to its value in monitoring clinical responsiveness and 
resistance to the p2l 013CR-ABL protein tyrosine kinase inhibitor, 
imatinib. 19,20 In this regard, it has been shown that normal 
cells contain little pCRKL whereas CRKL is predominantly 
phosphorylated in CML. The mechanism of CRKIL phos- 
phorylation is not certain but it is known that the SH3 domain 
on CRKIL binds to the proline-rich region on p2l 
OBCR-ABL12,36 
and the tyrosine 207 residue on the SH3 domain is essential for 
CRKL phosphorylation in p2l OBCR-ABL_PoSitive cel 
IS. 36 CLSM 
has revealed that only a small portion of CRKL and p2l 
OBCR-ABL 
foci colocalize completely while other foci partially over- 
lap, touch or are separate. This unexpected distribution of 
p2l OBCR-ABL and CRKL suggests that the association between the 
proteins is in a state of dynamic equilibrium (Figure 8), which 
may presumably be determined by the dissociation constant 
of proteins in the complex for one another and possibly by 
competition of p2l OBCR-ABL binding proteins. 
We have also shown that the percentage colocalization of 
pCRKL and p2l 013CR-ABL is low (Figure 9) which implies various 
potential mechanisms of CRKL phosphorylation in CML: (1) that 
CRKL binds to p2l OBCR-ABL irrespective of its phosphorylation 
status and/or (2) CRKL phosphorylation does not depend on 
p2l OBCR-ABL and CRKL complex formation and/or (3) p2lOl3cR'ABL 
does not phosphorylate all the cellular CRKL. The first 
mechanism is supported by other studies which have reported 
that CRKL phosphoýlation may not depend on the direct 
interaction of p2 I OB RAU and CRKL 36 and the lack of CRKL 
phosphorylation does not prevent the binding of p2l OSCR-ABIL 
and CRKL . 
37,38 The low level of colocalization between 
p2l OBCR-ABL and CRKL or pCRKL was unexpected therefore 
we calculated the proportion of p2 1013CR-AIR and CRKL in com- 
plex with other adaptor proteins. We examined the colocali- 
zation of CBL and GR132 because they have been shown 
to complex with p2lo BCR-ABL and CRKL. CBL can bind 
p210 BCR-ABL6,39,40 and CRKL 
6,40 directly and also acts as a 
linker between p2 I OICR-ABL and CRKL. GR132 binds p210BcF-ABL 
directly via the tyrosine 177 residue 
3,41-43 and CRKL indireCoy. 42'44 
Alternatively, GR132 may bind to ABIL in a similar way as CRKL 
and CBL . 
45 Figure 10 (a-d) shows that a large proportion 
of protein still remains uncompiexed when the colocalization 
of p2 1 OBCR-ABL -GRB2 (a), p210 
BCR-ABL 
-CBL (b), CRKL-GRB2 (c) 
and CRKL-CBL (d) was analysed implying that this pattern of 
association is not unique to p2l OBCR-AI3L -CRKUpCRKL com- 
plexes. The low level of association between p210 
SCRAOL and 
partner proteins raises questions about the 
function of the foci, 
UnI rea I ed 0 ho tit-, Imatinih it-raft. (l 16 
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12 
for example do they act as site for assembly of signalling 
proteins that would support our dynamic equilibrium hypo- 
thesis? Does the p2l OBCR-ABL in the diffuse region also have an 
important role in signal transduction in CMU 
Deregulated tyrosine kinase is a major feature of CML and this 
can be inhibited by the use of imatinib that has improved CML 
treatment significantly. Imatinib, a 2-phenylaminopyrimidine 
derivative is a small molecule tyrosine kinase inhibitor which 
targets p2l OBCR-ABL , 
ABL, c-Kit and platelet-derived growth 
factor receptor . 
46 4" Our data imply that treating cells with 
imatinib promotes nuclear localization of p2l OBCR-AL_PoSitive 
foci in BV173 and CD34+ cells (Figure 11) and confirm 
previous reports . 
23 We have also shown that imatinib dissoci- 
ates certain p2l OBCR-ABL-associated protein complexes (unpub- 
lished data). Nishihara et A'9 showed that there is a change in 
levels of phosphorylated p2l OBCR-ABL, CBL and CRKL within 
minutes of treatment with 30 gm imatinib in the TF-1 BCR-ABL 
cell line. They also demonstrated by co-IP that p2l OBCR-ABL 
complexed to CRKL and CBL and CBL bound to CRKL in these 
cells was reduced within 30min or less post-treatment with 
30 gm imatinib but total protein levels of p21 OEICR-ABL, CRKL and 
CBL remain unchanged. 
in summary, we believe that our work raises some iT 
1 
Frtant 
CR CR ABL 
questions about the biology and localization of p2 0 '- 
The results support the use of CLSM as an alternative approach 
to the investigation of multimolecular protein complexes in CML 
and how their composition may change with disease stage, 
cellular maturation and exposure to therapeutic agents like 
imatinib and new generation tyrosine kinase inhibitors. 
Acknowledgments 
The work was done under the tenure of a Leukaernia Research 
Fund Gordon Piller PhD Studentship. 
References 
1 Nowell P, Hungerford DA. A minute chromosome in human 
chronic granulocytic leukemia. Science 1960; 132: 1497-1501. 
2 Konopka JB, Witte ON. Detection of c-abl tyrosine kinase activity 
in vitro permits direct comparison of normal and altered abl gene 
products. Mol Cell Biol 1985; 5: 3116-3123. 
,3 
Pendergast AM, 'Ouilliam LA, Cripe LD, Bassing CH, Dai Z, Der Q 
et al. BCR-ABl induced oncogenesis is mediated by direct 
interaction with the SH2 domain of GRB-2 adaptor protein. Cell 
1993; 75: 175-185. 
4 Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. 
Crkl is the major tyrosine-phosphorylated protein in neutrophils 
from patients with chronic myeiogenous leukemia. I Biol Chem 
1994; 269: 22925-22928. 
.5 
Salgia R, Uemura N, Okuda K, Li J, Pisick E, Sattler M et A CRKL 
links P21 OBCR-ABL with paxillin in chronic myelogenous leukemia 
cells. I Biol Chem 1995; 270: 29145-29150. 
6 Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E 
et al. The proto-oncogene product p120CBL and the adaptor 
proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and 
p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. 
Oncogene 1996; 12: 839-846. 
7 Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Borrello 
MG et al. Constitutive phosphorylation of SHC proteins in 
human 
tumors. Oncogene 1995; 11: 899. 
8 Skourides PA, Perera SA, Ren R. Polarized distribution of Bcr-AbI 
in migrating myeloid cells and co-localization of Bcr-Abl and 
its 
target proteins. Oncogene 1999; 18: 1165-1176. 
9 Marley SB, Gordon MY. Chronic myeloid leukaemia: stem cell 
derived but progenitor cell driven. Clin Sci (London) 2005; 
109: 
13-25. 
10 Maxwell SA, Kurzrock R, Parsons SJ, Talpaz M, Gallick GE, 
Kloetzer WS et A Analysis of P21 Obcr-abl tyrosine protein ki nase 
activity in various subtypes of Philadelphia chron-K)some-positiye 
cells from chronic myelogenous leukemia patients. Cancer Res 
1987; 47: 1731-1739. 
11 Guo J, Wang J, Arlinghaus R. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia 
patients. Cancer Research 1991; 51: 3048-3051. 
12 Patel H, Marley SB, Gordon MY. Detection in primary chronic 
myeloid leukaemia cells of p21OBCR-ABL1 in complexes with 
adaptor proteins CBL, CRKL, and GRB2. Genes Chromosomes 
Cancer 2006; 45: 1121-1129. 
13 ten Hoeve J, Morris C, Heisterkamp N, Groffen J. Isolation and 
chromosomal localization of CRKL, a human crk-like gene. 
Oncogene 1993; 8: 2469-2474. 
14 cle Jong R, Haataja L, voncken JW, Heisterkamp N, Groffen J. 
Tyrosine phosphorylation of murine CRKL. Oncogene 1995; 11: 
1469-1474. 
15 Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. 
Identification of Crk1 as the constitutively phosphorylated 39-kD 
tyrosine phosphoprotein in chronic myelogenous leukemia cells. 
Blood 1994; 84: 2912-2918. 
16 ten Hoeve J, Kaartinen V, Fioretos T, Haataja L. Cellular inter- 
actions of CRKL, an SH2-SH3 adaptor protein. Cancer Res 1994; 
54: 2563-2567. 
17 ten Bosch GIA, Kessler JH, Blom J, Joostan AM, Gambacorti- 
Passerini C, Melief CJM et al. BCR-ABL oncoprotein is expressed 
by platelets from CML patients and associated with a special 
pattern of Crkl phosphorylation. Br J Haematol 1998; 103: 
1109-1115. 
18 ten Hoeve J, Arlinghsaus RB, Guo JQ Heisterkamp N, Groffen J. 
Tyrosine phosphorylation of CRKL in Philadelphia' leukemia. 
Blood 1994; 84: 1731-1736. 
19 White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB et al. 
In vitro sensitivity to imatinib-induced inhibition of ABL kinase 
activity is predictive of molecular response in patients with 
de novo CML. Blood 2005; 106: 2520-2526. 
20 Hamilton A, Elrick L, Myssina S, Copland M, Jorgensen H, Melo JV 
et al. BCR-ABL activity and its response to drugs can be 
determined in CD34+ CIVIL stem cells by CrkL phosphorylation 
status using flow cytometry. Leukemia 2006; 20: 1035-1039. 
21 Phee H, Rodgers w, Coggeshall KM. Visualization of negative 
signaling in B cells by quantitative confocal microscopy. A40/ Cell 
Biol 2001; 21: 8615-8625. 
22 Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, 
Kurzrock R. Subcellular localization of Bcr, Abl, and Bcr-AbI 
proteins in normal and leukemic cells and correlation of 
expression with myeloid differentiation. I Clin Invest 1993; 92: 
1925-1939. 
23 Vigneri P, Wang JY. Induction of apoptosis in chronic myelogen- 
ous leukemia cells through nuclear entrapment of BCR-ABL 
tyrosine kinase. Nat Med 2007; 7: 228-234. 
24 Melo J. Inviting leukemic cells to waltz with the devil. Nat 84ed 
2001; 7: 156-157. 
25 Abramoff MD, Magelhaes. P], Ram SJ. image processing with 
Image). Biophotonics Int 2004; 11: 36-42. 
ent of co-localiza- 26 Manders EEM, Verbeek F), Aten JA. Measurern 
tion of objects in dual-colour confocal images. I Microsc 1993; 
169: 375-382. 
27 Gomperts; BD, Kramer IM, Tatham PER. Signal Transduction, 
origins and Personalities. Signal Transduction. Academic 
Press: 
London, UK, 2002, pp 1-14. 
28 Melo JV. The diversity of BCR-ABL fusion proteins and 
their relationship to leukemia phenotype. Blood 1996; 
8& 
2375-2384. 
29 de Lemos JAR, de Oliveria CM, Scerni ACC, Bentes AQ, Beltr3`0 
AC, Bentes IRG et al. Differential molecular response of the 
transcripts B2A2 and 133A2 to imatinib mesylate 
in chronic 
myeloid leukemia. Genet mol Res 2005; 4: 
803-811 - 
30 perego RA, Costantini M, Cornacchini G, Garganini L, 
Biachi C, 
Pungolino E et al. Possible influences of B2A2 and B3A3 
BCR/ABL 
protein structure on thrombopoiesis in chronic myeloid 
leukaemia. 
Eur J Cancer 2000; 63: 1395-1401. 
31 Mills KI, Benn P, Bimie GD. Does the breakpoint within the major 
breakpoint cluster region (M-bcr) influence the 
duration oi the 
Leukemia 
chronic phase in chronic myeloid 
leukemia? An analytical 
comparison of current 
literature. Blood 1991; 75: 1155-1161. 
32 Guinn BA, Evely RS, Walsh V, 
Gikes AF, Burnett AK, Mills KI. 
An in vivo and in vitro comparison of the effects of b2a2 and 
b3a2 p210BCR-ABL splice variants on murine 32D cells. Leuk 
Lyrnphorna 2000; 37: 393-404. 
33 Copland M, Hamilton A, Elrick LL Baird JW, Allan EK, jordanides 
N et at. Dasatinib (BMS-354825) targets an earlier progenitor 
population than imatinib in primary CML but 
does not eliminate 
jhý quiescent fraction. Blood 2006; 107: 4532-4539. 
34 Deýg LW, Chiu 1, Strominger JL. MLL 5 protein forms intracellular 
foci, and overexpression inhibits cell cycle progression. Proc Natl 
Acad Soc 2004; 101: 757-762. 
35 Chen J, Yu WM, Daino H, Broxmeyer HE, Druker B), Qu CK. 
SHP-2 phosphatase is required for hematopoietic cell transforma- 
tion by Bcr-Abl. Blood. 2007; 109: 778-785. - 
36 Heaney C, Kolibaba K, Bhat A, Oda T, Ohno S, Fanning S et al. 
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL 
transformation. Blood 1997; 89: 297-306. 
37 dejong R, ten Hoeve J, Heisterkamp N, Groffen J. Tyrosine 207 in 
CRKL is the OCR/ABL phosphorylation site. Oncogene 1997; 14: 
507-513. 
38 Senechal K, Heaney C, Druker B, Sawyers C. Structural require- 
ments for function of the CrkI adapter protein in fibroblasts and 
hematopoietic cells. Mol Cell Biol 1998; 18: 5082-5090. 
39 Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H 
et al, Differential expression and signaling of CBL and CBL-B in 
BCR/ABL transformed cells. Oncogene 2002; 21: 1423-1433. 
40 Bhat A, Kolibaba K, Oda T, Ohno-jones S, Heaney C, 
Druker Bj. Interactions of CBL with BCR-ABL and CRKL in 
BCR-ABL-transformed myeloid cells. J Biol Chem 1997; 272: 
16170-16175. 
Sukicellular distributim of p2lO"-AK 
H PaW et a/ 
0 
13 
41 Puil L, Lui J, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al. Bcr-Abl oncoproteins bind directly to activators of the RAS 
signalling pathway. EMBO 11994; 13: 764-773. 
42 Tauchi T, Boswell SH, Leibowitz D, Broxmeyer HE. Coupling 
between p2lObcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent 
link to RAS activation pathway. J Exp AW 1994; 179: 167-175. 
43 Sattler M, Mohi MG, Pride YB, Quinnan LIZ, Malouf NA, Podar K 
et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer 
Cell 2002; 1: 479-492. 
44 Gaston 1, Johnson Kj, Oda T, Bhat A, Reis K Langdon W eir al. 
Coexistence of phosphotyrosine-dependent and -independent inter- 
actions between Cbl and Bcr-Abl. Eý9 Herriatol 2004; 32: 113-121. 
45 Ren R, Ye Z, Baltimore D. AN protein-tryrosine kinase seýects the 
Crk adaptor as a substrate using SH3-binding sites. Genes Dev 
1994; 8: 783-795. 
46 Druker Bj, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S 
et al. Effects of a selective inhibitor of the AN tyrosine kinase on 
the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566. 
47 Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine 
kinase inhibitor CGP57148B selectively inhibits the growth of 
BCR-ABL-positive cells. Blood 1997; 90: 3691-3698. 
48 Marley SB, Deininger MW, Davidson R), Goldman JM, Gordon 
MY. The tyrosine kinase inhibitor ST1571, like interferon-alpha, 
preferentially reduces the capacity for amplification of granulo- 
cyte-macrophage progenitors from patients with chronic myeloid 
leukemia. Exp Hematol 2000; 28: 551-557. 
49 Nishihara T, Miura Y, Tohyama Y, Mizutani C, Hishita T, Ichiyama 
S et al. Effects of the tyrosine kinase inhibitor imatinib mesylate 
on a Bcr-Abl-positive cell line: suppression of autonomous cell 
growth but no effect on decreased adhesive property and 
morphological changes. Int j Hematol 2003; 78: 233-240. 
Leukemia 
chronic phase in chronic myeloid 
leukemia? An analytical 
comparison of current 
literature. Blood 1991; 75: 1155-1161. 
32 Guinn BA, Evely RS, Walsh V, Gikes AF, Burnett AK, Mills KI. 
An in vivo and in vitro comparison of the effects of b2a2 and 
b3a2 p210BCR-ABL splice variants on murine 32D cells. Leuk 
Lymphoma 2000; 37: 393-404. 
33 Copland M, Hamilton A, Elrick Lj, Baird JW, Allan EK, Jorclanides 
N et at. Dasatinib (BMS-354825) targets an earlier progenitor 
population than imatinib in primary CML 
but does not eliminate 
the quiescent fraction. Blood 2006; 107: 4532-4539. 
34 Deng LW, Chiu 1, Strominger JIL. MLL 5 protein forms intracellular 
foci, and overexpression inhibits cell cycle progression. Proc Natl 
Acad Soc 2004; 101: 757-762. 
35 Chen J, Yu WM, Daino H, Broxmeyer HE, Druker Bj, Qu CK. 
SHP-2 phosphatase is required for hematopoietic cell transforma- 
tion by Bcr-Abl- Blood, 2007; 109: 778-785.. 
36 Heaney C, Kolibaba K, Bhat A, Oda T, Ohno S, Fanning S et al. 
Direct binding of CRKL to BCR-ABL is not required for; BCR-ABL 
transformation. Blood 1997; 89: 297-306. 
37 de)ong R, ten Hoeve J, Heisterkamp N, Groffen J. Tyrosine 207 in 
CRKL is the BCR/ABL phosphorylation site. Oncogene 1997; 14. 
507-513. 
38 Senechal K, Heaney C, Druker B, Sawyers C. Structural require- 
ments for function of the CrkI adapter protein in fibroblasts and 
hematopoietic cells. Xfoi Cell Biol 1998; 18: 5082-5090. 
39 Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H 
et A Differential expression and signaling of COL and CBL-B in 
BCR/ABL transformed cells. Oncogene 2002; 21: 1423-1433. 
40 l3hat A, Kolibaba K, Oda T, Ohno-jones S, Heaney C, 
Druker Bj. Interactions of CBL with BCR-ABL and CRKL in 
BCR-ABL-transformed myeloid cells. I Biol Chem 1997; 272: 
16170-16175. 
Subcellular disbibubw of p2lOom-OL 
H Platel et al 
a 
13 
41 Puil L, Lui J, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al. Bcr-Abl oncoproteins bind directly to activators of the RAS 
signalling pathway. EMBO 11994; 13: 764-773. 
42 Tauchi T, Boswell SH, Leibowitz D, Broxmeyer HE. Coupling 
between p2lObcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent 
link to RAS activation pathway. I Exp Med 1994; 179: 167-175. 
43 Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K 
et al, Critical role for Gab2 in transformation by BCR/ABL. Cancer 
Cell 2002; 1: 479-492. 
44 Gaston 1, Johnson Kj, Oda T, Bhat & Reis M, Langdon W ef al. 
Coexistence of phosphotyrosine-dependent and -independent inter 
actions between CbI and Bcr-Abl. EW Hernatol 20(9; 32: 113-121. 
45 Ren R, Ye Z, Baltimore D. AbI protein-tryrosine kinase selects the 
Crk adaptor as a substrate using SH3-binding sites. Genes Dev 
1994; 8: 783-795. 
46 Druker Bj, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S 
et al. Effects of a selective inhibitor of the Abl tyrosine kinase on 
the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566. 
47 Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine 
kinase inhibitor CGP57148B selectively inhibits the growth of 
BCR-ABL-positive cells. Blood 1997; 90: 3691-3698. 
48 Marley SB, Deininger MW, Davidson Rl, Goldman JM, Gordon 
MY. The tyrosine kinase inhibitor ST1571, like interferon-alpha, 
preferentially reduces the capacity for amplification of granulo- 
cyte-macrophage progenitors from patients with chronic myeloid 
leukemia. Exp Hematol 2000; 28: 551-557. 
49 Nishihara T, Miura Y, Tohyama Y, Mizutani C, Hishita T, Ichiyarna 
S et A Effects of the tyrosine kinase inhibitor imatinib mesylate 
on a Bcr-Abl-positive cell line: suppression of autonomous cell 
growth but no effect on decreased adhesive property and 
morphological changes. Int J Hematol 2003; 78: 233-240. 
Leukemia 
